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MYCOBACTERIUM W  ADJUVANT IMMUNOTHERAPY IN PULMONARY 
TUBERCULOSIS –  PROTOCOL FOR A SYSTEMATIC REVIEW 
SHAHEEN PANDIE, MARK ENGEL, ZITA KERBELKER, BONGANI MAYOSI 
University of Cape Town, Faculty of Health Sciences, Department of Medicine 
ABSTRACT 
BACKGROUND 
Tuberculosis (TB) remains a major health problem in the developing world, accounting for 
approximately 2 million deaths per year. The search for appropriate and applicable therapies to reduce 
the burden of TB is essential. Mycobacterium w (M w) is a heat-killed immune-modulating vaccine 
designed to attenuate the effects of TB infection and reduce the time to sputum negativity, thereby
improving cure rates and decreasing transmission rates.
HYPOTHESIS
The use of M w immunotherapy in patients with pulmonary TB (PTB) is associated with a reduction in
time to sputum negativity (i.e. proxy for cure).
OBJECTIVES 
To assess the effects of M w immunotherapy on sputum conversion in participants with PTB.
SEARCH METHODS 
Two independent investigators will perform a comprehensive search for randomised and quasi-
randomised controlled trials of M w use in PTB. This will include: 
 An electronic search of the following trial registries: The Cochrane Infectious Diseases Group
specialised trials register, the Cochrane Controlled Trials Register, the Pan African National
Clinical Trials Registry (PACTR), the World Health Organisation (WHO) International Clinical
Trials Registry Platform (ICTRP), and ClinicalTrials.gov
 An electronic search of the following databases: The Cochrane Library (February 2010 Issue),















 A handsearch of the reference lists of identified articles, abstracts, and conference proceedings
including: The International Union Against Tuberculosis and Lung Disease World Congress
(IUATLD), The American Thoracic Society International Congress (ATS) and The European
Respiratory Society World Congress (ERS)
 Correspondence to authors, experts and organisations working in the field of TB
immunotherapy requesting information about unpublished or work-in-progress data.
SELECTION CRITERIA 
Studies selected for review will be randomised or quasi-randomised controlled trials of M w treatment 
in participants with PTB. 
DATA COLLECTION AND ANALYSIS 
Data will be extracted using a standardised data extraction form. Each article will have an assessment of 
risk of bias, which will include information on sequence generation, allocation concealment, blinding, 
incomplete outcome or missing data, and selective outcome reporting. Data will be analysed using
Review Manager 5.0.15 (RevMan5), comparing M w to control for the outcomes of: (i) sputum
















DESCRIPTION OF THE CONDITION 
The 2009 Global Tuberculosis Control Update estimated that there were 9.4 million incident cases, 11.1 
prevalent cases and 1.82 million deaths (0.52 million in HIV positive individuals) attributed to 
tuberculosis (TB). The major burden of disease is concentrated in the developing world (WHO 2009). 
The annual incidence continues to increase in Africa because of the human immunodeficiency 
virus (HIV) epidemic (Murray 2004). In South Africa, TB has been identified as a major public health 
challenge. In the World Health Organization’s (WHO) 2008 Global high-burden TB rankings, South 
Africa ranked 4th out of 22 (WHO 2008). This epidemic has been compounded by the emergence of drug
resistant TB. Multi-drug resistant (MDR) TB is defined as resistance to both isoniazid and rifampicin, 
the two drugs regarded as the most effective anti-tuberculous treatment. Extensively drug resistant 
(XDR) TB is defined as MDR plus resistance to a fluoroquinolone and a second-line injectable agent. On
a global scale, MDR TB is reported to account for 10% of the 9 million new cases of TB that occur 
annually (Mitnick 2007). Current treatment strategies for TB, MDR TB and XDR TB include prolonged 
oral and injectable drug therapies. Treatment regimens are problematic because of high pill burdens
and toxicity, which result in low cure and treatment completion rates. Therefore, the investigation of 
new, applicable anti-tuberculous strategies is essential.
The immunopathogenesis of TB involves a complex interplay between bacteriostatic and bactericidal 
immune pathways. Bacteriostatic processes result in a walled off granuloma, while the bactericidal 
processes of autophagy, apoptosis, and cytotoxic T-cell destruction, result in cell death (Churchyard 
2009). A combination of the traditionally known T-Helper 1 response (key cytokines include 
INFgamma, TNF-ɣ, IL-15) and cytotoxic T-lymphocyte (CTL) killing is thought to provide the optimal 
immune protection against TB. The T-Helper 2 response (IL-4, TGF-ß, IL -10) directly reduces the
immune response to TB by both delaying the maturation of Th1 cells, and inhibiting the production of 
cytokines that drive Th1 and CTL cells. Therefore, the ideal immunotherapeutic strategy would be to 
inhibit Th2 while enhancing the protective Th1 and CTL pathways.
DESCRIPTION OF THE INTERVENTION 
Mycobacterium w (M w) is a non-pathogenic, saprophytic, rapidly growing atypical Mycobacterium 
species with immuno-potentiating properties. Recent polyphasic taxonomic analysis classified M w as a 
distinct species, Mycobacterium indicus pranii, placing it in the Runyon Group IV along with M Vaccae, M 
fortuitum and M smegmatis (Saini 2009). Its uniqueness stems from its ability to undergo antigen-

















stimulates a Th1 cellular immune response against shared epitopes for both Mycobacterium leprae and 
Mycobacterium tuberculosis. An extensive body of data supports the safety and efficacy of M w in the 
prevention and treatment of leprosy (Nath 1998, Sharma 2005). Laboratory, animal and clinical work 
investigating M w use in TB suggests reduction in time to sputum conversion, a proxy for cure, and thus 
a potential reduction in spread of disease (Rieder 1996). 
HOW THE INTERVENTION MIGHT WORK  
The precise mechanism of action of M w is not understood. M w shares B- and T-cell antigen epitopes 
with Mycobacterium leprae and with Mycobacterium tuberculosis (Ganju 1990, Singh 1991). The initial 
work (animal trials and phase I - III human clinical trials) has resulted in the widespread use of M w as 
adjuvant treatment for leprosy. This outcome is testament to the hypothesis that the use of M w as an 
immune modulator for diseases with overlapping Mycobacterium antigens is both scientifically 
plausible and clinically relevant to investigate. In humans, injection of heat-killed M w was tested as an 
adjunct to standard antibiotic therapy in phase 3 clinical trials of lepromatous leprosy. Participants 
with leprosy received multidrug therapy (MDT) plus M w, while the control arm received MDT plus 
placebo injection. This study showed that bacteriological clearance was more rapid in the M w group (P 
< 0.03). There was also an associated decrease in the number of organisms (bacillary load), shorter 
duration of antibiotic therapy, and earlier discharge from care (Zaheer 1995, Sharma 2000, Kaur 2002). 
In healthy contacts of leprosy patients, M w was associated with protection from lepromatous infection 
(Sharma 2005). Sharma et al vaccinated a total of 24060 household contacts with M w or placebo in a 
double-blind, randomised trial. Participants were followed up for 8-10 years, at 3 yearly intervals. M w 
showed a protective efficacy of 68%, 59% and 39.3% at the respective follow-up intervals. The safety 
and efficacy of M w has thus been w ll established through widespread use as adjuvant therapy for the 
treatment and prevention of leprosy. 
As regards TB, multiple laboratory studies have demonstrated that mice immunised with heat-killed M 
w had increased Th1 lymphocyte and macrophage activity, with a cytokine environment that was 
predominantly IL2 and INFgamma. In addition, immunised mice were protected from sub-lethal 
challenge with M. tuberculosis (Gupta 2009, Guleria 1993, Singh 1992). Human data of heat-killed M w 
use as immunotherapy for active TB are not definitive.  Results from published and unpublished clinical 
trials suggest that M w administration is associated with a reduction in time to sputum negativity and 
improved cure rates (Patel 2002, Patel 2003, Luhadia 2004). In addition, Katoch reviewed the 
participants (healthy contacts) of the leprosy studies looking for evidence of new TB infection (Katoch 
2008). The results suggest that M w significantly (P < 0.01) reduced the rate of new TB infection. In 

















with no reports of serious adverse events. All published studies have concluded that M w is safe. 
Reported side effects are related to local injection site erythema, induration and pain. 
WHY IT IS IMPORTANT TO DO THIS REVIEW  
The aim of this systematic review is to summarise the evidence of the effectiveness of M w vaccination 
as adjunctive treatment for PTB. There is currently no consensus on the effectiveness of immune-
modulating vaccines use in TB. This information will be of help to policy makers, healthcare 
practitioners and researchers in this area. 
Our hypothesis is that in patients with PTB: 
 M w immunotherapy is associated with a reduction in time to sputum conversion (i.e. proxy for 
cure) 
 M w immunotherapy is associated with a decrease in mortality 

















To review the available data as regards M w usage in PTB, focusing on the effects of M w 
immunotherapy on: 
 Cure/ sputum conversion 
 Mortality 
 Adverse reactions. 
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW 
TYPES OF STUDIES  
All randomised and quasi-randomised controlled trials of M w immunotherapy in participants 
diagnosed with PTB. 
TYPES OF PARTICIPANTS  
Participants diagnosed with PTB either by sputum smear microscopy, sputum culture or culture 
of material from a clinically affected anatomical site. 
TYPES OF INTERVENTIONS  
Intervention: Inoculation with at least one dose of heat-killed M w. 
Control: Placebo injection or no control administered. 
Chemotherapy for TB must be according to WHO guidelines for category I and category II TB. 
TYPES OF OUTCOME MEASURES  
PRIMARY OUTCOMES  
To determine the effect of M w therapy on: 
 Sputum conversion (sputum culture negativity) during the course of TB treatment ( assessed at 


















SECONDARY OUTCOMES  
To determine the frequency of: 
 Serious adverse reactions (fatal, life threatening or requiring hospitalisation) 
















SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
We plan to do a detailed literature search for data pertaining to the use of M w in PTB. Selected articles 
will then be reviewed for standardised data extraction and presentation in the format of a meta-
analysis. 
The project team will consist of three main contributors: 
 Dr. Shaheen Pandie (SP), who will function as the primary investigator and be responsible for all 
aspects of the project including final data analysis and publication(s) that may arise 
 Mark Engel (ME), who will be responsible for independently completing the literature search 
and act as co-supervisor 
 Dr. Zita Kerbelker (ZK), who will be responsible for independently completing the data 
extraction, thereby verifying the data collected and generated 
 Professor Bongani Mayosi (BM) who will function as the project supervisor. 
SP and ME will perform an exhaustive and comprehensive search to identify all relevant studies 
regardless of language or publication status (published, unpublished, in press and in progress).   
ELECTRONIC SEARCHES  
This process will include searching the following journal and trial databases: 
 Cochrane Central Register of Controlled Trials (CENTRAL) latest issue 
 MEDLINE 1966 to March 2011 
 OVID 1980 to March 2011 
 LILACS 1982 to March 2011 (La Literatura Latinoamericana y del Caribe de Information en 
Ciencias de la Salud) (www.bireme.br) 
 Cochrane Infectious Diseases Group Specialised Trials Register 
 Pan African National Clinical Trials Registry (PACTR) 
 World Health Organisation (WHO) International Clinical Trials Registry Platform (ICTRP) 
 ClinicalTrials.gov     
















 Tuberculosis AND (“Mycobacterium w” OR immunotherapy OR immunoadjuvant OR 
immunomodulator OR immu-vac OR Mycobacterium indicus pranii), cross referenced with an 
isolated search for “Mycobacterium w”. 
ADDITIONAL SEARCHES  
We will perform a handsearch of the reference lists of identified articles and relevant review articles. 
We will also do a manual search of abstracts or proceedings of the following conferences (2000 to 
present): 
 The International Union Against Tuberculosis and Lung Disease World Congress (IUATLD) 
 The American Thoracic Society International Congress (ATS) 
 The European Respiratory Society World Congress (ERS) 
In addition, we will send correspondence to all the authors of the relevant articles for any updates on 
their research. Finally, individuals and organisations working in the field of TB immunotherapy will be 
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DATA COLLECTION AND ANALYSIS 
SELECTION OF STUDIES  
SP and ZK will review all relevant material identified from the above search. After reading the titles and 
abstracts of the identified articles, we will acquire the full text articles of all citations deemed to meet 
the inclusion criteria. These articles will be independently inspected to verify that they meet the pre-
specified inclusion criteria. 
DATA EXTRACTION AND MANAGEMENT  
We will then extract the data using a standardised data extraction form (Appendix 1). Any 
discrepancies will be resolved through discussion of the original articles with ME and BM. The following 
characteristics will be extracted from each included study: 
 Administrative details 
o trial identification number; title; author(s); published or unpublished; year of 
publication; number of studies included in paper; year in which the study was 
conducted; and details of other relevant papers cited 
 Verification assessment 
o assessment to ensure that the study met the inclusion criteria for the systematic review 
 Details of study  
o study design; duration and completeness of follow-up; country and location of study; 
informed consent; and ethics approval 
 Details of participants  
o setting; number; relevant baseline characteristics; and category of PTB (I or II) 
 Details of intervention  
o M w dosage; duration; and mode of administration 
 Details of control  
o placebo or no vaccine control; and completeness of treatment 
 Details of outcomes  
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 Notes  
o general comments 
ASSESSMENT OF RISK OF BIAS IN INCLUDED STUDIES  
Each included study will also be assessed for risk of bias. The assessment will include information on 
sequence generation, allocation concealment, blinding, incomplete outcome data or missing data, 
selective outcome reporting and other sources of bias. Each methodological component will be assessed 
as being adequate, inadequate or unclear as per the Cochrane Handbook of Systematic Reviews of 
Interventions (Higgins 2008). 
MEASURES OF TREATMENT EFFECT  
Data will be analysed using Review Manager Version 5.0.15 (RevMan5). Outcomes (sputum conversion, 
death, adverse events) will be considered as dichotomous variables. Outcome measures will be 
calculated using risk ratios and 95% confidence intervals.  
DEALING WITH MISSING DATA  
Every effort will be made to contact the original authors or investigators of the selected articles to help 
resolve the issues of missing or incomplete data.   
ASSESSMENT OF HETEROGENEITY  
Heterogeneity between trials will be assessed using the chi-squared test set at a 10% level of 
significance. The impact of any statistical heterogeneity will be quantified using the I2 statistic 
(Appendix 2). If there is an acceptable degree of heterogeneity and it is appropriate to pool the data, the 
Mantel-Haenszel statistical method and Random Effects Analysis Model will be used; and the results 
will be presented in the form of a meta-analysis. If we are unable to combine the studies, the data will 
be presented in a narrative form. 
SUBGROUP ANALYSIS AND INVESTIGATION OF HETEROGENEITY  
In addition to evaluating all PTB participants, we also plan to analyse the subgroups of Category I (new 
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POTENTIAL STUDY SHORTCOMINGS / LIMITATIONS 
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APPENDIX 2: HIGGENS I2 
 
Higgins I2 = Q-df / Q  x 100% 
Where  
Q = χ2 statistic 
 df = degrees of freedom 
I2 calculates the proportion of variation in the effect estimates 
that is due to heterogeneity rather than chance 
Thresholds for interpreting I2: 
0 – 40 % = might not be important 
30 – 60 % = moderate 
50 – 90 % = substantial 
75 – 100% = considerable 
From “Analysing Data and Undertaking Meta-analyses”:  Higgins JPT, Green S. Cochrane Handbook for 

























APPENDIX 3: IMPI TRIAL OVERVIEW 
 
Title The IMPI (Investigation of the Management of Pericarditis) Trial 
A Pilot Trial of Adjunctive Prednisolone and Mycobacterium w 
Immunotherapy in Tuberculous Pericarditis 
ClinicalTrials.gov Identifier: NCT00810849 
Study Size 1400 participants from Africa and India. 
Study Design International multi-centre randomised controlled, double-blind, 2x2 
factorial design trial of: 
a) Prednisolone vs. placebo and/or 
b) Mycobacterium w vs. placebo 
Primary Objective To assess the effects of Prednisolone and/or Mycobacterium w 
immunotherapy on mortality and pericardial complications (i.e. 
constriction and tamponade). 
Inclusion Criteria Confirmed pericardial effusion on echocardiography. 
Evidence of definite or probable tuberculous pericarditis, signified by at 
least one of the following: 
Tubercle bacilli found in stained smear or culture of pericardial fluid, or 
Tubercle bacilli or caseating granulomata found on histological 
examination of pericardium, or 
Tubercle bacilli found in stained smear or culture of sputum, gastric or 
lymph node aspirate, or 
Lymphocytic pericardial exudates with elevated ADA activity 
Tygerberg Index Score > 6 
Within 1 week of starting anti-tuberculous treatment.  
 Availability of fixed address and contactable relatives. 
Willingness to participate for the full duration of the trial (24 months). 
Exclusion Criteria Presence of an alternative cause of pericardial disease, e.g. penetrating 
chest trauma in the preceding 12 months; and malignancy. 
Use of corticosteroids within the previous month. 
History of hypersensitivity or allergy to the Mycobacterium w vaccine. 
 Pregnancy.  
 Age < 18 years. 

















Mycobacterium w or matching placebo given intradermally on day 0 





Mrs. Veronica Francis, Project Manager 
Department of Medicine, H47 Old Main Building, Groote Schuur Hospital 
University of Cape Town, Observatory  7925 
Telephone: +27-21-4472777; Fax: +27-21-4472765 
Randomisation Tel. No.: +27-72-9011126 
Email Address: veronica.francis@uct.ac.za 
Population Health 
Research Institute  
(PHRI) 
PHRI, Hamilton General Hospital, 237 Barton Street East 
Mac Clinic, 2nd Floor Room 252 
Hamilton, Ontario  L8L  2X2  Canada 
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Tuberculosis (TB) remains a global health catastrophe. The 2009 Global TB Control Update 
reported 9.4 million incident cases and 11.1 prevalent cases of TB; with 1.82 million TB 
associated deaths (0.52 million in human immunodeficiency virus [HIV] positive individuals1). 
The major burden of disease is concentrated in the developing world.  In Africa, the annual 
incidence continues to increase because of the HIV epidemic2 . In South Africa, TB has been 
identified as a major public health challenge. The epidemic has been compounded by the 
emergence of drug resistant TB. Multi-drug resistant (MDR) TB is defined as resistance to both 
isoniazid and rifampicin, the two drugs regarded as the most effective anti-tuberculous 
treatment. On a global scale, MDR TB is reported to account for 10% of the 9.4 million new cases 
of TB that occur annually3.  Extensively drug resistant (XDR) TB is defined as MDR plus 
resistance to a fluoroquinolone and a second-line injectable drug. Current treatment strategies 
for drug-sensitive, MDR and XDR TB include prolonged oral and injectable drug therapies. 
Treatment regimens are problematic because of high pill burden and drug toxicity, which result 
in low cure and treatment completion rates. Therefore, the investigation of new anti-
tuberculous treatment strategies is essential. To date, there has been extensive research into the 
immunopathogenesis of TB, and possible immuno-therapies that could supplement current 
anti-tuberculous therapies4. 
The objectives of this literature review are: 
1. To review the recent advances in TB immunotherapy 
2. To provide background information on the immune modulator Mycobacterium w (M w) 
3. To review the use of M w therapy in pulmonary TB (PTB) 
 
LITERATURE SEARCH STRATEGY 
For general background information, electronic sources such as MEDLINE, Google Scholar, and 
EMBASE were searched using key words such as: tuberculosis, immunotherapy, vaccines, 

















For the formal systematic review of “Mycobacterium w immunotherapy in treating pulmonary 

















As a result of advancements in the understanding of the immunopathogenesis of TB, there has 
been an increasing interest in immunotherapies as adjunctive treatments to standard TB drug 
regimens. There are three major categories of immunotherapeutic agents: 
1. Immune modulators:  alter the nature of the immune response 
2. Immunosuppressives:  suppress the immune response 
3. Supplement effector cytokines: assist anti-microbicidal activity 
IMMUNE MODULATORS 
MYCOBACTERIUM VACCAE (M. VACCAE) 
Murine models have shown that M. vaccae induces the perfect cytokine and immune milieu for 
protection against TB. M. vaccae induces T-regulatory cells responsible for inhibiting the T-
helper 2 (Th2) response, whilst stimulating T-helper 1 (Th1) and cytotoxic T-lymphocyte (CTL) 
responses5 . A systematic review of M. vaccae treatment for TB analysed 8 trials involving a total 
of 2140 adult participants. The meta-analysis suggested no significant effect on mortality (RR 
1.09, 95% CI 0.83 to 1.42; 1741 participants, 4 trials), and only a small effect on participants 
who were sputum negative or culture negative at 2 months. The conclusion drawn was that M. 
vaccae was of no benefit and further trials were not warranted. A major criticism of the meta-
analysed trials was under-dosing, with 7 out of the 8 trials reviewed only giving a single dose of 
M. Vaccae 6. The focus has now turned to multi-dose schedules, and the results of a meta-
analysis performed in China reviewing 11 trials focusing on multi-dose M. vaccae concluded that 
it is an effective adjuvant. As a result, M. vaccae has been approved for MDR-TB treatment in 
China7. 
MYCOBACTERIUM W (M W) 
Discussed in detail later. 
HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN 
Intravenous immunoglobulin (IVIg) is used for a variety of inflammatory disorders (e.g. 
idiopathic thrombocytopenic purpura, Kawasaki disease, Guillain Barre syndrome). It has been 

















mechanism is due to a subset of anti-inflammatory immunoglobulins with fully sialylated 
oligosaccharides9. No human data are available yet. 
HE2000 (16Α-BROMOEPIANDROSTERONE) 
HE2000 is a modified form of the steroid dehydroepiandrosterone (DHEA). In mouse models it 
was shown to be therapeutic and to accelerate bacillary clearance in TB10. The precise 
mechanism is unclear. In a small study comprising 25 HIV positive participants, HE2000 
reduced the incidence of TB co-infection10, 11. 
NEUTRALISING ANTIBODIES TO INTERLEUKIN-4 (IL-4) 
TGF-β (a polypeptide of the transforming growth factor beta superfamily of cytokines) is known 
to be detrimental in TB. Neutralising IL-4 antibody decreases TGF-β and this beneficial 
therapeutic effect has been proved in mouse model12, 13. A humanised antibody to IL-4 
(pascolizumab) has been developed, but has not yet undergone clinical trials.   
DNA VACCINE ENCODING A MYCOBACTERIAL PROTEIN (HEAT SHOCK PROTEIN 65) 
The immune response targets proteins such as Mycobacterial heat shock protein (HSP) 65. DNA 
vaccines encoding proteins that modulate the immune response are novel, and are currently in 
Phase I human clinical trials14. 
PLANT EXTRACTS (E.G. DZHERELO) 
Dzherelo is an over-the-counter phytoconcentrate containing multiple plant extracts. A small, 
open-labelled study assessing the adjunctive use of Dzherelo in TB patients shows promising 
results15. No randomised controlled trials have been done as yet. 
IMMUNOSUPPRESSIVE THERAPY 
THALIDOMIDE AND THALIDOMIDE ANALOGUES 
TNF-α is essential for granuloma formation16. Thalidomide partially inhibits TNF-α, thereby 
preventing granuloma formation, and thus rendering bacilli in an actively growing state, which 
are then more susceptible to antimicrobials. There have been phase I studies demonstrating 

















However, a study of high dose thalidomide in children with TB meningitis was stopped early 
because of excess adverse events18. Thalidomide analogues have been produced to reduce toxic 
side effects, but these agents are still in the early phases of testing. 
ETANERCEPT  
Etanercept is a soluble TNF-α receptor. It was evaluated in a small, case-controlled study of 16 
HIV positive participants with TB. It was considered safe and suggested a significant reduction 
in the time to sputum conversion19. Further studies are waranted. 
HIGH-DOSE PREDNISONE/PREDNISOLONE 
Clinical trials using adjunctive prednisolone as anti-TB treatment in participants with PTB have 
shown great promise; particularly as regards the time to sputum conversion and reduction of 
constitutional symptoms20, 21. There are, however, concerns regarding detrimental side-effects 
such as glucose intolerance, hypertension and fluid retention. In HIV positive patients, there was 
a transient increase in the plasma HIV RNA viral loads, which receded when treatment was 
completed. There was no significant increase in opportunistic infections. In order to reduce 
these side-effects, future studies may have to look at reducing steroid dosages, or at introding 
novel routes of administration (e.g. inhaled, nasal).   
SUPPLEMENT EFFECTOR CYTOKINES 
RECOMBINANT HUMAN INTERFERRON GAMMA 
Interferron gamma is a crucial cytokine for defence against bacterial infections. Recombinant 
human (rh) INFgamma has been trialled in aerosol, subcutaneous and intramuscular forms. 
Initial studies in MDR participents showed minimal, non-sustained benefit21,22. In 2009 Dawson 
et al published a study that concluded that the use of adjuvant recombinant interferon in 
participants with cavitary PTB can reduce inflammatory cytokines, improve constitutional 
symptoms, and reduce time to sputum conversion23. 
OTHER CYTOKINES 
Other cytokine effectors such as rh-IL-2 and rh-Granulocyte-Macrophage Colony-Stimulating 
Factor (rh GM-CSF) have been investigated. IL-2 showed promise as adjuvant treatment to drug-
resistant TB, but showed no benefit in a study of drug-sensitive TB patients 24,25, 26. In one small 

















faster sputum conversion27. In addition, it has been shown to have an adjuvant role in boosting 
the protection afforded by bacillus Calmette-Guerin (BCG)-derived vaccines28. 
The common theme illustrated in this synopsis of immunotherapies, is the need for further 
investigation. An appropriate starting point would therefore be to critically review the available 
















MYCOBACTERIUM w  
INTRODUCTION 
Mycobacterium w (M w) is a non-pathogenic, saprophytic, rapidly growing atypical 
Mycobacterium species with immuno-potentiating properties. Recent polyphasic taxonomic 
analysis classified M w as a distinct species, Mycobacterium indicus pranii, placing it in the 
Runyon Group IV along with M vaccae, M fortuitum and M smegmatis29. Its uniqueness stems 
from its ability to undergo antigen-driven blast leukocyte transformation. Recent scientific 
experiments have shown that M w exerts its influence on the innate immune system at the level 
of the Toll-like-receptor (TLR) and TLR-ligands. It has the ability to inhibit TLRs (especially TLR 
3, 4, 5, 6, 7, 8, 9) and antagonise TLR ligands30. This finding has spurred new interest into the 
potential benefits of M w usage, particularly in conditions that are associated with up-regulation 
or over-expression of TLRs, such as sepsis and chronic airway diseases. Interestingly, PTB is 
also associated with selective up-regulation of TLRs31. 
RECOGNISED USES OF M w 
An extensive body of data supports the safety and efficacy of M w in the prevention and 
treatment of leprosy32,33. There are two different clinical manifestations of leprosy i.e. 
tuberculoid and lepromatous. In the milder tuberculoid form, mycobacterium proliferation and 
destruction are relatively contained by a cell-mediated immune response. Mycobacteria are 
engulfed by macrophages, but initially survive because the phagosomes and lysosomes do not 
fuse34. Macrophages require activation by Th1 lymphocytes for phagosome-lysosome fusion. 
The complete process of mycobacterial destruction involves: (i) Th1-macrophage activation, 
followed by (ii) phagosome-lysosome fusion, and (iii) mycobacterial destruction by proteases 
resulting in (iv) mycobacterial peptide fragments binding to MHC class II molecules and finally, 
(v) presentation at the cell surface to CD4 T cells35. 
Th1 or Th2 cell differentiation is determined by the cytokine milieu produced after the 
undifferentiated CD4 helper T cell recognises the antigen presented on the MHC class II 
molecules of infected macrophages. IL-12 and INFgamma promote differentiation of Th1 
subtypes, leading to a cell-mediated immune response and the less severe tuberculoid 
manifestation of the disease. Th1 cells specific for M. leprae antigens are capable of activating 
macrophages and inducing destruction. Lepromatous leprosy, on the other hand, results from 

















humeral immune responses. Secretion of IL-4 and IL-6 lead to the T cell differentiation into the 
Th2 subtypes. B cells are activated to make neutralising antibodies, which are not able to reach 
intracellular bacteria and therefore constitute an ineffective immune response. M. leprae are 
able to grow in macrophages, resulting in tissue destruction35. 
When administered as an intra-dermal heat killed vaccine, M w stimulates a Th1 cellular 
immune response against shared epitopes for both Mycobacterium leprae and Mycobacterium 
tuberculosis36-38. As explained above, the stimulation of the Th1 response leads to an improved 
cell-mediated immune response, and therefore less severe tuberculoid disease.  
M w was tested as an adjunct to standard antibiotic therapy in phase 3 clinical trials of 
lepromatous leprosy. Participants with leprosy received multidrug therapy (MDT) plus M w; 
while the control arm received MDT plus placebo injections. These studies showed that 
bacteriological clearance was more rapid in the M w group (p<0.03)39. There was also an 
associated decrease in the number of organisms (bacillary load), shorter duration of antibiotic 
therapy was required; and earlier discharge from care was possible39-41. 
In healthy contacts of leprosy patients, M w was associated with protection from leprosy 
infection. Sharma et al vaccinated a total of 24,060 household contacts with M w or placebo in a 
double-blind randomised trial. Participants were followed at 3 yearly intervals for 8 to 10 years. 
M w showed a protective efficacy of 68%, 59% and 39.3% at the respective follow-up 
intervals33. The safety and efficacy of M w has thus been well established through widespread 
use as adjuvant therapy for leprosy treatment and prevention. 
M w AND TB 
The immunopathogenesis of TB is similar to that of leprosy. The initial immune response to TB 
infection results in either active disease or protection against disease. This immune response 
involves a complex interplay between bacteriostatic and bactericidal immune pathways. 
Bacteriostatic processes results in a walled off granuloma, while the bactericidal processes of 
autophagy, apoptosis, and cytotoxic T-cell destruction, result in cell death42. A combination of a 
Th1 response (key cytokines include INFgamma, TNFα, IL-15) and the CTL killing is thought to 
provide the optimal immune protection against TB. A Th2 response (IL-4, TGFβ, IL -10) directly 
reduces the immune response to TB by both inhibiting the maturation of Th1 cells, and 
inhibiting the production of cytokines that drive Th1 and CTL cells. Therefore, the ideal 


















Multiple laboratory studies have demonstrated that mice immunised with heat-killed M w had 
increased Th1 lymphocyte and macrophage activity, with a cytokine environment that was 
predominantly IL2 and INFgamma43. In addition, immunised mice were protected from sub-
lethal challenge with M. tuberculosis44, 45.  
Human data of heat-killed M w use as immunotherapy for active TB are not definitive.  Results 
from published and unpublished clinical trials investigating M w administration in patients with 
PTB suggest a reduction in time to sputum negativity and improved cure rates46-48. In addition, 
Katoch reviewed the healthy contacts of the leprosy studies’ participants looking for evidence of 
new TB infection. The results suggest that M w significantly (p<0.01) reduced the rate of new TB 
infection49. There is, however, concern as regards the quality of the available data, particularly 
in terms of methodological flaws.  
The aim of the proposed systematic review is to evaluate the evidence of the effectiveness of M 
w vaccination as adjunctive treatment for PTB. This critical evaluation of the available data will 
include assessment of: (i) risk of bias, (ii) heterogeneity, and (iii) comparison of available data 
sets in the form of a meta-analysis. 
M w USAGE IN OTHER CONDITIONS 
M w AND HIV 
It has become increasingly difficult to separate the entities of TB and HIV. As mentioned 
previously, out of the 1.82 million TB associated deaths that were reported in 2009, 0.52 million 
were in HIV positive individuals1. For this reason, it would be important to know if there was 
any impact of M w usage in HIV infected individuals. 
There is limited data of M w use in the HIV population. The only relevant conclusions that can be 
drawn from work done by Kharkar, is that M w was safely used in a cohort of 55 HIV positive 
participants without any major adverse events, and no reports of immune reconstitution 
inflammatory syndrome (IRIS)50. Further evidence of the safety of heat-killed atypical 
mycobacterium immune-modulating vaccines can be drawn from the work done with M vaccae 
vaccine, which is similar in structure and immune mechanism to M w. The literature suggests 
that the use of heat-killed TB vaccines is safe in the HIV population and at least as effective as in 
non-HIV individuals6, 51. Proper randomised controlled trials are both necessary and essential, 


















M w AND CANCER 
Immunotherapy with bacillus Calmette-Guérin (BCG) instillation is well recognised as adjuvant 
therapy for high-risk non-muscle invasive bladder cancer52. In view of this, M w has been 
trialled for use as an adjuvant immunotherapy in various types of cancers including invasive 
bladder cancer, non-small cell lung cancer, and head and neck cancers. 
 Chaudhuri et al investigated the use of Mycobacterium w adjunctive therapy with radiation 
therapy in the management of invasive bladder cancer. Even though it was a small trial (only 5 
patients), at the two year follow up period, all the patients were disease free53.  
Sur’s controlled trial showed that the use of M w immunotherapy as adjuvant to combination of 
chemotherapy and radiotherapy in non-small lung cancer showed an improvement in quality of 
life (measured by Karnofsky performance scores), a significant regression of tumour size in the 
intervention group, and an overall improvement in lung functions. This was also, however, a 
very small study, with only 10 participants in each arm54. 
In a non-randomised trial of M w adjuvant treatment as palliative care for advanced head and 
neck cancers, M w was considered safe and beneficial for improving the quality of life55. 
MISCELLANEOUS USES OF M w 
M w has also been trialled in a variety of miscellaneous conditions, including psoriasis, asthma, 
and genital warts30, 56-58.  These were mostly pilot or proof of concept studies, with small sample 
sizes and results that could not be generalised.     
SAFETY OF M w 
In terms of safety, M w has been administered to thousands of patients in multiple trials and 
studies, with no reports of serious adverse events. The accepted chronology of the “normal” 
local skin reaction to the vaccine is: 
1. A small pustule between days four to five 
2. Mild ulceration between days seven and ten 

















 Any skin changes that are not in keeping with this sequence of events are considered an 
accelerated or exaggerated reaction i.e. adverse reaction47. Even so, all published studies have 

















The HIV-TB epidemic is a health crisis, and current therapeutic options for TB are suboptimal. 
Investigating immunotherapeutic interventions is one of the options that may facilitate the fight 
against TB. Understanding the immunopathogenesis of TB is crucial in the development of 
appropriate anti-TB strategies59. Laboratory, animal and clinical work investigating M w use in 
TB suggests a reduction in time to sputum conversion (a proxy for cure), and thus the potential 
to reduce the spread of disease. The aim of this systematic review is to summarise the evidence 
of the effectiveness of M w vaccination as adjunctive treatment for PTB. This information will be 
helpful for policy makers, healthcare practitioners and researchers in the field of TB 
management and control. 
FUTURE RESEARCH 
There are currently several trials in progress evaluating M w as adjuvant therapy (Appendix 2). 
The trials that are specifically related to M w usage in patients with TB: 
 The Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary 
  Tuberculosis (Category I) Patients (ClinicalTrials.gov Identifier: NCT00341328) 
 The Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary 
Tuberculosis (TB) Retreatment Patients (ClinicalTrials.gov Identifier: NCT00265226)  
 The Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in 
Tuberculous  
Pericarditis: IMPI (ClinicalTrials.gov Identifier: NCT00810849) 
These three large, randomised controlled trials would hopefully provide more definitive 
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APPENDIX 1: SEARCH STRATEGY (FROM FORMAL PROTOCOL) 
INCLUSION CRITERIA 
TYPES OF STUDIES  
All randomised and quasi-randomised controlled trials of Mycobacterium w immunotherapy in participants 
diagnosed with PTB. 
TYPES OF PARTICIPANTS  
Patients diagnosed with PTB either by sputum smear microscopy, sputum culture or culture of tissue/samples from 
other parts of the body. 
TYPES OF INTERVENTIONS  
Intervention: Inoculation with at least one dose of heat killed M w. 
Control: Placebo injection or no control administered.  
SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
SP and OA will perform an exhaustive and comprehensive search to identify all relevant studies regardless of 
language or publication status (published, unpublished, in press and in progress).   
ELECTRONIC SEARCHES  
This process will include searching the following journal and trial databases: 
 Cochrane Central Register of Controlled Trials (CENTRAL) – latest issue  
 MEDLINE 1966 to March 2011 
 EMBASE 1980 to March 2011 
 LILACS 1982 to March 2011 (La Literatura Latinoamericana y del Caribe de Information en Ciencias de la 
Salud) (www.bireme.br)  
 Cochrane Infectious Diseases Group Specialised Trials Register 
 Pan African National Clinical Trials Registry (PACTR) 
 World Health Organisation (WHO) International Clinical Trials Registry Platform (ICTRP) 
 ClinicalTrials.gov     
The following search terms (including the use of MeSH terms) will be used:  
 tuberculosis AND (“Mycobacterium w” OR immunotherapy OR immunoadjuvant OR immunomodulator OR 


















OTHER RESOURCES  
We will perform a hand-search of the reference lists of identified articles and relevant review articles. We will also do 
a manual search of abstracts or proceedings of the following conferences (2000 to present): 
 The International Union Against Tuberculosis and Lung Disease World Congress (IUATLD) 
 The American Thoracic Society International Congress (ATS) 
 The European Respiratory Society World Congress (ERS)  
In addition, we will send correspondence to all the authors of the relevant articles for any updates on their research. 
Finally, individuals and organisations working in the field of TB immunotherapy will be consulted for information 
regarding unpublished data and work in progress. 
APPENDIX 2: CURRENT TRIALS USING MYCOBACTERIUM W (TRIAL NUMBER 
AVAILABLE AT CLINICALTRIALS.GOV) 
 
1. STUDY OF MYCOBACTERIUM W IN BCG REFRACTORY SUPERFICIAL TRANSITIONAL 
CELL CARCINOMA OF BLADDER 
Condition: Superficial Transitional Cell Carcinoma 
Intervention: Biological: Mycobacterium w 
2. A STUDY OF MYCOBACTERIUM W PLUS DOCETAXEL FOR HORMONE REFRACTORY 
METASTATIC PROSTATE CANCER 
Condition: Hormone Refractory Prostate Cancer 
Interventions: Biological: Mycobacterium w 
Drug: Docetaxel 
3. A PILOT TRIAL OF ADJUNCTIVE PREDNISOLONE AND MYCOBACTERIUM WITH 
IMMUNOTHERAPY IN TUBERCULOUS PERICARDITIS 
Condition: Tuberculous Pericarditis 
Interventions: Drug: Prednisolone 
Biological: Mycobacterium w immunotherapy 
4. STUDY OF MYCOBACTERIUM W IN SUPERFICIAL TRANSITIONAL CELL CARCINOMA 
OF BLADDER 
Condition: Superficial Transitional Cell Carcinoma of Bladder 
Interventions: Biological: Mycobacterium w 


















5. EFFICACY AND SAFETY OF IMMUNOMODULATOR AS AN ADJUNCT THERAPY IN NEW 
PULMONARY TUBERCULOSIS (CATEGORY I) PATIENTS 
Condition: Tuberculosis 
Intervention: Biological: Intradermal injection of Mycobacterium w 
6. A STUDY OF MYCOBACTERIUM W IN COMBINATION WITH PACLITAXEL PLUS 
CISPLATIN IN ADVANCED NON SMALL CELL LUNG CANCER 
Condition: Non Small Cell Lung Cancer 
Interventions: Drug: Paclitaxel & Cisplatin 
Biological: Mycobacterium w 
7. EFFICACY AND SAFETY STUDY OF IMMUNOMODULATOR AS AN ADJUNCT THERAPY 
IN PULMONARY TUBERCULOSIS (TB) RETREATMENT PATIENTS 
Condition: Tuberculosis 
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MYCOBACTERIUM W  ADJUVANT IMMUNOTHERAPY IN 
PULMONARY TUBERCULOSIS –  A SYSTEMATIC REVIEW 
PANDIE S, ENGEL M, KERBELKER Z, MAYOSI BM 





Tuberculosis (TB) remains a global health catastrophe, with the major burden of disease 
concentrated in the developing world.  Current TB chemotherapies include prolonged oral and 
injectable drugs. High pill burdens and drug toxicities result in low cure and treatment 
completion rates. The investigation of new, applicable anti-TB strategies is therefore essential. 
Immunotherapies that manipulate the immune-pathogenic pathways of TB provide attractive 
options as possible adjuncts to standard TB chemotherapies. Mycobacterium w is a heat-killed 
immune-modulating vaccine designed to attenuate the effects of TB, reduce time to sputum 
conversion, and thereby decrease transmission and improve cure rates. 
OBJECTIVES  
To evaluate Mycobacterium w (M w) immunotherapy as an adjunct to chemotherapy in 
participants with pulmonary TB (PTB). 
 
 
SEARCH STRATEGY  
In March2011, we searched the Cochrane Infectious Diseases Group Specialised Register, 
CENTRAL (The Cochrane Library 2010, issue 1), MEDLINE, OVID, LILACS, the Pan African 
National Clinical Trials Registry (PACTR), the World Health Organisation (WHO) International 
Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov. In addition, we handsearched 

















conferences: the International Union Against Tuberculosis and Lung Disease World Congress 
(IUATLD), the American Thoracic Society International Congress (ATS) and the European 
Respiratory Society World Congress (ERS). Individuals and organisations working in the field of 
TB immunotherapy were also consulted for information regarding unpublished data and work 
in progress. 
SELECTION CRITERIA  
Randomised and quasi-randomised controlled trials of M w immunotherapy versus placebo (or 
no control) for participants with PTB. 
DATA COLLECTION AND ANALYSIS  
Two of the authors (SP and ZK) independently extracted data and assessed trial quality. 
Discrepancies were resolved through discussion with a third independent reviewer (ME). 
Dichotomous outcomes were analysed using risk ratios (RR) and 95% confidence intervals (CI). 
MAIN RESULTS  
Three trials (four papers) involving a total of 368 participants were included. All four papers 
had methodological flaws including inadequate or unclear sequence generation, allocation 
concealment, blinding, selective reporting, and other forms of bias. The interpretation of results 
must be viewed in this context. 
Overall, 173 participants received multi-dose M w and 168 participants received either a 
placebo vaccine or no alternative. M w immunotherapy was effective at reducing the time to 
sputum conversion at days 15 (RR 2.31; 95% CI 1.75 to 3.06; P < 0.001) and 30 (RR 1.83; 95% 
CI 1.12 to 2.98; P = 0.02) for both category I (new) and category II (re-treatment) TB 
participants. After day 30, benefit was only demonstrated in the category II TB (Day 60: RR 
1.50; 95% CI 1.10 to 2.03; P = 0.01, Day 120: RR 1.35; 95% CI 1.05 to 1.72; P = 0.02, and Day 
120+: RR 1.34; 95% CI 1.11 to 1.62; P = 0.003). We were unable to perform a meta-analysis for 





















Even though the meta-analysis suggests benefit as regards the time to sputum conversion, the 
available data on M w immunotherapy for participants with PTB are methodologically flawed. It 
is therefore difficult to advocate for routine M w usage as an adjuvant to TB chemotherapy. The 
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PLAIN LANGUAGE SUMMARY 
MYCOBACTERIUM W IMMUNOTHERAPY FOR PEOPLE WITH PULMONARY 
TUBERCULOSIS 
Immunotherapies are injections or vaccines that alter the way the human body responds to an 
infection. These therapies are often derived from actual organisms, like the organisms that 
cause leprosy and tuberculosis (TB). In preparing the immunotherapy, the organisms are killed 
by exposure to heat, and the remaining particles are used to produce the injection or vaccine. As 
a result of this heat killing process, there is no risk of the injection causing an infection. 
Mycobacterium w (M w) is an immunotherapy. Scientists and doctors have studied the response 
to M w in both mice and humans. The research suggests that it may be beneficial in people with 
TB, especially in that it reduces the time it takes for the TB organisms to clear from the lungs. 
The trials conducted thus far strongly suggest that the addition of M w to standard TB treatment 
produces better results. Our review analysed three trials that used M w as immunotherapy. 
Even though the results of this overview support the fact that M w improved the time it took for 
sputum to become TB-organism free (sputum conversion), the trials themselves were poorly 
designed, making it difficult to put much statistical weight behind the results. 
Thus, given the lack of valid evidence, we recommend that a well-structured, well-designed trial 
needs to be conducted in order to answer the question about the effectiveness of M w as an 

















Tuberculosis (TB) remains a global health catastrophe. The 2009 Global TB Control Update 
reported 9.4 million incident cases and 11.1 prevalent cases of TB; with 1.82 million TB-
associated deaths (0.52 million in HIV positive individuals). The major burden of disease is 
concentrated in the developing world (WHO 2009). In Africa, the annual incidence continues to 
increase because of the Human Immunodeficiency Virus (HIV) epidemic (Murray 2004). The 
TB-HIV epidemic has been compounded by the emergence of drug resistant TB. Multi-drug 
resistant (MDR) TB is defined as resistance to both isoniazid and rifampicin, the two drugs 
regarded as the most effective TB chemotherapy. On a global scale, MDR TB is reported to 
account for 10% of the 9 million new cases of TB that occur annually (Mitnick 2007). 
Extensively-drug resistant (XDR) TB is defined as MDR plus resistance to a fluoroquinolone and 
second-line injectable. Current treatment strategies for drug-sensitive, MDR and XDR TB include 
prolonged oral and injectable drug therapies. Treatment regimens are problematic because of 
high pill burdens and drug toxicities, which result in low cure and treatment completion rates. 
The investigation of novel, applicable anti-tuberculosis strategies is therefore essential. 
The immunopathogenesis of TB involves a complex interplay between bacteriostatic and 
bactericidal immune pathways. Bacteriostatic processes result in a walled-off granuloma, while 
the bactericidal processes of autophagy, apoptosis, and cytotoxic T-cell destruction, result in cell 
death (Churchyard 2009). A combination of the traditionally known T-helper 1 (Th1) response 
(key cytokines include interferon (IFN) gamma, tumour necrosis factor (TNF) alpha, and 
interleukin (IL) 15) and cytotoxic T-lymphocyte (CTL) killing is thought to provide the optimal 
immune protection against TB. The T-helper 2 (Th2) response (IL-4, Transforming Growth 
Factor (TGF) beta, IL -10) directly reduces the immune response to TB by both delaying the 
maturation of Th1 cells, and by inhibiting the production of cytokines that drive Th1 and CTL 
cells. Therefore, the ideal immunotherapeutic strategy would be to inhibit Th2 while enhancing 
the protective Th1 and CTL pathways. 
  
Mycobacterium w (M w) is a non-pathogenic, saprophytic, rapidly growing atypical 
Mycobacterium species with immuno-potentiating properties. Recent polyphasic taxonomic 
analysis classified M w as a distinct species, Mycobacterium indicus pranii, placing it in the 
Runyon group IV along with M Vaccae, M fortuitum and M smegmatis (Saini 2009). Its 
uniqueness stems from its ability to undergo antigen-driven blast leukocyte transformation. 
Recent scientific experiments have shown that M w exerts its influence on the innate immune 

















TLRs (especially TLR 3, 4, 5, 6, 7, 8, and 9) and antagonise TLR ligands (Khamar 2008). This 
finding has spurred new interest in the potential benefits of M w usage, particularly in 
conditions that are associated with up-regulation or over-expression of TLRs, such as sepsis and 
chronic airway diseases. Interestingly, PTB is also associated with selective up-regulation of 
TLRs (Chang 2006). 
An extensive body of data supports the safety and efficacy of M w in the prevention and 
treatment of leprosy (Nath 1998, Sharma 2005). Laboratory, animal and clinical work 
investigating M w use in TB suggests reduction in time to sputum conversion (a proxy for cure), 
and thus a potential reduction in spread of disease.  
M w shares B and T-cell antigen epitopes with Mycobacterium leprae and Mycobacterium 
tuberculosis (Ganju 1990, Singh 1991). The initial work (animal trials and phase I - III human 
clinical trials) has resulted in the use of M w as an adjuvant treatment for leprosy. This outcome 
is testament to the hypothesis that the use of M w as an immune modulator for diseases with 
overlapping Mycobacterium antigens, is both scientifically plausible and clinically relevant to 
investigate. 
In humans, injection of heat-killed M w was tested as an adjunct to standard antibiotic therapy 
in phase three clinical trials of lepromatous leprosy. Participants with leprosy received multi-
drug therapy (MDT) plus M w, while the control arm received MDT plus a placebo injection. This 
study showed that bacteriological clearance was more rapid in the M w group (P < 0.03) (Zaheer 
1995). There was also an associated decrease in the number of organisms (bacillary load), 
shorter duration of antibiotic therapy, and earlier discharge from care (Zaheer 1995, Sharma 
2000, Kaur 2002). In healthy contacts of leprosy patients, M w was associated with protection 
from leprosy infection (Sharma 2005). Sharma et al vaccinated a total of 24,060 household 
contacts with M w or placebo in a double-blind, randomised controlled trial. Participants were 
followed at 3 yearly intervals for 8-10 years. M w showed a protective efficacy of 68%, 59% and 
39.3% at the respective follow-up intervals. The safety and efficacy of M w has thus been well 
established through widespread use as an adjuvant therapy for leprosy treatment and 
prevention. 
As regards TB, multiple laboratory studies have demonstrated that mice immunised with heat-
killed M w had increased Th1 lymphocyte and macrophage activity, with a cytokine 
environment that was predominantly IL-2 and IFN-gamma. In addition, immunised mice were 
protected from sub-lethal challenge with M. tuberculosis (Gupta 2009, Guleria 1993, Singh 
1992). Human data of heat-killed M w use as immunotherapy for active TB are not definitive.  
Results from published and unpublished clinical trials suggest that M w administration is 

















Patel 2003, Luhadia 2004). In addition, Katoch reviewed the participants (healthy contacts) of 
the leprosy studies looking for evidence of new TB infection (Katoch 2008). The results suggest 
that M w significantly (P < 0.01) reduced the rate of new TB infection. 
In terms of safety, M w has been administered to thousands of participants in multiple trials and 
studies, with no reports of any serious adverse events. The accepted chronology of the “normal” 
local skin reaction to the vaccine is: 
(1) a small pustule between days four to five; 
(2) mild ulceration between days seven and ten; and 
(3) formation of a scab by 1 month post administration. 
Any skin changes that are not in keeping with this sequence of events are considered an 
accelerated or exaggerated reaction i.e. adverse reaction (Luhadia 2004). Even so, all published 
studies have concluded that M w is safe, with reported side effects invariably being self-limiting. 
The TB-HIV epidemic is a health crisis, and current therapeutic options for TB are sub-optimal. 
Immunotherapeutic interventions may facilitate the fight against TB. Understanding the 
immunopathogenesis of TB is crucial in the development of appropriate anti-TB strategies 
(Dheda 2010). Laboratory, animal and clinical work investigating M w use in TB suggests a 
reduction in time to sputum conversion (a proxy for cure), and thus the potential to reduce the 
spread of disease. This systematic review aims to analyse the evidence of the effectiveness of M 
w vaccination as an adjunctive treatment for PTB. This information will be helpful for policy 

















To evaluate M w immunotherapy as an adjunct to chemotherapy in participants with PTB. 
We reviewed the available data as regards M w usage in PTB, focusing on the effects of M w 
immunotherapy on: 
(1) sputum conversion; 
(2) mortality; and 
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CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW 
TYPES OF STUDIES  
Randomised and quasi-randomised controlled trials of M w immunotherapy in participants 
diagnosed with PTB. 
TYPES OF PARTICIPANTS  
Participants diagnosed with PTB either by sputum smear microscopy, sputum culture, or 
culture of material from a clinically affected anatomical site. 
TYPES OF INTERVENTIONS  
Intervention: inoculation with at least one dose of heat-killed M w. 
Control: placebo injection or no control. 
Other: chemotherapy for TB (according to World Health Organisation (WHO) guidelines for 
category I and category II TB). 
TYPES OF OUTCOME MEASURES  
PRIMARY OUTCOMES  
To determine the effect of M w therapy on: 
(1) sputum conversion (sputum culture negativity), assessed at days 15, 30, 60, 120, and 
beyond 120; and 
(2) mortality. 
SECONDARY OUTCOMES  
To determine the frequency of: 
(1) serious adverse reactions (fatal, life threatening or requiring hospitalisation); and 
















SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
We performed a detailed literature search for reports pertaining to the use of M w in PTB. 
Selected articles were reviewed for standardised data extraction and analysis. 
The project team consisted of three main contributors: 
(1) Dr. Shaheen Pandie (SP), who functioned as the primary investigator and was 
responsible for all aspects of the project; 
(2) Mr. Mark Engel (ME), who was responsible for independently completing the literature 
search and verifying the data that were collected, as well as functioning as co-supervisor 
on the project; 
(3) Dr. Zita Kerbelker (ZK), who was responsible for independently extracting the data; and  
(4) Professor Bongani Mayosi (BM) who functioned as the project supervisor. 
We performed an exhaustive and comprehensive search to identify all relevant studies 
regardless of language or publication status (published, unpublished, in press and in progress). 
ELECTRONIC SEARCHES  
This process included searching the following journal and trial databases: 
(1) the Cochrane Infectious Diseases Group Specialised Trials Register 
(2) CENTRAL (The Cochrane Library 2010, issue 1); 
(3) MEDLINE (January 1966 to March 2011); 
(4) OVID (January 1980 to March2011); 
(5) LILACS (La Literatura Latinoamericana y del Caribe de Information en Ciencias de la 
Salud)(January 1982 to March 2011); 
(6) the Pan African National Clinical Trials Registry (PACTR); 
(7) the World Health Organisation (WHO) International Clinical Trials Registry Platform 
(ICTRP); and 
(8) ClinicalTrials.gov. 
The following search terms (including the use of MeSH terms) were used: tuberculosis AND 
(“Mycobacterium w” OR immunotherapy OR immunoadjuvant OR immunomodulator OR Immu-
vac® OR Mycobacterium indicus pranii) cross-referenced with an isolated search for 

















SEARCHING OTHER RESOURCES  
We performed a handsearch of the reference lists of identified articles and relevant review 
articles. We also did a manual search of abstracts or proceedings of the following conferences: 
(1) the International Union Against Tuberculosis and Lung Disease World Congress 
(IUATLD) (January 2000 to May 2010); 
(2) the American Thoracic Society International Congress (ATS) (January 2000 to May 
2010); and 
(3) the European Respiratory Society World Congress (ERS). 
In addition, we sent correspondence to the authors of the relevant articles, enquiring about any 
updates on their research. Finally, we consulted individuals and organisations working in the 
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DATA COLLECTION AND ANALYSIS 
SELECTION OF STUDIES  
SP and ZK reviewed all relevant material identified from the above search. After reading the 
titles and abstracts of the identified articles, we acquired the full text articles of all citations 
deemed to meet the inclusion criteria. These articles were then independently inspected to 
verify that they met the inclusion criteria. 
DATA EXTRACTION AND MANAGEMENT  
We extracted the data using a standardised data extraction form (Appendix 1). Any 
discrepancies were resolved through discussion of the original articles with BM. The following 
characteristics were extracted from each included study: 
(1) Administrative details: trial identification number, title, author (s), published or 
unpublished, year of publication, number of studies included in the paper, year in which 
the study was conducted, and details of other relevant papers cited; 
(2) Verification assessment: assessment to ensure that the study met the inclusion criteria 
for the systematic review; 
(3) Details of study: study design, duration and completeness of follow-up, country and 
location of study, informed consent, and ethics approval; 
(4) Details of participants: setting, number and relevant baseline characteristics, category of 
PTB (I or II); 
(5) Details of intervention: M w dosage, duration, and mode of administration; 
(6) Details of control: placebo or no vaccine control, completeness of treatment; 
(7) Details of outcomes: sputum conversion at various stages of therapy, mortality, adverse 
events; and 
(8) Notes: general comments. 
ASSESSMENT OF RISK OF BIAS IN INCLUDED STUDIES  
We independently examined the components of each included trial for risk of bias. The 
assessment focused on information regarding sequence generation, allocation concealment, 
blinding, incomplete outcome or missing data, selective outcome reporting and other sources of 

















per the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008). It was then 
recorded on the data collection sheet. 
MEASURES OF TREATMENT EFFECT  
Data were analysed using Review Manager 5.0. Outcomes (sputum conversion (cure), death, 
adverse events) were considered as dichotomous variables. Outcome measures were calculated 
using risks ratios (RR) with 95% confidence intervals (CI). 
DEALING WITH MISSING DATA  
We made every effort to contact the original authors or investigators of the selected articles to 
help address the issues of missing or incomplete data.   
ASSESSMENT OF HETEROGENEITY  
Heterogeneity between trials was assessed using the chi-squared test set at a 10% level of 
significance. The impact of statistical heterogeneity was quantified using the I2 statistic 
(Appendix 2). Because there was an acceptable degree of lack of heterogeneity, it was 
appropriate to pool the data. Using the Mantel-Haenszel statistical method and random-effects 
model, the results were generated in the form of a meta-analysis. Data that could not be 
analysed as part of the meta-analysis are presented in a narrative form. 
SUBGROUP ANALYSIS AND INVESTIGATION OF HETEROGENEITY  
In addition to evaluating all PTB participants, we analysed the subgroups of category I (new 
infections) and category II (retreatment or relapse) PTB. The same statistical analysis was used 
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DESCRIPTION OF INCLUDED STUDIES 
Luhadia (Luhadia 2004) presented the findings of his single-blind, placebo-controlled study of 
M w as immunotherapy for treating PTB at the National Conference on Pulmonary Diseases 
(NAPCON) in India in 2004. Two hundred sputum-positive participants were randomised to 
either M w or placebo, with background standard TB chemotherapy. There were 100 category I 
(new cases) and 100 category II (retreatment) TB cases. 0.1 ml M w or saline placebo was given 
intradermally on days zero, 15, 30, 60 and then two-monthly until completion of treatment. The 
diagnosis of TB was made on sputum examination. Sputum samples were collected at each 
follow-up visit (days 0, 15, 30, 60, and 120). Radiographs were performed on days zero, 60, 120, 
and at the end of treatment. For the category I group, 50 participants were randomised to M w, 
and 50 to the placebo arm. The same division occurred with the category II participants (50 M w 
versus 50 placebo). The groups were evenly matched for age (mean age 35.5) and weights 
(41kg in males and 32kg in females). 
In the category I subgroup, sputum conversion was 97% at 15 days and 100% at 30 days in the 
M w group compared to 42% at 15 days and 75 % at 30 days in the placebo group. At the end of 
two months (60 days) the control group reach 93.5% sputum conversion rate. M w thus 
preponed sputum conversion by 45 days. There were no deaths or adverse reactions reported. 
In the category II sub-group, 41% sputum conversion was achieved at the end of 15 days in the 
M w arm; while it took 60 days to achieve a 39% sputum conversion in the placebo arm. There 
were four deaths, two reported in each arm respectively. The M w arm also had two participants 
with an accelerated local skin reaction. 
Patel (Patel 2002) completed a single-centre pilot study that randomised 134 consecutive PTB 
participants who were sputum positive. Both category I (58) and category II (76) cases were 
randomly assigned to TB chemotherapy plus M w, or TB chemotherapy alone. M w was 
administered on day one, then fortnightly for two months. Sixty-nine participants were 
randomised to the M w arm and 65 to the control arm. Sputa specimens were collected for 
laboratory examination before treatment, and then on days 15, 30, 45 and 60. The laboratory 
examiner was blinded to the type and duration of treatment. The M w treatment group had a 
significantly faster sputum conversion rate at days 15, 30, and 45 overall; and for both category 
I and category II subgroups. The sputum conversion rate achieved at day 60 in the control arm 
was achieved at day 30 in the M w group, i.e. M w preponed sputum conversion by at least 30 
days. No major adverse events were reported, and local side effects like skin induration and 

















Even though these results are very impressive, a major criticism of the trial is the flawed 
methodology. Even though the two arms seem to be evenly matched (69 versus 65 
participants), there was inequality in the sex distribution (102 males and 32 females), and in the 
category I and II subgroups. It is not clear whether this reflects a lack of appropriate sequence 
generation, allocation or stratification of the randomisation. As a result, the M w arm had 20 
category I and 49 category II participants, while the control arm had 38 and 27 respectively. In 
addition, it is not clear whether the category I and II subgroups were prespecified. 
In 2003, Patel (Patel 2003) published a post-hoc analysis of the 2002 paper. It involved a 
records review of the category II TB participants that were originally enrolled in the trial. Sputa 
samples were analysed at three, five and eight months (for sputum negative participants); and 
at four, six and nine months (for sputum positive participants). Again, the laboratory technician 
was blinded to the treatment type and duration. The total number of category II cases reviewed 
was 76, of which 49 were in the M w arm and 27 in the control group. Participants that were 
randomly assigned to the M w arm received 0.2 ml M w (0.1 ml in each deltoid) at day one, then 
0.1 ml fortnightly for two months. No placebo was given to the control arm. All the participants 
completed the respective treatments. The results showed that sputum clearance at follow up 
visits (three and four months, and 2 months post-intensive phase of TB treatment) was better in 
the M w arm. The M w arm also had lower treatment failure rates. No major adverse events, 
including all-cause and TB-related mortality, were reported. As mentioned previously, this is a 
post hoc analysis of a non-a priori specified subgroup with unequal numbers in the two 
comparative groups, which makes the value of the data questionable and non-generalisable. 
Parikh's (Parikh 2006) study was a randomised, double-blind, placebo-controlled trial 
investigating the role of M w in the management of TB hydropneumothorax as an adjuvant to TB 
chemotherapy and intercostal tube drainage (ICTD). Thirty-four participants with TB-related 
pleural effusions (including category I and II TB participants, both sputum smear positive and 
negative) were randomised to M w or control arms. Eighteen participants were randomised to 
M w plus TB chemotherapy and ICTD (4 out of 18 smear positive, 14 out of 18 smear negative, 2 
out of 18 category I, and 16 out of 18 category II). M w was administered intradermally (0.2 ml 
on day zero, followed by 0.1 ml on days 15, 30, 60, 120, 180 and till the end of TB treatment). 
Sixteen participants were randomised to the control arm which included TB chemotherapy and 
ICTD (3 out of 16 smear positive, 13 out of 16 smear negative, 2 out of 16 category I, and 14 out 
of 16 category II). 
The M w arm had faster time to removal of ICTD with 72% removal within 22 days versus 
37.5% in the control arm. The decision to remove the ICTD was determined by the attending 

















compare number of days taken for removal of ICTD between the two groups: the M w arm had a 
faster (15.1 ± 8.58 days) removal as compared to the control arm (43.9 ± 31.6 days); with a P 
value of < 0.001. Sputum conversion was faster in the M w arm (18.8 ± 7.5 days) compared to 
the control arm (96.7 ± 40.4 days), with a P value of < 0.012. 
This was a very small study, with only 7 out of 34 participants being sputum positive. There was 

















RESULTS OF LITERATURE SEARCH 






















FIGURE 1: FLOW DIAGRAM OF SEARCH RESULTS 
Figure 1 summarises the results of the literature search. There were three studies (four papers) 
that met the inclusion criteria. Two studies were randomised controlled trials using M w as an 
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immunotherapy in confirmed PTB (category I and II) (Luhadia 2004, Patel 2002), one study was 
a post-hoc analysis (with extended follow up) of M w usage in category II participants (Patel 
2003), and one study included participants with TB pleural effusions (Parikh 2006). Two of the 
papers were published (Patel 2002, Patel 2003), while the remaining two were abstracts 
presented at conferences (Luhadia 2004, Parikh 2006). 
METHODOLOGICAL QUALITY 
Figures 2 and 3 are graphic representations of the assessment of risk of bias including the 
components of allocation, blinding, dealing with incomplete data, selective reporting and other 
potential sources of bias. All these components were assessed as being adequate, inadequate or 
unclear (Higgins 2008). Limited information was provided as regards the aspects of 
randomisation (i.e. sequence generation and allocation concealment). All three studies were 
regarded as either inadequate or unclear. For all three studies, blinding was considered 
adequate in terms of the primary outcome. For other outcomes (adverse events, clinical and 
radiological improvements), the blinding was inadequate. There was no missing data in any of 
the studies. Two out of the three studies (Patel 2002, Luhadia 2004, Parikh 2006) include 
reporting on all the expected outcomes, and were therefore scored as adequate. The Patel 2003 
paper could be considered as selective reporting because there was no pre-specification of the 
category II TB subgroup. All three studies are at risk of other sources of bias, including selection, 
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SUMMARY OF THE MAIN RESULTS  
Three trials (four papers) involving 368 participants were included. There was a total of 341 
confirmed, smear positive PTB participants. 158 Were regarded as category I TB, 176 as 
category II TB, and 7 were unclassified. Overall, 173 participants (70 category I, 99 category II, 
and 4 category uncertain TB) received multi-dose M w immunotherapy therapy, and 168 
participants (88 category I, 77 category II, and 3 category uncertain TB) received either placebo 
vaccinations or no alternative. All participants had standard TB chemotherapy as per WHO 
guidelines. The meta-analysis was performed for the following outcomes of sputum conversion 
at days 15, 30, 60, 120 and beyond. Participants were divided into the subgroups of category I 

















SPUTUM CONVERSION AT DAY 15 
See Analysis 1.1, Figure 4 
M w usage has a significant effect on early sputum conversion from positive to negative at day 
15 (P < 0.001). The meta-analysis included 341 participants. Overall, the M w group had 88 
sputum negative participants out of 173, compared to 37 out of 168 in the control arm; with a 
risk ratio (RR) of 2.31 and a 95% confidence interval (CI) of 1.75 to 3.06. These results were 
reflected throughout the subgroups of category I (RR 2.25; 95% CI 1.64 to 3.09; P < 0.001) and 
category II (RR 2.25; 95% CI 1.33 to 4.51; P < 0.001). The uncertain category had 3 participants 
in the M w group and nil in the control group (RR 5.6 and a wide 95% CI 0.39 to 79.7). There 
was lack of heterogeneity (chi squared = 0.71; I2 = 0%) making it appropriate to combine the 
studies and the subgroup. 
FIGURE 4: FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.1 


















SPUTUM CONVERSION AT DAY 30 
See Analysis 1.2, Figure 5 
M w usage has a significant effect on sputum conversion from positive to negative at day 30 (P = 
0.02). Of the 173 participants in the M w group, 109 were sputum negative, compared to 65 out 
of 168 in the control group (RR 1.83; 95% CI 1.12 to 2.98). Results for the subgroups were 
similar: category I TB subgroup had a RR of 1.34 with a 95% CI 1.07 to 1.66; and category II TB 
subgroup had a RR 2.28 and a 95% CI 1.37 to 3.77. There was heterogeneity within the 
subgroups (chi squared = 12.20; I2 = 67%). 
FIGURE 5: FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.2 



















SPUTUM CONVERSION AT DAY 60 
See Analysis 1.3, Figure 6 
At day 60, the effect of M w on sputum conversion is no longer statistically significant for 
category I TB (RR 1.17; 95% CI 0.88 to 1.56; P = 0.19), and overall (RR 1.38; 95% CI 0.99 to 1.92; 
P = 0.06). There was still statistically significant benefit for the category II subgroup (RR 1.50 
and 95% CI 1.10 to 2.03; P = 0.001). Again, the groups seem to be heterogenous (Chi2 = 12.94 
and I2= 69%). 
FIGURE 6: FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.3 


















SPUTUM CONVERSION AT DAY 120 AND BEYOND 
See Analysis 1.4, Analysis 1.5, Figure 7 and Figure 8 
Only participants in the category II TB and uncertain category subgroups were reported on at 
day 120. In the M w group, 77 participants (out of 103) had converted to sputum negative, 
compared to 41 out of 80 in the control group (RR 1.35; 95% CI 1.05 to 1.72; P = 0.02). 
Beyond day 120, only data on the category II TB subgroup is reported. The benefit of M w usage 
for sputum conversion extends beyond 4 months in participants with category II TB (RR 1.34; 
95% CI 1.11 to 1.62; P = 0.003). 
FIGURE 7: FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.4 
SPUTUM NEGATIVE AT DAY 120. 
 
FIGURE 8: FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.5 


















MORBIDITY AND MORTALITY 
Luhadia 2004 reported 2 deaths in the M w group and 2 deaths in the control group, as well as 2 

















METHODOLOGICAL QUALITY  
A major criticism of all the included studies is methodological flaws. These include published or 
presented data that do not meet the criteria set out in the CONSORT statement (Schulz 2010); 
making it difficult to provide any meaningful commentary on issues of randomisation, allocation 
concealment, and sources of bias. 
ALLOCATION  
As regards the aspects of randomisation (i.e. sequence generation and allocation concealment), 
all three studies provided limited information, and were therefore regarded as either 
inadequate or unclear. The lack of adequate randomisation seriously influences the way in 
which the results of all three studies are interpreted.  
BLINDING  
In terms of the primary outcome of sputum conversion, ensuring that the laboratory technician 
is blinded to both type and duration of therapy is the most pivotal step in ensuring the blinding 
process. For all three studies, blinding of assessors was considered adequate in terms of the 
primary outcome. For secondary outcomes (adverse events; clinical and radiological 
improvements), the blinding was inadequate. In general, the blinding process for vaccines that 
cause "normal" or "accepted" skin reactions, is difficult. Even with placebo vaccines (saline), less 
of a skin reaction is expected, making it difficult to blind a clinical assessor. We therefore 
considered that there is sufficient evidence to only evaluate our primary outcome. 
INCOMPLETE OUTCOME DATA  
No loss to follow up was reported, nor were there any missing data in the studies. 
SELECTIVE REPORTING  
For all three studies, there was no protocol available for review even after correspondence with 
the authors. Despite this, it is clear that two out of the three studies include reporting on all the 
expected outcomes, and were therefore scored as adequate. We considered the Patel 2003 


















OTHER POTENTIAL SOURCES OF BIAS  
Due to the possible errors in randomisation, all three studies are at risk of other sources of bias 
including selection, performance, and detection bias.  
The lack of placebo control in Luhadia’s 2004 study may have led to bias in the evaluation of 
clinical outcomes such as adverse reactions, clinical improvement, and radiological resolution; 
as the assessor was not blinded to the intervention.  
There is strong selection or referral bias evident in Patel 2002, Patel 2003 and Parikh 2006. 
These manifested as discrepant category I and II TB participants, and uneven numbers of males 
to females being enrolled. In Parikh 2006 there was also assessment bias in that the timing of 
intercostal drain removal was clinician determined. 
EFFICACY OF M w  
The meta-analysis of the included trials suggest that M w has a significant effect on sputum 
conversion for both category I and II TB at days 15 (P < 0.001) and 30 (P = 0.02). From day 60 
onwards, the benefit persists for those participants with category II TB (day 60 P = 0.001; day 
120 P = 0.02; and day 120+ P = 0.003). However, results were not available for all the outcomes 
we wished to evaluate. Out of the three included studies, only Luhadia 2004 reported deaths 
and adverse events.  
In the comparison of the M w group to the control arm, M w early in the course of TB treatment 
was favoured in terms of reducing the time to sputum conversion. These results were reflected 
throughout the subgroups of category I and category II at days 15 and 30. These results suggest 
that M w usage has a significant effect on early sputum conversion from positive to negative.  
By day 60, the initial effect of M w seems to taper for category I TB, and categories I and II 
combined. This may reflect the efficacy of the intensive phase of the WHO recommended anti-
tuberculous treatment (WHO 2009). By the end of 2 months, standard therapy usually results in 
bacteriological clearance in approximately 75% (range 61.7 to 90.9%) of drug-sensitive smear 
positive cases (Rieder 1996).  For the category II subgroup, the benefit of M w seems to persist 
at day 60. This is consistent with the understanding that category II TB patients require an 
extended intensive phase of anti-tuberculous treatment (Rieder 1996).  
Only participants in the category II TB and uncertain category TB subgroups were reported at 
day 120. In the M w group, 77 out of 103 participants had converted to sputum negative, 
compared to 41 out of 80 in the control group, confirming that the benefit of M w usage for 

















implies that category II TB participants benefit from M w administration even after being on 
anti-tuberculous treatment for more than 4 months.  
Only Luhadia 2004 reported on mortality and adverse reactions. Because so few events were 
reported, it is impossible to make any meaningful statistical assumptions, though it seems 
unlikely that the deaths were attributable to M w.  
Even though the other papers eluded to self-limiting skin reactions, there was no formal 
reporting of adverse skin reactions. There appears to be an "accepted" degree of local reaction 
to the M w injection. Only reactions that occur too rapidly or that progress beyond mild 
ulceration are regarded as adverse. The lack of reporting on adverse events (including death) 
made it impossible to report these outcomes in the format of a meta-analysis. 
QUALITY OF THE EVIDENCE  
The above meta-analysis provides support for the efficacy of M w usage in participants with 
PTB, clearly demonstrating a significant reduction in the time to sputum conversion. 
Unfortunately, these results are overshadowed by the methodological flaws identified in the 
assessment of risk of bias. Inadequate randomisation, sequence generation, allocation 
concealment, and various forms of bias (selection, clinical, or performance) make the results of 
the included studies unreliable. For some of the measured outcomes, there appeared to be a 
moderate degree of heterogeneity. This is most likely attributable the combination of above 


















IMPLICATIONS FOR CLINICAL PRACTICE  
The use of M w immunotherapy for reducing the time for sputum conversion in participants 
with PTB appears promising, but the available data are methodologically flawed, with multiple 
sources of bias. There is insufficient evidence to make recommendations for clinical practice. 
IMPLICATIONS FOR RESEARCH  
This review has demonstrated the need for well-structured, randomised controlled trials 
assessing the role of M w adjuvant therapy. There are three such trials currently recruiting 
participants (NCT00265226; NCT00341328; NTC00810849). 
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CHARACTERISTICS OF INCLUDED STUDIES 
LUHADIA 2004 
Methods Randomised placebo-controlled trial set in Udaipur, India 
Sequence generation: no information provided 
Allocation concealment: no information provided 
Blinding: single-blind 
Participants 200 Sputum smear positive PTB participants
CATEGORY I (new diagnosis)
Total: 100 participants
Mean age: 36 years
Mean weight: 36.7 kg
M w arm: 50 participants
Control arm: 50 participants
CATEGORY II (retreatment)
Total: 100 participants
Mean age: 35 years
Mean weight: 37.7 kg
M w arm: 50 participants
Control arm: 50 participants
Interventions Intervention: 0.1 ml of M w administered intradermally on days 0, 15, 30, and
60; and then two monthly until TB treatment is complete
Control: placebo - 0.1 ml of saline administered intradermally (as above)
Other: all participants received standard TB treatment as per WHO guidelines
Outcomes Sputum conversion (on days 15, 30, 60, 120, and 120+) 
Adverse events (including death and skin reactions) 
Other clinical (weight gain) and radiological improvements 
Notes This paper was presented as a poster presentation at the National Conference 
on Pulmonary Diseases (NAPCON) in 2004 
There is limited data as regards the methodology of the trial 

















RISK OF BIAS TABLE 
Item Judgement Description 
Adequate sequence 
generation? 
Unclear No information provided 
Paper states that it is a randomised controlled trial, but does not 









Even though there is no detail provided about the blinding, the primary 
outcome of sputum negativity is a laboratory-assessed outcome that is 
unlikely to be influenced by whether or not the participant or clinician 





For the secondary outcomes (adverse events, clinical improvement and 
radiological resolution), single blinding is insufficient. Both the 





No missing data 
Free of selective 
reporting? 
Yes Study protocol is not available but it is clear that the presented reports 
include all expected outcomes 
Free of other bias? No Performance bias. 
Only single-blind (it is not specified if the laboratory technician, 
clinician or the participant were blinded) 
May influence the evaluation of clinical outcomes such as adverse 
reactions, clinical improvement and radiological resolution 
PARIKH 2006 
Methods Randomised, placebo-controlled trial set in India 
Primary aim was to evaluate if the addition of M w to standard TB 
chemotherapy would reduce the time to intercostal tube drainage (ICTD) 
removal in participants with TB hydropneumothoraces 
Sequence generation: no information provided 
Allocation concealment: no information provided 
Blinding: double-blind 
Participants 34 Participants with TB hydropneumothoraces diagnosed using Light's 
criteria* 
4 Smear positive PTB participants enrolled into M w arm 
3 Smear positive PTB participants enrolled into control arm 

















Interventions Intervention: M w 0.2 ml on day zero, followed by 0.1 ml on days 15, 30, 60, 
120, 180, and until completion of TB chemotherapy 
Control: placebo administered as above 
All patients received standard TB treatment as per WHO guidelines 
Category I: rifafour, isoniazid, pyrazinamide and ethambutol (RHZE) for two 
months; and rifampicin and isoniazid for four months 
Category II: streptomycin plus RHEZ (SRHEZ) for two months; RHEZ for one 
month; and HER for five months 
Outcomes Resolution of hydropneumothorax and removal of ICTD 
Sputum conversion 
Weight gain 
Notes This paper was presented as a poster presentation at the TB Vaccines for the 
World Conference in 2006 
Limited data is provided as regards the methodology of the trial 
The authors were contacted in this regard, but no reply was received 
According to Light's criteria (Light 1972), a pleural effusion is likely exudative 
if at least one of the following exists: 
 The ratio of pleural fluid protein to serum protein is greater than 0.5; 
 The ratio of pleural fluid LDH to serum LDH is greater than 0.6; or 
 Pleural fluid LDH is greater than 0.7 times the normal upper limit for 
serum 
RISK OF BIAS TABLE  


















Even though it is not stated clearly, the only way there can be a 
double-blind is if a placebo was administered and neither the 





No missing data 
Free of selective 
reporting? 
Yes Study protocol is not available but it is clear that the presented 
reports include all expected outcomes 
Free of other bias? Unclear 

















only four category I participants and 30 category II participants 
Clinical bias: assessment of severity of hydropneumothoraces and 
timing of ICTD removal were clinician dependant 
PATEL 2002 
Methods Quasi-randomised controlled pilot study set in Ahmedabad, India 
Sequence generation: no information provided 
Allocation concealment: no information provided 
Blinding: single-blind 
Participants OVERALL 
134 Consecutive smear positive PTB participants (102 males and 32 females; 
mean age 36.2 years (range 15 to 75 years)) 
M w arm: 69 
Control arm: 65 
CATEGORY I 
Total: 58 participants 
M w arm: 20 
Control arm: 38 
CATEGORY II 
Total: 76 participants 
M w arm: 49 
Control arm: 27 
Interventions Intervention: 0.2 ml (0.1 ml in each deltoid) M w intradermal injection given on 
day zero, followed by 0.1 ml fortnightly for two months 
Control: no placebo given 
All participants received standard TB treatment as per WHO guidelines 
Category I: RHZE for two months and RH for four months 
Category II: SRHEZ for two months, RHEZ for one month, and HER for five 
months 
Outcomes Sputum conversion 
Adverse reactions 
Notes Inequality in number of male to female participants, and the ratio of category I 
to category II participants, give the impression that there was an error in 
randomisation. 
RISK OF BIAS TABLE  
Item Judgement Description 
Adequate sequence 
generation? 
No No information has been provided as regards randomisation 

















suspicious of the method of randomisation 
Failure to stratify or pre-specify the groups in terms of category I 
versus category II has resulted in unequal numbers of participants 
in comparative groups 






Laboratory technician blinded to treatment allocation 
Blinding? (Secondary 
outcome: Adverse events) 
No Single-blind 
Insufficient for the assessment of adverse events 
Incomplete outcome data 
addressed? 
Yes 
No missing data 
Free of selective 
reporting? 
Yes Study protocol is not available, but it is clear that the published 
reports include all expected outcomes 
Free of other bias? No Selection or referral bias: more males than females, and more 
category II than category I participants 
PATEL 2003  
Methods Follow-up of selected group (category II) from Patel 2002 pilot study 
Quasi-randomised controlled pilot study set in Ahmedabad, India 
Sequence generation: no information provided 
Allocation concealment: no information provided 
Blinding: single-blind 
Participants 134 Consecutive smear positive PTB participants 
M w arm: 69 
Control arm: 65 
CATEGORY II 
Total: 76 participants 
M w arm: 49 
Control arm: 27 
No additional baseline data available 
Interventions Intervention: 0.2 ml (0.1 ml in each deltoid) M w intradermal injection given on 
day zero, followed by 0.1 ml fortnightly for two months 
Control: no placebo given 
All participants received standard TB treatment as per WHO guidelines 
Category II: SRHEZ for two months, RHEZ for one month, and HER for five 
months 

















Notes Presented as a separate paper, but participants are from the Patel 2002 paper 
It is unclear whether category II group of participants was a prespecified 
subgroup 
RISK OF BIAS TABLE  
Item Judgement Description 
Adequate sequence 
generation? 
No No information has been provided as regards randomisation 
The unequal numbers of male to female participants makes one 
suspicious of the method of randomisation 
Failure to stratify or prespecify groups in terms of category I 
versus category II has resulted in unequal numbers of 
participants in comparative groups 






Laboratory technician blinded to treatment allocation 
Blinding? (Secondary 
outcome: Adverse events) 
No Single-blind 
Insufficient for the assessment of adverse events 
Incomplete outcome data 
addressed? 
Yes 
No missing data 
Free of selective reporting? No Study protocol is not available 
The published reports do not include all expected outcomes 
Free of other bias? No Selection or referral bias: more males than females 
Category II subgroup was not pre-specified 
CHARACTERISTICS OF EXCLUDED STUDIES 
CHADDA 2002  
Reason for exclusion Not a randomised controlled or quasi-randomised controlled trial 
KATIYAR  
Reason for exclusion Not a randomised controlled or quasi-randomised controlled trial 
KATOCH 2008  


















MARTHUR 2006  
Reason for exclusion Not a randomised controlled or quasi-randomised controlled trial 
ZHOU 2002  
Reason for exclusion Intervention used was Bacillus Calmette Guerin (BCG), not M w 
 
CHARACTERISTICS OF ONGOING STUDIES  
NCT00265226  
Study name Efficacy and safety study of immunomodulator (Mycobacterium w) as an adjunct 
therapy in category-II pulmonary tuberculosis along with assessment of immunological 
parameters 
Methods In progress 
Interventional, treatment, randomised, double-blind (subject and investigator), placebo 
controlled, parallel assignment, safety and efficacy study 
Participants Category II PTB participants who meet the eligibility  criteria 
Interventions Intervention: intradermal administration of Mycobacterium w, total of 6 doses given 0.2 
ml at baseline and then 0.1 ml after interval of two weeks, up to eight weeks 
Control: placebo 
Category II TB chemotherapy according to guidelines 
Outcomes PRIMARY OUTCOME MEASURES 
The time to sputum conversion  
SECONDARY OUTCOME MEASURES 
Adverse reactions (assessment of safety) 
Participant's and physicians’ global assessment of the clinical cure 
Starting date March 2005 until December 2010 
Contact information Surendra K Sharma, M.D., Ph.D 
sksharma@aiims.ac.in 
Notes On correspondence, Dr. Sharma had no preliminary data available 
NCT00341328 
Study name Efficacy and safety of immunomodulator (Mycobacterium w) as an adjunct therapy in category I 
pulmonary tuberculosis and along with assessment of immunological parameters 
Methods In progress 
Treatment, randomised, double-blind (participant and investigator), placebo-controlled, parallel 

















Participants INCLUSION CRITERIA 
 Participants of either sex aged between 18 to 60 yrs 
 Newly diagnosed PTB cases with at least two sputum samples that are positive on 
sputum microscopy 
 Participants willing to give informed consent 
EXCLUSION CRITERIA 
 Known hypersensitivity to category I TB chemotherapy 
 Known history of MDR and XDR TB (patients with Mycobacterium tuberculosis resistant 
to one or more drugs will be excluded) 
 Secondary immunodeficiency states: HIV, organ transplantation, diabetes mellitus, 
malignancy, treatment with corticosteroids 
 Hepatitis B and C positivity 
 Participants with known extrapulmonary TB 
 Currently receiving cytotoxic therapy, or having received it within the last three months 
 Pregnancy and lactation 
 Participants with a known seizure disorder 
 Participants with known symptomatic cardiac disease, such as arrhythmias or coronary 
artery disease 
 Participants with abnormal renal function 
 Participants with abnormal hepatic function (bilirubin = 1.5 mg/dl; AST, ALT, SAP more 
than 1.5 x ULN; PT = 1.3x control) 
 Participants with haematological abnormalities 
 Seriously ill and moribund patients with the complications of low lung reserve, marked 
tachypnoea, chronic cor pulmonale, congestive cardiac failure, BMI<15, and severe 
hypoalbuminaemia (< 2.5 g/dl) 
 Participants unlikely to survive for more than six months 
 Participants unable to comply with the treatment regimen 
 Participants with a history of alcohol or drug abuse 
Interventions Intervention: Intradermal injection of Mycobacterium w 
A total of 6 doses are given: 0.2 ml at baseline and then 0.1 ml after interval of two weeks up to 
eight weeks 
Control: placebo 
Outcomes PRIMARY OUTCOME MEASURES 
The time to sputum conversion 
                                                                                                                                                                   
SECONDARY OUTCOME MEASURES 
Adverse reactions 
Participant's and physicians' global assessment of clinical cure 
Starting date March 2007 
Contact 
information 






















Methods Interventional, treatment, randomised, double-blind (participant, caregiver, 
investigator, outcomes assessor), placebo controlled, factorial assignment, safety and 
efficacy study 
Participants INCLUSION CRITERIA 
Participants with a suspected tuberculous pericarditis will be eligible if they meet all 
three of the following criteria: 
 A confirmed pericardial effusion on echocardiography; 
 Evidence of definite* or probable** tuberculous pericarditis; and 
 Within one week of starting of anti-tuberculous treatment. 
EXCLUSION CRITERIA 
 Presence of an alternative cause of pericardial disease e.g. penetrating chest 
trauma in the preceding 12 months, or malignancy 
 Use of corticosteroids within the previous month 
 Hypersensitivity or allergy to the Mycobacterium w vaccine 
 Pregnancy 
 Age < 18 years 
Interventions PREDNISOLONE / PLACEBO  
Intervention: six-week tapering course of prednisolone 
Control: same number of identically-coated placebo tablets 
Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a 
dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 
mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, 
and 5 mg/day in the sixth week 
MYCOBACTERIUM w / PLACEBO  
Intervention: five doses of 0.1 ml of Mycobacterium w intradermally (on enrolment, at 
two weeks, four weeks, six weeks, and three months) 
Control: Identical regiment of normal saline placebo injections 
Outcomes PRIMARY OUTCOME MEASURES 
Composite end-point of death, constriction, or cardiac tamponade requiring pericardial 
drainage 
SECONDARY OUTCOME MEASURES 
Safety of immuno-modulator treatment 
Long-term feasibility of conducting a multi-centre trial in Africa and India 
Starting date December 2008 to December 2012 
Contact information Professor Bongani Mayosi bongani.mayosi@uct.ac.za 
Dr. Mpiko Nstekhe             mpiko.ntsekhe@uct.ac.za 
Notes The pilot phase of this study has been successfully completed, and the investigators 

















1 SPUTUM CONVERSION  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
1.1 Sputum negative at Day 15 3 341 Risk Ratio (M-H, Random, 95% 
CI) 
2.31 [1.75, 3.06] 
  1.1.1 Category I TB 3 158 Risk Ratio (M-H, Random, 95% 
CI) 
2.25 [1.64, 3.09] 
  1.1.2 Category II TB 3 176 Risk Ratio (M-H, Random, 95% 
CI) 
2.45 [1.33, 4.51] 
  1.1.3 Uncertain Category I or 
II TB 
1 7 Risk Ratio (M-H, Random, 95% 
CI) 
5.60 [0.39, 79.70] 
1.2 Sputum negative at Day 30 3 341 Risk Ratio (M-H, Random, 95% 
CI) 
1.83 [1.12, 2.98] 
  1.2.1 Category I TB 2 158 Risk Ratio (M-H, Random, 95% 
CI) 
1.34 [1.07, 1.66] 
  1.2.2 Category II TB 2 176 Risk Ratio (M-H, Random, 95% 
CI) 
2.28 [1.37, 3.77] 
  1.2.3 Uncertain Category I or 
II 
1 7 Risk Ratio (M-H, Random, 95% 
CI) 
7.20 [0.53, 97.83] 
1.3 Sputum negative at Day 60 3 341 Risk Ratio (M-H, Random, 95% 
CI) 
1.38 [0.99, 1.92] 
  1.3.1 Category I TB 2 158 Risk Ratio (M-H, Random, 95% 
CI) 
1.17 [0.88, 1.56] 
  1.3.2 Category II TB 2 176 Risk Ratio (M-H, Random, 95% 
CI) 
1.50 [1.10, 2.03] 
  1.3.3 Uncertain Category I and 
II TB 
1 7 Risk Ratio (M-H, Random, 95% 
CI) 
2.40 [0.66, 8.79] 
1.4 Sputum negative at Day 
120 
4 183 Risk Ratio (M-H, Random, 95% 
CI) 
1.35 [1.05, 1.72] 
  1.4.2 Category II TB 3 176 Risk Ratio (M-H, Random, 95% 
CI) 
1.48 [1.15, 1.91] 
  1.4.3 Uncertain category I or 
II TB 
1 7 Risk Ratio (M-H, Random, 95% 
CI) 
1.00 [0.62, 1.60] 
1.5 Sputum negative after day 
120 
2 176 Risk Ratio (M-H, Random, 95% 
CI) 

















  1.5.2 Category II TB 2 176 Risk Ratio (M-H, Random, 95% 
CI) 
1.34 [1.11, 1.62] 
2 MORBIDITY AND MORTALITY  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
2.1 Mortality 1  Risk Ratio (M-H, Random, 95% 
CI) 
No totals 
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GRAPHS AND FIGURES 
FIGURE 2  
 
RISK OF BIAS GRAPH: AUTHORS' JUDGEMENTS REGARDING EACH RISK OF BIAS ITEM 
PRESENTED AS PERCENTAGES ACROSS ALL INCLUDED STUDIES. 
FIGURE 3  
 
RISK OF BIAS SUMMARY: AUTHORS' JUDGMENTS REGARDING EACH RISK OF BIAS 

















FIGURE 4 (ANALYSIS 1.1)  
 
FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.1 SPUTUM 

















FIGURE 5 (ANALYSIS 1.2)  
 
FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.2 SPUTUM 

















FIGURE 6 (ANALYSIS 1.3) 
 
FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.3 SPUTUM 

















FIGURE 7 (ANALYSIS 1.4)  
 
FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.4 SPUTUM 

















FIGURE 8 (ANALYSIS 1.5)  
 
FOREST PLOT OF COMPARISON: 1 SPUTUM CONVERSION, OUTCOME: 1.5 SPUTUM 
NEGATIVE AFTER DAY 120. 
FIGURE 9 (ANALYSIS 2.1)  
 
FOREST PLOT OF COMPARISON: 2. MORBIDITY AND MORTALITY, OUTCOME: 2.1. 
MORTALITY. 
FIGURE 10 (ANALYSIS 2.2)  
 
FOREST PLOT OF COMPARISON: 2 MORBIDITY AND MORTALITY, OUTCOME: 2.2 

















APPENDIX 1 DATA EXTRACTION FORM  




Administrative details  
Study ID  
Trial Number  
Author(s)  
Publication details  
Year of Publication  
Number of studies in this paper  
Year in which study was concluded  
Other relevant papers cited  
 
Study Details  
Study Verification  
Study Design  
Type, duration and completeness of 
follow-up 
 
Country/ location of study  
Informed consent  
Ethics  
 
Participant details  
Setting / diagnosis  
Number  
Baseline characteristics  
 
Interventions (I) / Controls (C)  

















Risk of bias Judgement Description 
Adequate sequence generation 
Allocation concealment 
Blinding 
Incomplete outcome data addressed? 
Free of selective reporting? 
Free of other bias? 









Secondary outcomes  
Serious adverse reactions 


















APPENDIX 2 HIGGENS I2  
Higgins I2 = Q-df / Q  x 100% 
Where 
·         Q =chi 2 statistic 
·          df = degrees of freedom 
I2 calculates the proportion of variation in the effect estimates that is due to heterogeneity 
rather than chance 
Thresholds for interpreting I2: 
·         0 to 40 % = might not be important 
·         30 to 60 % = moderate 
·         50 to 90 % = substantial 
·         75 to 100% = considerable 
From “Analysing Data and Undertaking Meta-analyses”: Higgins JPT, Green S. Cochrane 



















Title Mycobacterium w immunotherapy for treating 
pulmonary tuberculosis – a systematic review 
Authors Pandie S, Engel M, Mayosi B 
Contribution of author(s) SP was responsible for the development of the protocol, 
reviewing the abstracts, data extraction, analysis of results, 
interpretation of the findings, and writing the final report. 
OA was responsible for independently performing the 
literature search and extracting the data. 
BM was the project supervisor. 
Issue Protocol first published 2009/12 
Review first published / 
Date of most recent 
amendment 
/ 
What’s new / 
Date new studies sought but 
not found 
Information not supplied 
Date new studies found but 
not yet included/excluded 
Information not supplied 
Date new studies found and 
included/excluded 
/ 
Date authors’ conclusion 
section amended 
/ 
Contact Address Dr Shaheen Pandie 
E 17 Cardiac Clinic 
Groote Schuur Hospital 
Observatory 





Cochrane Library number / 
Editorial Group / 
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Manager of the Postgraduate Unit
Postgraduate Office 
University of Cape Town
RE: Format of Masters in Medicine (M.Med) Submission
My Masters in Medicine dissertation is a systematic review entitled:
MYCOBACTERIUM W IMMUNOTHERAPY FOR TREATING PULMONARY TUBERCULOSIS
– A SYSTEMATIC REVIEW
The final document has been submitted in four parts: 
Part A - Protocol for the systematic review 
The protocol has been completed using The Cochrane Collaboration format. The original 
document was completed using Review Manager 5 (Rev.Man5). The document has not yet been 
officially published by The Cochrane Collaboration, and for this reason the printed document 
and the original document may differ slightly. The original Rev.Man5 protocol has been included 
in Part D as an additional appendix. 
Part B – Literature review 
The literature review focuses on both adjunctive therapies used in tuberculosis and 
Mycobacterium w immunotherapy itself. The Cochrane Collaboration format does not make 














completed in a general style fit for publication in most journals. The reference style chosen was 
for The Lancet Infectious Diseases. The Lancet Infectious Diseases “Information for Authors” has 
also been included in Part D as an appendix, even though this is not the primary journal for 
publication. 
Part C – Manuscript 
The final manuscript has been completed using The Cochrane Collaboration format. The original 
document and statistical analyses were completed using Review Manager 5 (Rev.Man5). The 
document has not yet been officially published by The Cochrane Collaboration, and for this 
reason the printed document and the original document may differ slightly. The original 
Rev.Man5 protocol has been included in Part D as an additional appendix. 
Part D – Appendices 
All correspondence, data sheets, resource material, style guides and original documentation 
have been included in Part D as appendices. Some of these appendices may also appear in Parts 
A to C.  
Thanks 
Shaheen Pandie 
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What 's new? 
Correct ions and changes in version 3.0 (October 2005) 
Secti on Change 
Rationale for new version. version 3.0 Content extensively revised and formatted; table of contents revised 
and index added: streamlined content to exclude guidance on 
grammar. where appropriate: many sections restructured and 
relocated. 
Revised terms used throughout the Cochrane Style Guide to reflect 
changes in official Cochrane Collaboration guidance: this includes 
implementing term inology changes approved by The Cochrane 
Collaboration Steering Group. Providence, April 2005 
About the Cochrane Style Guide New section added to provide general information about the 
Cochrane Style Guide 
Author contact detail s Added guidance on correct format for entering into Review Manager 
or Archie ' 
Cochrane Styl e Guide references Footnoted references; deleted general references 
Computer software New section added to help explain role of different types of software 
used by The Cochrane Collaboration and in The Cochrane Ubrary 
(on Wiley InterScience) 
Currency Modified guidance 
Li sts Modified guidance to allow different formats for ordered lists 
Names: family New section added; includes specific guidance for Ch inese and 
Dutch names 
Names: specific to The Cochrane Collaboration Clarified which names officially start with 'The': also clarified that 'in 
The Cochrane Library' is correct (not 'on The Cochrane Library'), 
P value Clarified guidance 
References Included guidance on how to enter references for commonly used 
reference types into Review Manager: amended guidance for citing 
references in text of Cochrane Reviews 
Removed UK (Bri tish] or USA [American] English Put in English language: regional diffe rences (changed to British and 
and '-ize' and '-ise' American English) with '-ize' as an example 
Trade names changed to 'Brand and trade names' To clarify that both use same format 
Units and systems of measure Included guidance about the International System of Units/Le 
Systeme International d'Unites (SI); moved relevant information to 
this section . such as standard unit abbreviations; this changes the 
guidance regarding the abbreviation for 'litre ' 
, archie.cochrane.org 















Abbrev iations and acronyms 
Use abbreviations and acronyms only if they are widely known and not using them could make reading 
tedious. Write in full in the first instance and follow it immediately by the abbreviated version or 
acronym in brackets. If the review or document is long, it may be sensible to explain each abbreviation 
in each section of the text, such as the 'Background' and 'Discussion' in a Cochrane Review, in 
add ition to the 'Abstract' and tables. 
Abbreviations and acronyms should follow the style conventions in Table 1. Some terms, particularly 
statistical terms, are commonly abbreviated in Cochrane documents (Table 2), while others should be 
avoided (Table 3). 
Table 1 Formatting abbreviations and acronyms 
Guidance .; X 
Use upper·case letters to explain World Health Organization (WHO) or world hea lth organization (WHO) or 
the abbreviation or acronym only if angiotensin converting enzyme (ACE) Angiotensin Converting Enzyme (ACE) 
required by abbreviated term 
No full stops between letters of The Medical Research Council (MRC) The MRC funded the research. 
abbreviation or acronym. or at end funded the research. The MRC. funded the research. 
of abbreviation version or acronym 
The M.R.C. funded the research. unless at end of a sentence 
Form plurals by adding ' 5 ' : no The Review Group Co-ordinators (RGCs) The Review Group Co-ordinators 
apostrophe ('s) needed unless met early in the morn ing. (RGC's) met early in the morning. 
used to indicate possession The Cochrane Revi ew Group's (CRG's) The CRG's were asked to provide 
decision . information. 
Bold may occasionally be used to CRASH trial (corticosteroid randomisation -
Indicate letters used to form an after significant head injury) 
acronym or abbreviation 
Avoid abbreviating terms that cou ld the level of glycosylated haemoglobin the level of Hb A 1 
be unclear to the general 
readership 
Table 2 Common ly used abbreviat ions 
Term Abbreviat ion 
absolute risk reduction ARR 
control group risk2 CGR 
controlled clinical trial CCT 
confidence interval CI 
degrees of f reedom (abbreviation is lower case) df 
mean difference3 MD 
number needed to treat to harm4 NNTH 
number needed to treat to benefits NNTB 
2 Formerly called control event rate; change approved by The Cochrane Collaboration Steering Group, Apri l 2005, Item 13.7, 
www.cochrane.org/ccsg/cCSQ_minutes.Jlf0vidence_april05.htm 
3 Formerly called weighted mean difference; change approved by The Cochrane Collaboration Steering Group, Apri l 2005, Item 13.7, 
www.cochrane.org/ccsg/cCSQ_minutes.Jlfovidence_april05.htm 
.. Formerly called number needed to harm; see previous footnote 
5 Formerly called number needed to treat; see previous footnote. 
















Peto odds ratio 





standardized mean difference 
Table 3 Abbreviations to avoid 











Latin abbreviations used for 
dosing 
Hg for mercury (for example) 
qd. bd. bid. bds. tds. tid. etc 
number no. 
versus vs 
-These might be appropriate for tables if footnoted 
Abstract: Cochrane Revi ew 
Guidance on the format and content of Cochrane Review abstracts is available in the Cochrane 
Handbook for Systematic Reviews of Interventions.7 
Act ive and passive voice 
The active voice is preferable to the passive voice ; see the examples in Table 4. 
Table 4 Active and passive voice 
Active voice 
Two authors extracted data. 
The editor wi ll provide feedback. 
Additional f igure: Cochrane Review 
Passive voice 
Data were extracted by two authors. 
Feedback wi ll be provided by the editor. 
Use the 'Gu idelines for preparing Additional figures in Cochrane reviews's to ensure the published 
figures are satisfactory, and appendix, 'Considerations and recommendations for figures in Cochrane 
reviews: Graphs of statistical data', of the Cochrane Handbook for Systematic Reviews of 
Interventions' for advice on which types of graphs to include. 
o Formerty called relative risk; see previous footnote. 
7 W'Iffl.cochrane.org/resourcesihandbooklindex.htm; Section 3. 
8 www.cc-ims.netlRevManfAdditionaUigures. pdf 
e www.cochrane.orglresourcesJhandbooklindex.htm; Appendices. 















Avoid using 'andlor' because it is not explicit. Try rephrasing the sentence; for example, 'fever andlor 
headache .. .' to 'fever or headache, or both . 
Author contact details: Cochrane Review 
Table 5 outl ines the preferred Cochrane format for entering author contact detai ls in Cochrane 
Reviews. A consistent format will help ensure there is only one record per person entered in Archie ' 0, 
the web interface of The Cochrane Collaboration's Information Management System (IMS). 
Table 5 Entering author contact details in Review Manager and Archie 
Telephone and fax number 
(international notation 11 ) 
Guidance 
Separate groups of numbers using a +44 151 1234567 
space (not hyphens or full stops) 
Avoid using the trunk prefix '0' 




+44 .151.1 23.4567 
+44 0151123 4567 
+44 (0)1511 23 4567 
E-mail address 
(see footnote above) 
Web address 
Lower-case letters myname@domain.org Myname@domain.org 
Use without prefix http:// www.cochrane.org http:/twww.cochrane.org 
(see footnote above) 
Name: prefix and suffix 
Name: middle in itials 
c 
Use open punctuati on. ie without full 
stops 
Use Dr or MD; Dr or PhD 
Avoid punctuation 
Cochrane Review: content, structure, and format 
Mror PhD 
Dr Jones 
Mr Jones, MD 
Dr Jones 
Mr Jones, PhD 
David RA Jones 
Mr. or Ph.D 
Dr Jones, MD 
Dr Jones, MD 
Dr Jones. PhD 
Dr Jones. PhD 
David R.A. Jones 
Information on the content, structure, and format of Cochrane Reviews is available in the Cochrane 
Handbook for Systematic Reviews of Interventions. 12 
Common terms 
See Table 6. 
10 archiexochrane.Of"gf 
11 Telecommunication Standardization Sector of the International Telecommunication Union (ITU-T). Recommendation E.123: Notation for 
national and international telephone numbers, e-mail addresses and Web addresses (0212001). 















Table 6 Common terms 
care giver or caregiver (be consistent) 
Centers for Disease Control and Prevention (CDC) 
chi squared, chi-squared test (correct British English format) 
chi square, Ch i-square test (correct American English format) 
cross-ever study 
forest plot 13 
fixed-effect model 
follow up (noun or verb) or follow-up (adjective) 
The follow-up period was 10 weeks_ 
Seven participants were lost to follow up. 
handsearch 
We handsearc hed three journals. 
The handsearching process. 
health care (noun) or healthcare (adjective) 
The healthcare centre is nearby. (adjective) 
The health care was satisfactory. (noun) 
intention-to-treat analysis 
internet or Internet (be consistent) 
low-income, middle-income, and high-income countries 
Al ternatives to 'developing countries ' and 'developed countries' 
See the classificatioos at all countries aCCOrding to their economies 
on the Wor1d Bank website l~ 
multiple-drug resistance and multiple-drug resistant 
number needed to treat to benefrt 
number needed to treat to hann 
online 
partiCipant or person; participants or people (preferred terms) 
Use participant or person instead of subject or patient, untess it 
changes the meaning of the text 
If trials are exclusively conce rned with a single population, such as 








Centers for Disease Control (not Center or Centre) 
chi squared test 
chi square test 
cross over study 
forrest plot 
fi xed effect model (no hyphen) or fi xed effects model 
hand search or hand-search 
intention to treat analysis 
multidrug resistance and multidrug resistant 
number -needed-to-treat-to-benerrt 
number -needed-to-treat-tO-hann 
on-line (hyphenated) or on line (two separate V/Ords) 
percent 
random effects model (no hyphen) or random-eftect model 
(no 's' after 'effect') 
regime 
sub-group or sub group 
timepoint (one V/Ord) or time-point (hyphenated) 
lJ Lewis S, Clar1te M. Forest plots: trying to see the wood and the trees_ 8MJ. 2001 ;322(7300):1479-80. 
1. www.worklbank.OfQ/datalcounlrydassicountryclass.html ; ~Low-income and middle-income economies are sometimes referred to as 
developing ecooomies. The use of the term is convenient; it is not intended 10 imply that all economies in the group are experiencing similar 
development Of that other economies have reached a preferred or final stage of development Class ification by income does not necessari ly 
renect development sta lus .~ 

















The white participants 
wond wide web or Wond Wide Web (be consistent) 
Wood Health Organization 
)( 
web site (two wordS) 
white (noun); avoid caucasian unless there is a specific 
reason 
Wond Health Organisation 
computer software used to prepare and view Cochrane Reviews 
Different types of software are available within The Cochrane Collaboration and in Tile Coci1rane 
Library (on Wiley InterSclence) 
Review authors prepare Cochrane Reviews using Review Manager" , which is often abbreviated to 
RevMan. Different versions are available, denoted by the version number. The first number (4.2.7) 
changes only when the format of a Cochrane Review changes , such as when new sections are added. 
A change in the second number (4.2.7) indicates changes to the interface or that new functionality has 
been added, or both. A change to the third number (4.2 .7) refers to minor corrections with no new 
features , and it is not necessary to include this number in the citation when referencing the program. 
RevMan Analyses (Figure 1) is Review Manager's statistical program that analyses data to produce 
meta-analysis graphs. (RevMan Analyses replaces MetaView, which was available in version 4. 1). 
Stat istical Analysis (Figure 1) is software run by Wiley 17 to display the graphs in the published 
version of a review and is unrelated to RevMan Analyses Authors Wishing to cite the program they 
used for statistical analyses should cite RevMan Analyses or MetaView as appropriate. Some reviews, 
however, contain sentences such as "the pooled results showed an overall benefit of the intervention, 
see MetaView graph". It is now incorrect to use MetaView in this context because a reader may not 
understand what the authors are referri ng to. 
Figure 1 Screenshots of RevMan Ani.l lyses and Stlltistical Analysis 
RevMan An3 l yses~ Statistical Analys i s~'" 
- .... __ ..... - .... -Rt.~ ... ..... '-" 06- f" - .. - .. --- ~----.--_ .... _ -.. ,,-
... _... , .. ... _m_ .... '''' __ 
=:--...: r::;:.:. ... '<>;~ ......... 
....... "',--_ .. _ .. /._,,_ .... _ .... -
~."- ';:'- -.. "':,-
• • 
·Unpublished Review Manager version; ··Published Wiley version 
16 www.cc-ims.netlRevMan 
:: : ~ :::::: 
17 Introduced in Issue 1, 2005 because this was the first issue of The Cochrane Ubrary nol published simultaneously on the 
















Express currency as the currency abbreviation and amount (eg EUR 250), or as the currency symbol 
and amount (eg €250)'8 
o 
Dates 
Dates may be expressed in different ways, such as a specific date, a decade, or a century, as shown 
in Table 7. 
There are regional differences in expressing date formats. Cochrane documents use the day 
(numeral), month (always in full), and year (numeral) with no additional punctuation. Use this format 
instead of seasons, which can be confusing to people in different parts of the world. Decades are 
always expressed as numerals, and century numbers may be expressed as numerals or written in fu ll 
(eg 19th century or nineteenth century). 
Table 7 Examples of date formats 
1 May 








May 1 2000 or May 1, 2000 
7/11 (UK = 7 November; USA = 11 July) 
1960's or '60s 
An abbreviation for 'for example' from the Latin 'exempli gratia' that should only be used for lists within 
the text or in tables where 'for example' is inappropriate. Be consistent with your choice of punctuation 
(and use the same style for 'ie' and 'etc') (Table 8). 
Table 8 Formaning styles for eg, ie, and etc 
(e.g. men, 1NOffien, Children) 
(eg men, 'NOmen, children) 
(eg , men, women, Children) 
(i.e. men, 'NOmen, Children) 
(ie men, women, children) 
(ie, men, women, Children) 
English language: regional differences 
Style not applicable 
(men, 1NOmen, children, etc) 
(men, women, Children, etc.) 
There are regional differences in the English language, and Cochrane Review Groups support both 
British and American English. However, the choice should be applied consistently within a sing le 
Cochrane Review or document. For example, the '-ize' suffix (eg randomIZe) is often associated With 
American English and '-ise' (eg randomise) with British English, when in fact '-ize' is also commonly 
used in British English 
















Possible formatting styles are listed in Table 8. Use a comma before 'etc' ~ it follows more than one 
item in a list. 
F 
Feedback: Cochrane Review 
No specifi c style guidelines available for th is sect ion See the Feedback Management Advisory Group 
webDage' 9 for further information. 
Font effects: Cochrane Review 
Two font effects are available for use in the text in Review Manager: subscript and superscript. Bolh 
have specific uses, as descrrbed In Table 9. 
Table 9 Examples of subscript and superscript 
Subscript 
Superscript 
Font styles: Coch rane Review 
I\r1ember of chemical group: vitamin 03 vitamin 03 
Number of atoms: H~ 
I\r1ass number: 14C 





Five font styles are available for use In the text In Review Manager: regular, bold, italiC, bold italiC, 
and underline. These five styles (except underline) are used to create the different heading levels in 
Cochrane Reviews (see 'Headings: Cochrane ReView'). Avoid using font styles other than 'regular' for 
emphasis; instead use an alternative sentence structure or intensify the adjectives and adverbs to 
achieve this. 
Bold 
Bold may be used to indicate letters used to form an acronym or abbreviation (see 'Abbreviations and 
acronyms'). 
Italic 
Italic has other uses besides in headings (Table 10). 
• Titles and subtitles of books and journals; If 'The' forms part of the trtle, it should be In upper-
case and in italic. 
• Genus and species names; the genus name starts with an upper-case letter, and the species 
name is all lower case. 
There are also situations in which to avoid using ita lic. 
• Non-English words that have become naturalized into English should be in 'regular' style. 
• Punctuation around text in italic is in 'regular' style; for example, quotation marks, semicolons, 
and colons. 















Table 10 Examples of italic 
x 
Tit les of books and j ourna ls We looked through Brain Injury. We looked through Bra in Injury. 
We searched The Cochrane Ubrary for 
a particular review. 
We seardled The Cochrane Library for 
a particular review. 
Genus and species names 















Avoid underlining words because underlined texts can be confused with internet hyperlinks. 
G 
Glossary 
Terms commonly used in The Cochrane Collaboration and in Cochrane Reviews are defined in the 
'Glossary of Cochrane Collaboration terms,.20 
H 
Headings: Cochrane Review 
Five heading levels21 are available for use with in Review Manager (Table 11) Headings can be fixed 
or free. A fixed heading is one of the headings provided by Review Manager that cannot be altered . 
Free headings are inserted by the review author using the text formatting provided in Review 
Manager. Use sentence case (when only the first letter of the first word begins with an upper-case 
letter) for all free headings, and start the section text on next line. 
Occasionally it is necessary to follow one heading immediately with a subheading . In this case, insert 
one clear line of text between the two headings. 
20 www.cochrane.org/resourceslglossary.htm 






















In Cochrane Review tables 
Descript ion 
(Note: Appears in upper-case letters in the 
published Cochrane Review) 
Bold, sentence case 
(Note: Fixed headings appear as sentence 
case and bold letters in the published 
Cochrane Review (ie exactly the same as 
the free headings) 
Bold italic, sentence case 
Italic, sentence case 
Regular font style, sentence case 
Fixed or free 
Fixed (eg BaCkgrOUnd) 




The heading levels available for the text of Cochrane Reviews are not available in the 'Additional' or 
'Characteristics' tables. Instead use upper-case letters for a head ing or subheading; there should be 
no space between the subheading and the text that follows (Table 12). 
Table 12 Headings in Cochrane Review tables 
)( 
MALARIA MALARIA 
Malaria is endemic in some parts of the WOrld . 
Malaria is endemic in some parts of the world. 
Hyphens 
Hyphens are used to link two or more word compounds used as adjectives, such as 'six-week interval' 
and 'four-dose regimen'. Be aware that hyphens can sometimes change the meaning of a word, such 
as 'unionised' (with a union) and 'un-ionised' (without ions). 
ie 
An abbreviation for 'that is' from the Latin ' id esf that should only be used for lists within the text or in 
tables where 'that is' is inappropriate. Be consistent with your choice of punctuation (and use the same 
style for 'eg' and 'etc') (Table 8). 
Indentation in Cochrane Reviews 
Indentation is not supported In ReView Manager Do not attempt to arrange the layout of text uSing 
indentation because the layout wi ll change during the publica tion process. This will affect the visual 

















There are different ways of formatting lists, depending on the best way to display the information. Be 
consistent in the choice of formatting and numbering within a single document. Lists may form parts of 
sentences within a paragraph (Table 13). Sometimes each item in a list is displayed on a separate line 
using numbers {numbered list}, bullet points {bulleted list}, or ordered {using numbers or letters, or 
both to display different levels within a list}. 
Within paragraphs 
Table 13 Lists with in paragraphs : general guid.mce 
Guidance Example 
Separate each item with a comma I dectded to call Aika. Helen, carolyn, Hasifa, and Christy. 
Complex sentences: such as including several long phrases The conference included topics such as learning how to 
separated with commas, separate each point with a prepare a protocol; search databases and trial registers; and 
semicolon draH a Methods section. 
Note: The comma or semicolon before the "and" is optional (see 'Punctuation') 
Numbered, bulleted, and ordered 
Different styles are possible for these types of list. The style may depend upon using a 'platform 
phrase', which explains the type of items the list contains, and the choice of formatting, such as using 
standard numbering, bullet points, or an ordered approach {Table 14}. 
Table 14 Formatting lists 
Guidance Example 
Platfoml phrase and items are one sentence The programme aims to help you: 
(1) learn about systematic reviews; 
(2) develOp your protOCOl; and 
(3) learn oowto develOp your search strategy. 
The programme aims to help you: 
· learn about systematic reviews; 
• develop your protocol; 
• learn how to develop your search strategy. 
Platform phrase with a full stop before starting the list The programme aims to help you with the following. 
1. Leam about systematic reviews. 
2. Develop your protocol. 
3. Leam how to develop your search strategy. 
Independent list with no platform phrase (1 ) Australia (country) 
(a ) South Austra lia (state) 
(i) Kangaroo Va lley (town) 
1. Studies 
1.1 Randomized controlled trials 
1.2 Cohort studies 
Note: Do not attempt to format the list by using the tab or several spaces to indent the items because the fOfTllatting changes during the 





















Brand and trade name 
Both start with an upper -case letter; for example, Panadol (paracetamol drug) and Unilever 
(pharmaceutical company). Also see 'Pharmaceutical drugs'. 
Country or region 
The United Nations list of countries web page" is a useful resource for the correct spell ing of country 
names; it also prOVides the officia l abbreviations for each country name. Ensure that you use the most 
appropriate name for a country (Table 15). 
Table 15 Which country or regional name? 




Use the country name in use at the 
time when referring to the country 
Example: Thousands of people partiCipated 
in the trial in the Kazakh Soviet Socialist 
Republic in 1976. 
Optional to put the current name in 
braCkets 
Example: Thousands of people participated 
in the trial in the Kazakh Soviet Socialist 
Republic (now the Republic of Kazakhstan) 
in 1976 . 
Contemporary name 
British COlumbia (province) 
Cape Town 
Colombia (country) 





Great Britain, UK. and British Isles 
Great Bntain = England, Scotland, and 
Wales 
United Kingdom = Great Britain and 
Northem Ireland 
British Isles = United Kingdom and the Irish 
Republic 
Nether1ands and Holland 
Holland = name of two provinces of the 
Nether1ands - Noord-Holland and Zuid-
Holland 
Geographical areas that are part of the 




Example: Thousands of people participated 
in the trial in the Repu blic of Kazakhstan in 
1976. 
Modem name 
British Colombia (province) 
Capeto'Wl1 
Columbia (country) 

























upper case letter 
Western Australia; the West 
Geographical areas that are a general 
description start \oVith a lower-case letter 
southern Scolland and the south of Scotland 
)( 
Some family names have specific formatting depending on their location in a reference. These are 
often regional differences. For consistency In Cochrane Collaboration documents, Chinese names 
should follow a Westernized style, that is, first name followed by the family name. Formatting of Dutch 
family names should fo llow the style in Table 16. It is advisable to seek confirmation from Cochrane 
Review authors before modifying . 
T~ble 16 Dutch filmily nOlmes : general guidance 
Guidance Example 
First nil me (or ini1iOl I) before the 
family name 
van, de, der, and ler start with a Jower- Danielie van der Windt or DAWM van 
case letter der Windt,_. 
Only filmily name used, or initials 
<lfier the last name 
Van, De, Der, aoo Ter start with an Van der Windt et al or Van der Windt, 
upper-case letter DAWM .. 
Genus and species 
Genus name starts with an upper-case letter whi le the species name does not; both are in italic (Table 
10). 
Pharmaceutical drugs 
Refer to pharmaceutical drugs using the recommended International Nonproprietary Name (rI NN),23 
also known as the generic name, instead of the brand name. This system helps avoid confusion where 
common names for drugs differ around the world; for example, 'acetaminophen' is commonly used in 
the USA, but it is more commonly known as 'paracetamol' (also the rlNN) in the UK. If needed, 
however, place the brand name in brackets after the rI NN. An rlNN should start with a lower-case 
letter, while brand names start With an upper-case letter. For example, the rlNN for one type of 
antibiotic is 'ciproftoxacin'. This could be presented as 'ciprofloxacin ' alone or 'ciprofloxacin (Ciproxin)' 
if essential, but not as 'Ciproxin' alone. 
Useful resources for locating or checking the rl NN are the Bf/lis/1 NatIonal Formulary (BNF)" ; Clinical 
Evidence ('Drug nomenclature and brand names' web pages) 25, and the WHO Model Formulary 
(MF)26 
23 "International Nonproprietary Names (INN) facilitate the identification of phannaceutical substances or active pharmaceutical ingredients. 
Each INN is a unique name that is globally recognized and is public property. A nonproprietary name is atso known as a generic name: 
Wor1d Health Organization , Essential Drugs and Medicine POlicy, International Nonpropneiary Names; 
www.who.inUmedicinesiorganizationlqsmlactivitiesiqualityassuranceJinn/orginn.shtml 
Z& www.l>nf.orgl; provides information on medicines prescribed in the UK. 
Z5 www.dinicalevidence .comlceweb/resourcesldrug_names.jsp; lists the international name (r1NN or proposed INN (pINN», the com mon UK 
and USA names, and the UK and USA brand names. 





















Specific to The Cochrane Collaboration 
See Table 17 for the correct spelling and formatting of names specific to The Cochrane Collaboration. 
T~ble 17 N~mes specif ic to The Cochrane Collaboration 
)( 
author reviewer 
Cochrane Center Chinese Cochrane Centre US Cochrane Centre 
US Cochrane Center Chinese Cochrane Center 
Cochrane Centre 
Australasian Cochrane Centre 
Brazilian Cochrane Centre 
Canadian Cochrane Centre 
Dutch Cochrane Centre 
German Cochrane Centre 
Iberoamerican Cochrane Centre Australasian Cochrane Center 
Italian Cochrane Centre Brazilian Cochrane Center 
lberoamerican Cochrane Center 
ttalian Cochrane Center 
Nordic Cochrane Centre canadian Cochrane Center Nordic Cochrane Center 
South African Cochrane Centre Dutch Cochrane Center 
UK Cochrane Centre German Cochrane Center 
South African Cochrane Center 
UK Cochrane Center 
the COChrane Central Reg ister of Controlled Trials 
(CENTRAL) 
the COChrane Database of Methodology Reviews 
the Cochrane Database of Systematic Reviews 
The Cochrane COllabOration 
the COllaboration 
Use only when it is cumbersome to use the full name constantly in a 
single document Remember to use 'The Cochrane Collaboration' in 
full the first time and inform your readers that you will refer to it as 
'the Collaboration' from this point onwards. 
The COChrane Ubrary 
... in The Cochrane Uorary 
The COChrane Manual 
the Cochrane MethOdology Register 
Cochrane Protocol or COchrane protocol 
No policy on a particular format, only consistency within a single 
document 
Cochrane Review or Cochrane review 
No policy on a particu lar format, only conSistency within a single 
document 
COChrane Handbook for Systematic Reviews of 
Interventlons7 
Cochrane Review Group28 
the Cochrane sty1e Guide 




The COchrane Central Register of Controlled Trials 
(CENTRAL) 
The COChrane Database of Methodology Reviews 
The Cochrane Database of Systemaric Reviews 
the Cochrane CollabOration 
The COllaboration 
the COChrane Ubrary 
... on The Cochrane LiOralY 
the COChrane Manual 
The COchrane MethOdology Reg ister 
COChrane Reviewers ' Handbook 
Collaoorative Review Group 





27 Title changed in vers ion 4.2.4 from 'Cochrane Reviewers' HandOook' to current format 
~ Change approved by Th e Cochrane Collaboration Steering Group, April 2005, Item 13.7, 
www_cochrane_orQIccsglccs!Lminutesyrovidence_april05_htm 


















Review Group Co-ordinator Review Group Coordinator 
Review Manager ~ RevMan (abbreviation) ReYman 
Review Manager 4.1 or Review Manager 4.2 Review Manager version 4.1 or Review Manager version 4.2 
or Review Manager 4.2.7 (or any third number because it 
indicates a small bug fix) 
RevMan Analyses (only available from RevMan 4.2 and later RevMan Analysis 
versions) 
Statistical Analysis statistical Analyses 
Trials Search Co-ordinator Trial Search Co-ordinator 
Numbers 
The basic ru le is to spell out in full numbers and ordered events less than 10 (Table 18). However, 
there are some exceptions (Table 19). Numbers between 1000 and 9999 should contain no 
punctuation . Numbers with five or more digits should include commas (not decimal points or fu ll stops) 
(Table 20 ). Use 'from' and 'to' instead of a dash to describe a range of numbers (Table 21). Often 
judgement is needed to determine the best presentation for a set of numbers. 
Table 18 Basic rule for numbers and ordered events less than 10: write in full 
We sent the review to four referees. 
The 10 partidpants agreed. 
The 25 studies are available. 




We sent the review to 4 referees. 
The ten participants agreed. 
The twenty-five studies are available. 
33 adults and 5 chHdren partidpated. 
9th 
one hundred and twelfth 
Table 19 Exceptions to basic rule for numbers and ordered events less than 10 
Exception Guidance 
Sentence contains numbers < 10 and ~ Acceptable to use only numerals 
10 
Example 
from 2 to 12 years 
from 5% to 25% of the number of 
participants 
There were between 9 and 15 people in 
the room. 
Equations, numerical results, statistics 
Sentence starts with a number 
Number with a unit 
Tables (also see 'Tables') 
Numerals only 
Spell number 
Always use numerals 
Numerals for all numbers including 
those < 10 
lWIW.cochrane.orgistyteJcsg.htm 
2J2O 
OR 106 (95% CI 090 to 302) 
Eleven per cent of people .. 
Twenty authors attended the wor1<shop. 
































from three to nine participants 
-12 to-4 
from three - nine participants 
· 12· -4 
Tlle risk ratio was 0 .38 (95% CI 0.30 to 0.49) 
(MD ·11.11 h; 95% CI -20.04 to ·2.18) 
1%t0 10% 
The risk ratio was 0.38 (95% CI 0.30-0.49) 
(MD ·11 .11 h; 95% CI 20.04 .. 2.18) 
1% - 10% 
4 t05mg 4 ·5mg 
p 
Plain language summary30: Cochrane Review 
Information about the required structure and content of plain language summaries is provided in the 
Cocllfane Handbook for Systematic Reviews of Interventions." 
Pref ixes 
General guidance on the use of prefixes is in Table 22. 









Use a hyphen with 
• letters 
• names 
• words begin ing with 'j' 
t'NO-word compounds used as adjectives 
Use a hyphen if the following word starts with the 
same vowel 
No hyphen if following word starts with 'r' 
Use a hyphen if following word starts 'Hith 'a' 
Use a hyphen if following word starts 'Hith a vowel 
Either joined to the word it modifies or uses a 





anti-gas gangrene serum 





microbiology. microcirculation. microfilaria 
29 This is an exception to the style convention for SI units; see 'Units and systems of measure'. 
30 Former1y called synopsis; change approved by The Cochrane Collaboration steering Group, April 2005, Item 13.7, 
www.cochrane .orglccsglccs~minutes...providen ce_apriI05 .htm 

































Either joined to the word it modifies or uses a 
hyphen (it does not stand alone) 
Either joined to the word it modifies or uses a 
hyphen (it does not stand alone) 
Hyphenate if 'non' qual ifies more than one word 
Hyphen optional if qualifies one word 
No hyphen with Latin phrases 
One word unless following word starts with T 
Hyphen normally used wtlen following word starts 
with 'e' or 'i' 
Establ ished combinations generally one 'NOrd 
(except wtlen the word begins with an 'e') 
Example 
min itracheostomy, m ini~menta l state examination 
mutticentre, multi-agency 
non-insulin dependent, oon·proflt making 
non-smoker, nonvio(ent 
materia non medica, non sequitur 
postgraduate, postorbital, post-treatment 
pre...edampsia, pre-embryo, pre...exist, pre...exposure, 
pre·install, pre-industrial 
prearranged, prenatal , preoccupy, preSChool. pre-
empt 
In others the hyphen is not necessary, but is freely pre·medication, pre·tax, pre~war 
used if the compound is one made for the occasion 
(might be better to rewrite). or if any peculiarity in its 
form might prevent its elements from being instanUy 
recogniZed 
Use hyphen if following word starts with 'e' 
Rephrase wtlen there would be confusion with 
another word 
All compound words with 'self are !'NO YIIOrds 
Use a hyphen jf fallowing word starts with T 
Use a hyphen if following 'NOrd starts with 'b' 
Words starting with 'un-' are generally one word 
Rephrase wtlen there would be confusion with 
another word 
re...ed it, re-educate, re-establish, 
re...enter, re-enlist 
re-cover (cover again) and 
recover (get better) 
self limited 
semi-independent, semicolon 
sub-basal , sub-breed (note: sub-Saharan is one 
exception) 
unnoticeable, unopened, unpaid, unpick 
unionised (with a union) and 
un-ionised (without ions) 
General guidance on the use of punctuation is in Table 23. 






Guida ce Example 
Only use if part of a recognized trade name Procter & Gambfe 
Retain where it is used in the official journal title Journal of Pain & Palliative Care 
Pharmacotherapy 
Use round brackets for nested brackets 
Annals of Nutrition & Metabolism 
The standardized mean difference was -0.02 
(95% confidence interval (CI) -0. 13 to 0 .08). 
They included five references (only two of these 
'Were references to full papers (Smith 2002; 
Tay1or 2003» 
Follow with a lower-case letter unless it is Review topiC: cancer 




























Optional to use a comma before 'and' and 'or' in 
lists, but be consistent 
Use commas before 'and', 'or' , and 'bur in two-
phrase sentences (when these words join the 
two main clauses) 
Comma with 'which' and 'thal' 
Use a comma with 'which', but if the sentence 
reads well with 'that' instead of 'which' then 
probably no comma needed 
Use one space aner tne full stop32 
The percentage sign can be used in a block of 
text when it is used with a numeral 
Use 'per cent' instead of '%' when starting a 
sentence and when the number is written in full 
(ie not a numeral ). 
No space between the number and percentage 
sign 
See full stop 
Use double quotatiOn marks for quoting within 
dialogue and when quoting text from a written 
source 
Example 
I have read Cochrane Reviews about malaria, 
tuberculosis, and vaccines. 
I have read Cochrane Reviews about malaria, 
tuberculosis and vaccines. 
The reviews are written here, but they are 
available intemationally. 
The reviews are sent here by post, or they are 
sent here electronically. 
We produce Cochrane Reviews, which are 
relevant to healthcare workers. 
Note: the phrase after 'which' comments on trle 
reviews 
We produce Cochrane Reviews that are relevant 
to healthcare ItVOrkers. 
Note: the text after 'that' defines for whom the reviews 
are relevant 
Less than 90% of the participants completed the 
study. 
Three per cent of people 
Correct 15% 
In the study -12 partiCipants experienCed 
adverse effects- (Goodwin 1998). 
Use single quotation mar1<:s in all other instances The 'standard' approaCh is to ... 
and for referring to a specific section of a The study deta ils are in the 'Characteristics of 
Cochrane Review if it is not a hyper1ink induded studies'. 
References : entering and cit ing references in Cochrane Reviews 
There are different types of references in Review Manager: those for included, excluded, ongoing 
studies, and studies awaiting assessment, and those for the other types of reference sources listed in 
the 'Other references' section. Each reference has a unique identifier used throughout the review and 
to link It to the text of the review; these are called 'study identifiers (study IDs)' for the study references 
and 'reference identifiers (reference 105)' for the other references. 
Entering references into Review Manager 
References need to be entered into Review Manager using the designated fields (see 
Figure 2). Different reference Iypes, such as journal articles and internet publications, need 
information in different fields. 
J2 When publishers format Cochrane Reviews, one space is allocated after each full stop. This means if you use two spaces, they will be 















Figure 2 Screens hot of Review M~n~ger 4 .2 r eference fields 
R ..... ~'.ID· I 
R ...... '.fJ\» 
"-J"~/I""I9I'''''" r~,pWW""99 rl'OP"gIJ!"llO~'1f 
r 10el< reo.~ "cltol.~~~ r totr"Mo'~''''''' 
r I ..... altalt r CUnPLIW~~"rn r Dtho, 
Table 24 has gUidance on the correct way of entering data into the various references fields in Review 
Manager. Review Manager automatically inserts a fu ll stop after each line in the reference, so ensure 
that there are no ful l stops at the end of each reference field . 
Table 24 Entering re ferences into Rev iew M~nager33 
Field Guidance .. )( 
Study 10 or Reference 10 Preferred COchrane fonnat Gamer 2001 
uses last name of first author 
and year of publ ication; 
limited to 20 characters in 
Review Manager 
T'NO or more articles from Bushell 2000., 2000b, Bushell 2000 a, 2000 b, 
the same author from the 20000 2000 c (space between year 
same year and letter) 
Bushel 2000, 2000a, 2000c 
(no letter 'Nitti year) 
Authors List the first six authors Smith H, Tavender E, KJaes 
before using 'et al'; comma 0 , Hinds p, Remmington T, 
before 'et ai' optional , but be Sparkes V. et al 
consistent Smith H, Tavender E, KJaes 
0, Hinds P, Remmington T, 
Spar1<es V e\ al 
No 'and' before the final Smith H, Tavender E, KJaes Smith H, Tavender E, KJaes 
author 0 , Hinds P 0 , and Hinds P 
Article titles First letter of the first word in Antibiotics for treating Antibiotics For Treating 
13Reference details may be located through the following websites: Index Medicus Journal Abbreviations 
(ftpJ/nlmpubs.nlm.nih.gov/onlinefjOurnalslljiweb.pdf; PDF file of 3100+ journal titles, and their abbreviations, indexed in the National Ubrary 
of Medicine's Index Medicus); Entrez JournaJs database (WNW.ncbi.nlm.n ih.govlentrezlquery.fcgi?db=Journats; database for search ing 
journal titles of all joumals in Entrez databases); NLM Locator Plus (lOcatorplus.oovl; search for book and journa l titles in the United States 



























upper case; other \ .... onls in 
lower case unless proper 
nouns or require an upper-
case letter 
Include English translation 
only if provided by the 
JOUrnal or database 
Write in full using title case 
(each substantive word 
starts wtth an upper-case 
letter) 
Journal titles sometimes 
Change; use tiUe current at 
time of publication 
British Medical Journal (1857 to 
1988) '7 BMJ (1988 to present) 
Journal 01 the American Medical 
Assod ation (1883 '7 1960) '7 
JAMA (1960 to present) 
Include English translation in 
square brackets aner the 
original title only if translation 





The importance of vitamin A The importance of vitamin a 
Journal of Pflarmacy and 
Pharmacology 
Zhonghua Yi Xue Za Zhi 
[Chinese Medical Journal) 
324~8 , 556-60, 1093-8 
J Pharm Pflannacol 
Zhonghua Yi Xue Za Zhi 
(Chinese Medical Journal) 
324~28 , 556-560, 1093-
1098, and 1093-98 
The correct formats for entering commonly used reference types , such as journal articles and book 
chapters, are given in Table 25. The complete list of reference types and instructions on how to enter 
them into Review Manager 4.2 is available in RevMan User Guide" and in RevMan Help. Tile 
Cocllrane Manual" contains details on citing other products from The Cochrane Collaboration - Tile 
Cocllrane Library, a module in Tile Coc/lrane Library, a Cochrane Review from the Coc/lrane 
Database of MetllOdology Reviews, and Tile Cochrane Manual. 
Table 25 How to enter d iffe rent reference types 36 into Rev iew Manager 4 .2 
Reference type 
StJndard journa l Jrticle 
Reference type 
AuthOrs (AU) 
English title (TI) 
Joumallbooklsource (SO) 
Date of publication (YR) 
Volume (Vl) 
Issue (NO) 




Osrin 0, v aidya A, Shrestha Y, Baniya RB, Manandhar OS, 
Adhikari RK, et aI 
Effects of antenatal multiple micronutrient supplementation 
on birthweight and gestational duration in Nepal: doubte-




























JournOiI Olrticles in volume with supplement 
Reference type 
Authors (AU) 
Engl ish Utle (TI) 
Journallbooklsource (SO) 




ChJpter in J book 
Reference type 
Authors (AU) 
Engl iSh Utle (TI) 
Journallbooklsource (SO) 




Publisher name (PB) 
City of publication (CY) 
View citation 
Conference proceedings th3t do not use the S3me styl e 
JS J joumJI Jrtic le 
Reference type 
Journallbooklsource (SO) 
Date of pubficaUon (YR) 
EditOf(S) (ED) 
Publisher name (PB) 
EXOImpie 
955-62 
Osrin D, Vaidya A, Shrestha Y. Baniya RB, fllla nandhar DS, 
Adh ikari RK, et aJ. Effects of antenatal multiple micronutrient 
supplementation on birthweight and gestational duration in 




The IOng-tenn use of inhaled tObrarnydn in patients with 
cystiC fibrosis 
Journal of Cystic Rbrosis 
2002 
1 Sup~ 2 
194-8 
8o'WTTlan CM. The long-tenn use of inhaled tobrarnyd n in 
patients with cystic fibrosis. Journal of Cystic Fibrosis 2002; 
1 Sup~ 2:194-8 
Section of book 
Weinstein L, SWartz MN 
Patholog ic properties of invading microorganisms 




Sodeman WA Jr, Sodeman WA 
Saunders 
Ph iladelphia 
Weinstein L, SWartz MN Pathologic properties of invading 
microorganisms. In: Sodeman WA Jr, Sooeman WA, 
editor(s). Pathologic physiology: mechan isms of disease. 5th 
edition. Philadelphia: saunders, 1974:457-72. 
Conference proceedings 
Child abuse and neglect: a medical community response. 
Proceedings of the First AIVIA National Conference on Child 
Abuse and Neglect; 1984 IVk1r 3()..31 ; Chicago 
1985 
Vivian VL 




















City of publication (CY) 
View citation 
Paper in conference proceedings that does not use the 
same style as a journal artic le 
Reference type 
Authors (AU) 
English bUe (TI) 
Joumallbooklsource (SO) 
Date of publication (YR) 
Pages (PG) 
Editor(s) (ED) 
Publisher name (PB) 
City of publication (CY) 
View citation 
c omputer program 
Reference type 
English bUe (TI) 
Date of publication (YR) 
Edition (EN) 
Publisher name (PB) 
City of publication (CY) 
Medium (MD) 
View citation 
Public.ltions on the Internet 
Reference type 
Authors (AU) 
English tiUe (T I) 
Joumalibooklsource (SO) 




Vivian VL, editor(s). Child abuse and neglect: a medical 
community response. Proceedings of the First AMA. National 
Conference on Child Abuse and Neglect; 1984 Mar 30-31; 
Chicago. Chicago: American Medical Association, 1985. 
Conference proceedings 
Har1ey NH 
COmparing radon daughter dosimetric and risk models 
Indoor air and human health. Proceedings of the seventh 
Life Sciences Symposium: 1984 Oct 29-31 ; Knoxville (TN) 
1985 
69-78 
Gammage RB, Kaye SV 
Le'Nis 
Chelsea (MI) 
Har1ey NH. Comparing radon daughter dosimetric and risk 
models. In: Gammage RB, Kaye SV, editor(s). Indoor air and 
human health . ProCeedings of the Seventh Life Sciences 
Symposium; 1984 Oct 29-31; Knoxville (TN). Chelsea (MI): 
LewiS, 1985:69-78. 
Computer program 
Review Manager (RevMan) 
2003 
4.2 for W indows 
The Nordic Cochrane Centre, The Cochrane Collaboration 
Copenhagen 
CD-ROM and Internet 
Review Manager (RevMan) [Computer program). Version 4.2 
for W indows. COpenhagen: The Nordic COchran centre, The 
Cochrane Collaboration, 2003. 
Other 
Royal College of Physicians of Edinburgh and UK COchrane 
Centre 
Controlled trials from history 
www.rcpe.ac.uklcochraneJ 
(accessed 10 May 2000) 
Royal College of Physicians of Edinburgh and UK COchrane 
























English title (TI) 
Journallbooklsource (SO) 
Date of publication (YR) 
Issue (NO) 
View citation 




English title (TI) 
Joumallbooklsource (SO) 
Date of publication (YR) 
View citation 
Section of Cochrane Handbook for Systematic Reviews 
of IntelVentions with no section editors 
Reference type 
Authors (AU) 
English title (TI ) 
Journallbooklsource (SO) 
Date of publication (YR) 
View citation 
Section of Cochrane Handbook for Systematic Reviews 
of IntelVentions that has section editors listed 
Reference type 
Example 
WNW.rcpe.ac.uklcochraneJ (accessed 10 May 2000). 
COchrane Review 
Robinson PG, Deacon SA, Deery C, Heanue M, Walmsley 
AD, Worth ington HV, et al 
Manual versus powered toothbrushing for oral health 
COchrane Database of systematic Revie'NS 
2005 
2 
Robinson PG, Deacon SA, Deery C, Heanue M, Walmsley 
AD, Worth ington HV, et al . Manual versus powered 
toothbrushing for oral health. In: COchrane Database of 
systematic Reviews 2005, Issue 2 
Other 
Higgins JPT, Green S, editors. 
Cochrane Handbook for Systematic Reviews of Interventions 
4.25 [updated May 2005] 
lNWW.cochrane.orglresourcesJllandbooklhbOOk.htm 
(accessed 31 May 2005) 
Higgins JPT, Green S, ed itors. Cochrane Handbook for 
systematic Reviews of Interventions 4.2.5 (updated May 
2005). www.cochrane.orglresourceSihandbOOklhbook.htm 
(accessed 31 May 2005). 
Other 
Higgins JPT, Green S, editors 
Formulating the problem. Cochrane Handbook for 
systematic Reviews of Interventions 4.2.5 (updated May 
2005); Section 4 
lNWW.cochrane.orglresourcesJllandbooklhbOOk.htm 
(accessed 31 May 2005) 
Higgins JPT, Green S, ed itors. Formulating the problem. 
COchrane Handbook for Systematic Reviews of Interventions 
4.2.5 [updated March 2005); Section 4 . 
lNWW.cochrane.orglresourcesJllandbooklhbOOk.htm 





















Reference type Ex ample 
Authors (AU) Deeks JJ, Higgins JPT, Altman DG, editors. In: Higgins JPT, 
Green S, editors 
Engtish tiUe (TI) AnalySing and presenting results. COchrane Handtxx>k for 
systematic Reviews of Interventions 4.2.5 (updated May 
2005): section 8 
www.cochrane.orgiresourcesJhandoooklhtxx>k.htm 
(accessed 31 May 2005) 
Joumallbooklsource (SO) 
Date of publication (YR) 
View citation Deeks JJ, Higgins JPT, Altman DG, editors. In: Higgins JPT, 
Green S, editors. Analysing and presenting results .. 
COchrane Handtxx>k for Systematic Reviews of Interventions 
4.2.5 [updated March 2005): section 8 . 
www.cochrane.orgiresourCesJhandooOklhtxx>k.htm 
(accessed 31 May 2005). 
Citing references in the text o f Cochrane Reviews 
Guidance on insert ing references in Cochrane Reviews is in Table 26. 
Table 26 Citing references in the tex t of Cochrane Rev iews 
Guidance 
Separate with a semicolon 
List in alphabetical or chronological 
order, but be consistent INith in a single 
documenr7 
Robb 2001 ; Smith 2000 
Alphabetical: Bakri 1988a; Bakri 
1988b; Davis 2003; Slinn 2001 
Chronological: Bakn 1988a; Bakn 
1988b; Slinn 2001 ; Davis 2003 
)( 
Robb 2001, Smith 2000 
Alphabetica l: Bakri 1988a; Bakri 
1988b; Slinn 2001 ; Davis 2003 
Chronologica l: Bakn 1988a; Bakn 
1988b; Davis 2003; Slinn 2001 
No 'and' before the final reference Davis 2001 ; Oman 1968; Preston 1988; 
Slinn 2001 
Davis 2001; Oman 1988; Preston 1988; 
and Slinn 2001 
Can be used as part of a sentence or in 
round brackets INithin closest 
punctuation 
The study was successful (Robeson 
1990). 
The study was successful (Griffin 
1990); it confirmed previous findings 
(Howes 1995). 
Blaggs 1991 reports the ful l details. 
Note: make sure identifier is linked 10 the reference lisl 
s 
Search methods 
Citing databases and study regis ters 
The study was successful [Robeson 
1990). 
The study (Goffin 1990) was 
successful; it confirmed previous 
findings (Howes 1995). 
(BI09g5 1991) reports the full deta ils. 
The preferred format for the following databases IS all upper-case letters: MEDLINE, EMBASE, 
CENTRAL", OLDMEDLlNE, and CINAHL (not CINHAL). A number of databases use a mixture of 
lower-case and upper-case letters, for example, PsycLi T (not PsychLlT) and PsyclNFO (not 
PsychINFO). 
31 Change in version 3.0 in response to new feedback; further discussion welcomed. 
J8 The Cochrane Controlled Trials Register (CENTRAUCCTR) was renamed the Cochrane Central Register of Controlled Trials 



















Each Cochrane Review Group is responsible for preparing a register of studies in their area of 
expertise. The name of the register may vary, but it will follow one of the fol lowing formats depending 
on the Cochrane Review Group's choice: Cochrane [insert name] Group Specialized Register, 
Cochrane [insert name] Group Specialised Register, or Cochrane [insert name] Group Trials Register. 
The databases and trials registers that are searched for stUdies for a Cochrane Review are listed in 
two sections: the 'Abstract' and the 'Search strategy for identification of studies'. The databases and 
registers must be listed in the following order: Cochrane [insert name] Group Specialized Register (or 
Specialised Register or Trials Reg ister), CENTRAL, MEDLlNE, EMBASE, and any other databases. 
The date range of each search must be listed with each database; for example, CENTRAL (The 
Cochrane Library year, issue number), and for most other databases, such as MEDLlNE, it should be 
in the form 'MEDLINE (month year to month year)'. 
When this section is published in The Cochrane Library the text 'See: [Cochrane Review Group name] 
search strategy' is inserted automatically by the publishers below the heading. This links to the 
Group's module in TIle Cochrane Library where the search methods for the Group's Trials Register 
are described. There is no need to include a line of text refernng to the Cochrane Review Group's 
search strategy. 
Search terms 
Search terms consist of text words (preferred spelling is two words in Cochrane Reviews instead of 
'textword') and controlled vocabulary. The preferred format for referring to the National Library of 
Medicine's controlled vocabulary used for indexing art icles for MEDLINE (and PubMed) is MeSH (not 
MESH)."" 
Spacing 
See 'Punctuation', 'Symbols', and 'Units and systems of measure' for re levant guidance on spacing. 
Use one blank line between two paragraphs in a block of text Avoid indicating a paragraph break 
using indentation because Review Manager does not support this type of formatting. 
Stat istical and mathematical presentation 
General guidance on the presentation of statistical and mathematical values is in Table 27. Guidance 
on abbreviallng statistical terms commonly used In Cochrane Reviews is In Table 2. 






Two decimal places unless number very small 
(eg 0 .005) or the unit of measurement dictates 
otherwise 
Use full stops, not commas 
12.26 
120/80 mm Hg 
15.51 
Mathematical Avoid building mathematical fonnulae spaced 2 = 1 Q/5 
formulae over two or more lines in the text of the review, 
as text fonnatting '¥Yi ll change during publication 
process 
P value Use an upper-case 'P' (no italic) 
No hyphen between the 'P' and the value 
Uncommon to state that a P value is 'less than' 
or 'more than', instead use P < 0.05 
Y.I www.ncbi.nlm.nih.gov/entTezlquery.fcgi?db=mesh 
A P value of 0.05 was 
used as the cut-off value 









A P value of 0.05 was 
used as the cut-off value 





























For dichotomous outcomes, the RevfV\an 
Analyses and Statistical Analysis (see 
'Computer soHware used to prepare and view 
Cochrane Reviews' for description) use the 
headings nIN within each intervention ann, 
wnere n denotes the number of events and N is 
the sample size. It is preferable to standardize 
the use of nIN for these INhere possible. 
Only use abbreviations for summary statistic (eg 
RR or MD) and confidence interval (CI) if 
already defined (see 'Abbreviations and 
acronyms') 
separate summary statistic from its CI using a 
comma or semicolon if inside a single set of 
brackets 
Define the CI, eg 95% or 99% 
separate the Cis with 'to' instead of using a 
hyphen 
Symbols and special characters 
There was a statistically 
sign ificant intervention 
enect(P = 0.01). 
The risk ratio (RR) was 
0 .38 (95% confidence 
interval (CI) 0.30 to 0.49) 
_ was statistically 
s ignificant (RR 0.09, 95% 
CI 0.02 to 0.38) 
(odds ratio 1.11, 95% CI 
098 to 12 0) 
(mean difference -11.11 
hours; 95% CI -20.04 to 
-2.18) 
x 
There was a statistically 
significant intervention 
effect (P=0.01). 
(odds ratio 1.11, CI 0.98 to 
1.20) 
(mean difference -11.11 
hours: 95% CI -20.04 -
-2.18) 
Many different symbols and specia l characters are available for use in Review Manager (see Figure 
3). 
Figure 3 Symbols and special characters available in Rev iew Manager 4.2 
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Symbols, including those in Table 28, should be used in a block of text only if the descriptive version is 
cumbersome or inappropriate. 







Use 'r instead of 'per' where it is otherwise cumbersome 
10 mglkg (not 10 mg per kg) 
Spacing 
1 space either side 
1 space either side 
no spacing (10 gil) 














Symbol Description Spacing 
< less than (eg for percentages) 1 space either side 
fewer than (eg for people) 
> greater than 1 space either side 
more than 
= equals 1 space either side 
T 
Tables : Cochrane Review 
There are two types of tables in Cochrane Reviews: 'Characteristics' tables and 'Additional' tables. 
The 'Characteristics' tables - of included studies, excluded studies, and ongoing stud ies - have a 
defined format, with specific column headings. Review Manager automatically generates the row 
headings based on the reference lists, which means it is not possible to insert additional column or 
row headings in the 'Characteristics' tables. 'Add itional tables' allow authors to create tables for other 
types of infomlation. 
Formatting should be consistent within a sing le table. As with other parts of a Cochrane Review, the 
visual presentation of tables wi ll change during the publication process. It is important not to use return 
key within a single block of text (eg In a single word if the word runs over two lines) because the text 
layout will also change during the publication process. Refer to the sections on 'Abbreviations and 
acronyms' and 'Numbers' for addit ional guidance. 
Footnotes are a convenient way to define abbreviations and acronyms or display other explanatory 
notes. The 'Characteristics' tables have a specific footnotes section , unlike the 'Additional tables', 
which require a little imagination to include footnotes; for example, inserting an extra row at the botlom 
of the table and using one of the cells for the footnotes. Enter each footnote either on a new line or 
separate with a semicolon , remembering that all abbreviations and acronyms used in a table should 
be defined in the footnotes. 
Table 29 Example of footnote formatting 
Footnotes Footnotes 
DSS: dengue Shock syndrome DSS: dengue Shock syndrome; m : tuberculosis 
TB: tuberculosis 
Some tables, such as the 'Characteristics' tables, may include blocks of text Each block should start 
with an upper-case letter. It is optional to end each block with punctuation. 
Tautology 
Avoid using a tautology, which is "the saying of the same thing twice over in different words" (Pearsall 
199840) (Table 30). 
Table 30 EXOl mple of;) tautology 
Tautology .. 
We excluded trials of children with a history of headaches in We excluded trials of children with a history of headaches. 
the past. 




















Tense: Cochrane Review 
Write things you plan on doing in the future tense (such as in a protocol for a Cochrane Review) and 
things you have already done in the past tense (such as in a Cochrane Review) 
Titles : Cochrane Review 
Base the Cochrane Review title on the structure used for the vast majority of existing review titles in 
the Cochrane Database of Systematic Reviews {Table 31}_ If the review involves several interventions , 
start the title with ' Interventions' or more appropriate specific tenms, such as phanmacotherapy, 
psychological therapy, physical therapies, or surgery. Rarely mention specific outcomes in the title 
because the tit le should refiect all the outcomes included in the review; if included, use a colon to 
separate the outcome from the main title. 
Standardize titles by rarely using upper-case letters, avoiding the use of abbreviations, and avoiding 
superfluous elements (eg 'effects of, 'comparison of , 'a systematic review Of). Titles should not 
include unnecessary punctuation, such as a full stop at the end. 
Table 31 Structure for Cochrane Review titles 
Scenario 
Basic structure 
Comparing two active interventions 
Type of people being studied or 
location of intervention mentioned 
expliciUy 
Not specifying a particular 'health 
problem' (eg 'Home versus hospital 
birttl '), or if the intervention intends to 
innuence a variety of problems (eg 
'Prophylactic synthetic su rfactant in 
preterm infants') 
Sometimes you may need to spedty 
that the intervention is for preventing, 
treating, or preventing and treating the 
health problem(S): 
Ir necessary, rollO'N the word 'for' by 
'preventing', 'treating', or 'preventing and 
treating' This is better than using 'for the 
prevention of, etc. 
u 
Units and systems of measure 
Structure 
(intervention] for [health problem] 
(intervention A] versus ~ntervention B] 
for [health problem) 
~nterventionl for [health problem) in 
[participant groupllocationj 
~nterventionl in OR for [participant 
groupllocationj 
Example 
Antibiotics for acute bronch itis 
Immediate versus delayed treatment for 
cervical intraepithelial neoplasia 
Inhaled nitric oxide for respiratory 
failure in preterm infants 
Restricted versus liberal water intake in 
preterm infants 
Pool fendng for preventing drowning in 
children 
Amodiaquine for treating malaria 
Vitamin C for preventing and treating 
the common cold 
The International System of Units/Le Systeme International d'Unites (51) is the modem metric system 
of measurement. This system is made up of 5 1 base units (the foundation units) (eg metre), derived 
units (eg square metre), and non-SI units that are accepted for use with in the St (eg minute) . 
Table 32 lists 51 units that are commonly used in Cochrane Reviews. The full list of units and further 
information on this System is available on the International Bureau of Weights and Measures (BIPM) 
website.4 1 
4 1 www1.bipm.orgtenJs il 




















Table 32 Examples of commonly used units 
Unit name SymbOl Type 
kilogram kg base unit 
metre m base unit 
second 5 base unit 
cubic metre m' dertved unit 
degree Celsius ·C dertved unit 
metre per second nvs dertved unit 
square metre m' dertved unit 
day d non-$ I unit 
degree • non-51 unit 
hour h non-51 unit 
litre' I, L non-51 unit 
minute min non-5 1 unit 
minute non-51 unit 
second non-51 unit 
"The BIPM adopted the symbol 'I' in 1879; it then adopted the alternative 'L' in 1979 in order to avoid the fisk of confusion between the letter 
'r and the number ' 1' 
Sometimes it is necessary to express units in quantities greater or smaller than the base unit Table 33 
contains the SI prefixes commonly used in Cochrane Reviews to derive such quantities. 
Table 33 Prefix es for 5 1 units 
Factor Name and symbol Example 
10.1 deci (d) decilitre ('NIlere 'litre' is the base unit) 
10.2 centi (c) centimetre ('NIlere 'metre' is the base unit) 
10· milli (ffi ) millilitre 
10· microW) microlitre 
10' nano (n) nanogram 
SI units and their derivatives should follow the style conventions in Table 34. Unlike the 'Abbreviations 
and acronyms', it is not necessary to define the fu ll unit name on first use. 
Table 34 51 units
A2
: general guidance 
Guidance v 
Unit symbols are unaltered when plural 10 mg 
Unit symbols are not followed by a full stop, except if I added 60 mg of salt. 
followed by nannal sentence punctuatiOn 
It is clear to 'NIlich unit symbol a mmerical value belongs 20 'C to 30 'C or (20 to 30) 'C 




I added 60 mg. of salt. 
20 'C-30 'C or 20 to 30 'C 
123 ± 2 9 
42 These are a selection of style conventions from <physics.nisl.qov/cuuJUnitsJru les.html> (which contains a comprehensive list) and 
<WNW 1.bipm.0fQ/enlSil>. Cochrane Reviews may deviate from some of the style conventions due to the nature of Cochrane Review 






















Values of quanUUes use Arabic numerals and symbols for 
units 
One space between the numerical value and unit 
symbol,43 even lMlen the value is used in an adjeCUval 
sense 
Do not mix information with unit symbols or names 
Informal references to non-SI units, such as a historical 
quote using inches, are acceptable depending on the 
context 
Upper-case letters 
m =5 kg 
the current was 15 A 
25 
a 25 kg sphere 
the water content is 20 mLlkg 
It took five hours to travel 10 
miles in 1945_ 
x 
m = five kilograms 
m = fivekg 
the current was 15 amperes 
25 
a 25-kg sphere 
20 mL H,Olkg 
20 mL of waterlkg 
It took five hours to travel 10 
miles (16_09 km) in 1945 
Only use if there is a compelling reason not to use lower-case letters (such as the word being a proper 
noun). 
v 
Verbs: s ingle or p lural 
Group nouns can use either a single or plural verb, but the choice should be consistent within a single 
Cochrane Review or document; for example, 'the government has ... ' or 'the government have ... ' . 




















abbreviations, 3-4 , 8, 9, 11, 28, 30 
to avoid, 4 
abstracts, 4 
acronyms. see abbreviations 
active voice, 4 
add itional figures, 4 




entering contact details in a 
Cochrane Review, 5 
author {preferred term ). 15 
author contact details in a Cochrane 
Review, 5 
bold font, 9 
bold italic tonto 9 
brackets, 18 
brand and trade names , 13 
Brttish English, 8 
capital letters, 31 
Celsius (as 81 units of measure), 30 
chi squared (common term ), 6 
Chinese names, 14 
citing 




Cochrane Central Register of 
Controlled Tria ls (CENTRAL), 15 
Cochrane Centre, spell ing of, 15 
Cochrane Collaboration, The, 15 
Cochrane Database of MethOdology 
Reviews, 15 
Cochrane Database of Systematic 
Reviews, 15, 24 
Cochrane Handbook for Systematic 
Reviews of Interventions, 15, 24 
referencing, 24 
Cochrane Library, The, 15 
Cochrane Manual, The, 15 
Cochrane Methodology Register, 15 
Cochrane Protocol, 15 
Cochrane Review, 15, 24 
abstracts, 4 
additional fiQures , 4 
author contact details, 5 
content, 5 
feedbaCk, 9 
font effects, 9 
font styles, 9-10 
headinQs, 10-11 
indentation, 11 
plain language summaries, 17 
tables , 1" 16, 28 
tenses, 29 
titleS, 29 
Cochrane Review Group, 15 
Cochrane Style Guide, 15 
Collaboration, the, 15 
colons, 18 
commas, 19 
commoo terms, 5-7 
com puter software (see also MetaView, 
Review Manager, RevMan Analyses, 
Statistical Analysis), 7, 23 
coofldence intervals, 27 
cootact details in a Cochrane Review, 5 
Co-ordinating Editor, 15 
country names, 13-14 
cross-over study (common term), 6 
currency, 7-8 
dales, 8 
days (as 8 1 units of measure), 30 
dedmal places, 26 
dedmal points, 26 
degrees (as 81 un its of measure), 30 
drugs, 14 
Dutch names, 14 
eg (abbreviation), 8 
e-mail addresses, 5 
English language, and regional 
differences, 8 
etc (abbreviation), 9 
family names, 14 
fax numbers, 5 
feedback in a Cochrane Review, 9 
fixed-effect model (common term), 6 
follow up (common term), 6 
font effects, 9 
font styles, 9-10 
footnotes, 28 
forest plot (common term), 6 
full stops, 19 
genus and species, 14 
glossary for The Cochrane 
Collaboration, 10 
Qroup nouns, 31 
handsearch (common term), 6 
headings in Cochrane Reviews, 10-11 
heaMh ca re (common term), 6 
hOurs (as $ 1 units of measure), 30 
www.COChrane.orglstyteJcsg.htm 
hyphens, 11 
ie (abbreviation), 11 
income classification of studies, 6 
indentation in Cochrane Reviews, 11 
intention-la-treat analysis (common 
term), 6 
inteme~ 23 
internet (common term), 6 
inverted commas, 19 
-ise word endings, 8 
ital ic font , 9-10 
-ize word endings, 8 
kilOgrams (as $ 1 units of measure), 30 
lists, formatting, 12 
litres (as 81 units of measure), 30 
mathematical formulae, 26 
mathematical presentation, 26-27 
MeerKa~ 15 
MetaView, 7 
metres (as 8 1 units 01 measure), 30 
minutes (as 81 units of measure), 30 
MadMan, 15 
multiple-drug resistance (common 
term), 6 
names 
brand and trade , 13 
country, I3-14 
entering contact details in a 
Cochrane Review, 5 
fam ily, 14 
genus and spedes, 14 
pharmaceutical drug, 14 
region, 13-14 
speCifiC to The Cochrane 
Collaboration, 14- 16 
number needed to treat to benefit 
(common term), 6 
number needed to treat to harm 
(common term), 6 
numbers, presentation of, 16-17 
P value, 26 
parentheses, 18 
passive voice, 4 
per cent (common term), 6 
percentage Si<;lns, 19 
pharmaceutical drug names, 14 
plain language summaries, 17 
prefixes , 17-18 
punctuation, 9, 18-19 
Quotation maf1(s, 19 






















citing in the text of Cochrane 
Reviews, 19, 25 
entering into Review Manager, 19--
25 
reQimen (common term), 6 
reQion names, 13-14 
reQular font style, 9 
Review Group Co-ordinator, 16 
Review Manager, 7, 16 
entering contact details in a 
Cochrane Review, 5 
fonts, 9--10 
head ings, 9, 10-11 
indentation , 11 
lists, 12 
spacing, 26 
special characters, 27-28 
statistical presentation, 26-27 
symbols, 27-28 
tables, 28 
RevMan . .see Review Manager 
RevMan Analyses, 7, 16, 27 
sample and population size, 27 
search methods 
citing databases and study regiSters, 
25-26 
search terms, 26 
seconds (as 8 1 units of measure), 30 
SI units (International System of Units), 
29-31 
spaCing, 19, 26, 27, 31 
special characters. See symbols 
species. see genus and species 
speech marts, 19 
Statistical Analysis, 7, 16, 27 
statistical presentation, 26-27 
subgroup (common lerm ), 6 
subscript, 9 
WrNW.cochrane.orglstyleJcsg.htm 




tables in 3 Cochrane Review, 4, 1" 16, 2. 
tautology, 28 
telephone numbers, 5 
tenses in Cochrane Reviews, 29 
terms, common , 5-7 
titles for Cochrane Reviews, 29 
TrialS Search Co-ordinat()(, 16 
underl ine font, 9, 10 
units of measure , 29--31 
upper-case leiters, 31 
verbs, and group nouns, 31 
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trials must indude a summary of previous research findings and 
explain how this trial affects this summary. The relation between 
existing and new evidence should be illustrated by direct reference 
to an existing systematic review and meta-analysis; if neither 
exists, author5 are encouraged to do their own or to describe 
the qualitative association between their research and previous 
findings (see l ancet 2005; 366: 107-08), Cluster randomisedtrials 
should be reported according to extended CONSORT guidelines. 
Randomise<! trials reporting harms must be described according 
to extended CONSORT guidelines. All reports of randomised trials 
should include a section entitled 'Randomisation and masking' 
within the methods section. Studies of diagnostic accuracy should 
be reported according to STARO guidelines, Observational studies 
(cohort. case-control. or eross-se<:tional designs) must be reported 
according to the STROBE statement. Genetic as'>OCiation studies 
must be reported according to STREGA guidelines. Systematic 
reviews and meta-analyses must be reported according to PRISMA 
guidelines, 
All articles should 
be up to 3000 words with 30 references 
indude a semistructured summary with five paragraphs 
(Background. Methods. Findings. Interpretation. and Funding), 
not exceeding 250words and reporting only primary outcomes 
if space is short. In EES, you will be asked to copy and paste this 
section at the -Submit Abstract- submission stage 
use the SI system of units and the recommended international 
non-proprietary name (rINN) for drug names. Ensure that the 
dose, route, and frequerxy of administration of any drll9 you 
mention are correct 
use gene names apprOOJed by the Human Gene Organisation. 
New gene sequences should be deposited in a public database 
(GenBank. EMBL. or OOB1). and the accession number prOOJided. 
Autnorsof mieroarray papers should indude in their submission 
the information recommended by the MIAME guidelines. 
Author5 should also submit their experimental details to one of 
the publicly available databases: ArrayExpress orGEO 
include any necessary additional data as part of your EES 
submission. 
Meta-analysis 
In general. these should folkm the PRISM A guidelines. 
Manu5uipts should be structured around five sections: 
summary, introduction, methods. results. and discussion, Aim 
for a maximum length of about 3000 words and 75 references. 
Meta-analyses should also contain a semistructured summary as 
described previously for Articles. 
Review 
Reviews may be commissioned orsubmitted unsolicited. although in 
the latter case itwould bewise to send the Editor a one~page outline 
fi~t (email ideditorial@lancet.com)toensurethata review on the 
same subject has not already been commissioned. Manvscriptswill 
be assessed in-house and those considered suitable will be peer 
reviewed before an editorial decision is made. Reviews should either 
be definitive overviews of a major topic connected with infectious 
diseases or updatesof kllONledge ina narrower field of wrrent interest. 
Thewordcount should be between 3000and 5000 words. depending 
on the breadth of the topic. Reviews should begin with a summary 
of no more than 150words. which briefly cOOJer5 the content of the 
article. Use subheadings to break upthetext in the main bodyofthe 
article, and try todistribute references to the figures and tables evenly 
throughout the manuscript. References (maximum 150) should be 
chosen fortheir importance. ease of access. and for the -further reading-
opportunities they prOOJide. Following the references. author5 should 
consider supplying a short list of usefulwebsiteswhere reader5 can 
find further information on the subject, Thelancet Infectious Diseoses 
welcomes systematic reviews, which must be reported accordi n9 to 
PRISMA guidelines. 
When writing a literature review. complete transparency 
concerning the choice of material included is important. Reviews 
must therefore contain a brief section entitled Search strategy 
and selection criteria_ This should state clearly the sources (data-
bases. journals. Of book reference lists, etc)ofthe material covered 
and the criteria used to include or e:clude studies; for example, 
English language only or studies conducted after a specific date. 
Example: 
Data for this review were identified by searches of Medline. 
Current Contents, and references from relevantarticles; numerous 
articles were identified through seaKhesofthe extensive files of 
the author5. Search terms were "hand hygiene-, -h<mdwashing". 
-hygienic handwash-, "hand disinfection-, -handrub". "eross 
infection-, "epidemiology", "healthcareworker", and "behaviour". 
English and French language paper5were reviewed. 
Hist o r ical Review 
These should follow the same rules and guidelines as for Reviews, 
but should cOOJer the chronological developments in an important 
or interesti ng area of infectious diseases. 
Pef"5onal View 
These should be around 1500-3000 words in length, with a 
maximum of 75 references, These opinion pieces are thought-
provoking essays on an infection-related subject and must 
be prepared in a similar way to a Review article. Unsolicited 
contribut ions are welcome, but it is best to contact the Editor 
before submission to ensure that the proposed topic is suitable 
for the journal. 
Foru m 
These are a platform for discussing controversies in infectious 
diseases. Each Forum contains three or more 800 word opinion 
pieces written by infectious diseases specialists, researcher5, 
nurses, patients. and others with an interest in the topic under 
discussion. Suggestions for topics from the journal's readers are 
very welcome, 
Gran d Rou nd 
These use a brief case report as the starting point for a review of 
thepatient'sdiagnosis. Ratherthan rarity. weare looking for single 
cases that address common problems and evidence-based review 
of the implications of the case. Consent for publication must be 
obtained from the patient or ne:t of kin before submission (see 
Clinical Picture, below). The case report part of the text should 














be flO longer than 800 words, the review part no longer than 
3000words, and up to 75 references are allowed. 
Clinical Picture 
These should feature interesting clinical photographs. accompanied 
by a brief text of up to 300words. Illustration of a useful teaching 
point is more important than rarity. No references should be 
included. There should be no more than five autho~: at least one 
should have been clinically responsible for the patient. Consent 
for publication in print and electronically must be obtained from 
the patient before submission or, if this is not possible, from their 
next of kin. For further deta ils see below under Patients' consent 
<lod permission to publish. 
Errata 
Any substantial error in a published articlewill be (orre<ted as soon 
as possible. Blame is not apportioned; the objective is to set t he 
record straight. Please contact the editorial team if you spot a major 
error in the journal. 
General submi ssion g u ide lines 
Covering le tter 
We ask that you upload a brief covering letter at the -Enter 
Comments' stage of the online submission process. 
Authors and contributo rs 
We ask oil authof5 and all contributors (including mooicol writers 
and editors) to specify their individual contributions at the end of 
the text. The lancet Infectious Diseases will not publish any articles 
unless we have the signatures of all authors. We suggest you use the 
author signat ure form aod ei ther upload the signed copy with your 
submission. or fax to +44 (0) 1865 853 01]. In addition. please ioclude 
written consent of any cited individual(s) noted in ackna.vledgments 
or personal communications. 
Conflict of interest 
A conflict of interest exists If authors or their institutions 
have financial or personal relationships with other people 
or organisations that could Inappropria tely InHuence (bias) 
their actions. Financial relationships are easily identifiable. 
but conflicts can also occur bec:ause of personal relationships. 
academic competitiOn. or intellectual passion. A conflict can be 
actuol or potentiol, and full di~losure to The Editor is the safest 
COUrsE!. failure to di~lose conflicts might lead to publication o f 
a stotement in our Department of Error or even to retraction. 
All submissions to The lancet Infectioos Diseases must include 
di~losure of all relationships that could be viewed as presenting 
a potential conflict of interest (see l ancet 2001; 358; 854-56 ood 
lancet 2003: 361: 8-9). The Editor may use such information as a 
basis for editorial dedsions. and will publish such di~1osu res if they 
are believed to be important to readers in judging the manu~ript. 
The corresponding author should confirm t hat he or she had full 
access to all the data in the study and had final respon~bility for 
the decision to submit for publicotion. 
At the end of the text under a subheading "Conflicts of Interest". 
all authors mustdi~lose any financial and personal relationships 
wi th other people or organisations t ha t could inappropriately 
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Information for Autho rs 1 
influence (bias) t heir work. Examples of financiol conflicts 
Include empk7yment. consultancies. stock ownership. honoraria 
paid expert testimony. patents or patent applica tions. and travel 
grants, all within 3 years of be9lnning the work submitted. If 
there are no conflicts of interest. authors should sta te that. 
All authors are required to provide a Conflict of Interest 
Statement and should complete a standard form. whkh is 
iNaiiable at httpJ/www. icmje .orglcoi_di~losu re.pdf. This form 
con be uploaded with the manuscript at submission or faxed to 
+44 (0)1865 853017. For more informat ion see lancet 2009; 
374: 1395-96. 
for Comment Seminars. Revie'ws. and Series. The lancet 
Infectious Diseases will not publish if an author. within the past 3 
years. andwith a relevant com panyOf competitor. has any stodcs 
orshares. equity. a contract of employment or a named position 
on a company board; or has been asked by any organisation 
ot her than The lancet to write. be named on. o r to submit the 
paper (see l ancet 2004: 363: 2-3). 
Ro leof the fundi ng source 
All sources of funding should be declared as an acknowledgment 
at t he end of the text. At the end of t he Methods section. under a 
subheading " Role o f the funding source-. authOfs must describe the 
role of the study sponsor(s). if any. in study design; in the collection. 
analysis. and interpretationofcLlta; in the writing ofthereport;and 
in the decision to submit the paper for publiCiltion. If there is no 
Methods se<tion. the role of the funding source should be stated oS 
an acknowledgment. lfthe funding source had nosuch involvement 
the au t hors should so state. 
Ro le o f medical w rite r or e di t or 
If a medicol writer or editor was involved in the creation of your 
manu~ript we need a signed statement from the corresponding 
author to include their nome and information about funding 
of th is person. This information should be added to the 
Acknowledgment and/or Contributors section. We also require 
signed statements from any medicol writers or edit()(s declaring 
that they have given permission to be named as an author. as a 
contributor. or in the Acknowledgments section. 
Pe rmissions 
A statement indicating permission to reproduce previously published 
material to use illustrations or report inform.:ltion about identifiable 
people, or to name people for their contributions (personal 
communications. etc) will be requested should you r manu~ript 
be selected for further consideration. 
Patients' consent and permissio n to publis h 
Studies on patients or volunteers need et hics committee 
approval and informed consent w h ich should be documented 
in your paper. If there is an unavoicLlble risk of breach o f 
privacy--t>g. in a clinical photograph or in cose details-the 
patient's written consent. or that of the ne)(f of kin. to 
publication must be obtained. To respect your pat ient's privacy. 
please do not send the consent form to us. Instead. we require 
you to send a statement signed by yourself confirming that 
you have obtained consent from the patient using 
C_t form 
A consent form .. 
",,;til.ole ~t htIp"J/Www. 
dwmIo.o:I.theIon<" t axnl 
llatcootenu..>ets!;outhon/ttid· 
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principal degree. 3nd full Clddress(es) of the Cluthors. The nCime 
Clnd Clddress of the corresponding author should be separately Clnd 
deCirly indicCited. with telephone, fax. 3nd emClil details. 
References 
These should be in the ' Vancouver" style. numhered in the order 
in which they 3re first used in the Clrtide, Referencescited in items 
such as figures. panels, Clod tCiblesshould he numbered in sequence 
with those in the text according towhere the item is cited in the 
text. Titles of journCils should be abbreviated Clccording to Index 
Medicus style. References must be verified against original 
documents. 
Artwork 
Inclusion of illustrations (photographs, graphs, diagrams. etc) is 
a prerequisite for publication. Digital photography files should 
have a resolution of at least 300 dpi and be at least 7S mmwide. 
Please do not import illustrations into POW'erPoint or Word if 
they have originally been created in other software, Do not send 
any figures as bitmClp5. 
Addit ional in format ion 
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Receipt of your pClperwill be 'KkncmIedged bj elTlClil within 24-48 h. 
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Peer review 
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or Health-care OeveIopmentwili be peer-reviewed Othercootributions 
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CHARACTERISTICS OF STUDIES 
CHARACTERISTICS OF INCLUDED STUDIES 
LUHADIA 2004 
Methods Randomised placebo-controlled trial set in Udaipur, India 
Sequence generation: no information provided 
Allocation concealment: no information provided 
Blinding: single-blind 
Participants 200 Sputum smear positive pulmonary TB participants
CATEGORY I (new diagnosis)
Total: 100 participants
Mean age: 36 years
Mean weight: 36.7 kg
M w arm: 50 participants
Control arm: 50 participants
CATEGORY II (retreatment)
Total: 100 participants
Mean age: 35 years
Mean weight: 37.7 kg
M w arm: 50 participants
Control arm: 50 participants
Interventions Intervention: 0.1 ml of M w administered intradermally on days 0, 15, 30, and 60; and then two
monthly until TB treatment is complete
Control: placebo of 0.1 ml of saline administered intradermally (as above)
Other: all participants received standard TB treatment as per WHO guidelines
Outcomes 1. Sputum conversion (on days 15, 30, 60, 120, and 120+)
2. Adverse events (including death and skin reactions)
3. Other clinical (weight gain) and radiological improvements
Notes This paper was presented as a poster presentation at the National Conference on Pulmonary 
Diseases (NAPCON) in 2004 
There is limited data as regards the methodology of the trial 
The authors were contacted in this regard, but no reply was received 
RISK OF BIAS TABLE 
Item Judgment Description 
Adequate sequence 
generation? 
Unclear No information provided 
Paper states that it is a randomised controlled trial, but does not provide any details 



















conversion) negativity is a laboratory-assessed outcome that is unlikely to be influenced by whether or 





For the secondary outcomes (adverse events, clinical improvement and radiological 
resolution), single blinding is insufficient. Both the participant and the clinician should be 
blinded to the treatment allocation 
Incomplete outcome data 
addressed? 
Yes 
No missing data 
Free of selective 
reporting? 
Yes Study protocol is not available but it is clear that the presented reports include all expected 
outcomes 
Free of other bias? No Performance bias. 
Only single-blind (it is not specified if the laboratory technician, clinician or the participant 
were blinded) 
May influence the evaluation of clinical outcomes such as adverse reactions, clinical 
improvement and radiological resolution 
PARIKH 2006  
Methods Randomised placebo-controlled trial set in India 
Primary aim was to evaluate if the addition of M w to standard TB chemotherapy would reduce 
the time to intercostal tube drainage (ICTD) removal in participants with TB 
hydropneumothoraces 
Sequence generation: no information provided 
Allocation concealment: no information provided 
Blinding: double-blind 
Participants 34 Participants with TB hydropneumothoraces diagnosed using Light's criteria* 
4 Smear positive pulmonary TB patients enrolled into M w arm 
3 Smear positive pulmonary TB patients enrolled into control arm 
Limited baseline data provided 
Interventions Intervention: M w 0.2 ml on day zero, followed by 0.1 ml on days 15, 30, 60, 120, 180, and until 
completion of TB chemotherapy 
Control: placebo administered as above 
All participants received standard TB treatment as per WHO guidelines 
Category I: rifafour, isoniazid, pyrazinamide and ethambutol (RHZE) for two months; and 
rifampicin and isoniazid for four months 
Category II: streptomycin plus RHEZ (SRHEZ) for two months; RHEZ for one month; and HER 
for five months 
Outcomes 1. Resolution of hydropneumothorax and removal of ICTD 
2. Sputum conversion 
3. Weight gain 
Notes This paper was presented as a poster presentation at the TB Vaccines for the World 
Conference in 2006 
Limited data is provided as regards the methodology of the trial 
The authors were contacted in this regard, but no reply was received 
*According to Light's criteria (Light 1972), a pleural effusion is likely exudative if at least one of 
the following exists: 














2. The ratio of pleural fluid LDH to serum LDH is greater than 0.6; or  
3. Pleural fluid LDH greater than 0.7 times the normal upper limit for serum 
RISK OF BIAS TABLE 
Item Judgment Description 
Adequate sequence 
generation? 
Unclear No information provided 







outcome: Adverse events) 
Unclear Double-blind 
Even though it is not stated clearly, the only way there can be a double blind is if a 
placebo was administered and neither the participant nor the clinician knew which 
treatment was being administered  
Incomplete outcome data 
addressed? 
Yes 
No missing data 
Free of selective reporting? Yes Study protocol is not available but it is clear that the presented reports include all 
expected outcomes
Free of other bias? Unclear Selection or referral bias: unusual collection of TB participants, with only four category I
participants and 30 category II participants
Clinical bias: assessment of severity of hydropneumothoraces and timing of ICTD
removal were clinician dependant
PATEL 2002
Methods Quasi-randomised controlled pilot study set in Ahmedabad, India
Sequence generation: no information provided
Allocation concealment: no information provided
Blinding: single-blind
Participants OVERALL 
134 Consecutive smear positive pulmonary TB participants (102 males and 32 females; mean 
age 36.2 years (range 15 to 75 years)) 
M w arm: 69 
Control arm: 65 
CATEGORY I 
Total: 58 participants 
M w arm: 20 
Control arm: 38 
CATEGORY II 
Total: 76 participants 
M w arm: 49 
Control arm: 27 














followed by 0.1 ml fortnightly for two months 
Control: no placebo given 
All participants received standard TB treatment as per WHO guidelines 
Category I: RHZE for two months and RH for four months 
Category II: SRHEZ for two months, RHEZ for one month, and HER for five months 
Outcomes 1. Sputum conversion
2. Adverse reactions
Notes Inequality in number of male to female participants and the ratio of category I to category II 
participants, give the impression that there was an error in randomisation. 
RISK OF BIAS TABLE 
Item Judgment Description 
Adequate sequence generation? No No information has been provided as regards randomisation 
The unequal numbers of male to female participants makes one suspicious of the
method of randomisation
Failure to stratify or prespecify the groups in terms of category I versus category II
has resulted in unequal numbers of participants in comparative groups
Allocation concealment? Unclear No information provided 
Blinding? (Primary outcome: 
Sputum conversion) 
Yes Single-blind
Laboratory technician blinded to treatment allocation
Blinding? (Secondary outcome: 
Adverse events) 
No Single-blind
Insufficient for the assessment of adverse events




Free of selective reporting? Yes Study protocol is not available, but it is clear that the published reports include all 
expected outcomes
Free of other bias? No Selection or referral bias: more males than females, and more category II than
category I participants
PATEL 2003 
Methods Follow-up of selected group (category II) from Patel 2002 pilot study 
Quasi-randomised controlled pilot study set in Ahmedabad, India 
Sequence generation: no information provided 
Allocation concealment: no information provided 
Blinding: single-blind 
Participants 134 Consecutive smear positive pulmonary TB participants 
M w arm: 69 
Control arm: 65 
CATEGORY II 
Total: 76 participants 
M w arm: 49 














No additional baseline data available 
Interventions Intervention: 0.2 ml (0.1 ml in each deltoid) M w intradermal injection given on day zero, 
followed by 0.1 ml fortnightly for two months 
Control: no placebo given 
All participants received standard TB treatment as per WHO guidelines 
Category II: SRHEZ for two months, RHEZ for one month, and HER for five months 
Outcomes 1. Sputum conversion
Notes Presented as a separate paper; but participants are from the Patel 2002 paper 
It is unclear whether category II group of participants was a prespecified subgroup 
RISK OF BIAS TABLE 
Item Judgment Description 
Adequate sequence generation? No No information has been provided as regards randomisation 
The unequal numbers of male to female participants makes one suspicious of the
method of randomisation
Failure to stratify or prespecify groups in terms of category I versus category II has
resulted in unequal numbers of participants in comparative groups
Allocation concealment? Unclear No information provided 
Blinding? (Primary outcome: 
Sputum conversion) 
Yes Single-blind
Laboratory technician blinded to treatment allocation
Blinding? (Secondary outcome: 
Adverse events) 
No Single-blind
Insufficient for the assessment of adverse events




Free of selective reporting? No Study protocol is not available
The published reports do not include all expected outcomes
Free of other bias? No Selection or referral bias: more males than females
Category II subgroup was not prespecified
FOOTNOTES 
CHARACTERISTICS OF EXCLUDED STUDIES 
CHADDA 
Reason for exclusion Not a randomised controlled or quasi-randomised controlled trial 
KATIYAR 
















Reason for exclusion Not a randomised controlled or quasi-randomised controlled trial 
MARTHUR 2006  
Reason for exclusion Not a randomised controlled or quasi-randomised controlled trial 
ZHOU 2002  
Reason for exclusion Intervention used was Bacillus Calmette Guerin (BCG), not M w 
FOOTNOTES 
CHARACTERISTICS OF STUDIES AWAITING CLASSIFICATION  
FOOTNOTES 
CHARACTERISTICS OF ONGOING STUDIES  
NCT00265226  
Study name Efficacy and safety study of immunomodulator (Mycobacterium w) as an adjunct therapy in 
category-II pulmonary tuberculosis along with assessment of immunological parameters 
Methods In progress 
Interventional, treatment, randomised, double-blind (subject and investigator), placebo 
controlled, parallel assignment, safety and efficacy study 
Participants Category II pulmonary TB participants who meet the eligibility  criteria 
Interventions Intervention: intradermal administration of Mycobacterium w, total of 6 doses given 0.2 ml at 
baseline and then 0.1 ml after interval of two weeks, up to eight weeks 
Control: placebo 
Category II TB chemotherapy according to guidelines 
Outcomes PRIMARY OUTCOME MEASURES 
The time to sputum conversion  
SECONDARY OUTCOME MEASURES 
Adverse reactions (assessment of safety) 
Participant's and physicians’ global assessment of the clinical cure 
Starting date March 2005 until December 2010 
Contact information Surendra K Sharma, M.D., Ph.D 
sksharma@aiims.ac.in 
Notes On correspondence, Dr. Sharma had no preliminary data available 
NCT00341328  
Study name Efficacy and safety of immunomodulator (Mycobacterium w) as an adjunct therapy in category I pulmonary 














Methods In progress 
Treatment, randomised, double-blind (subject and investigator), placebo controlled, parallel assignment, safety 
and efficacy study 
Participants INCLUSION CRITERIA 
1. Participants of either sex aged between 18 to 60 yrs  
2. Newly diagnosed pulmonary TB cases with at least two sputum samples that are positive on sputum 
microscopy  
3. Participants willing to give informed consent 
EXCLUSION CRITERIA 
1. Known hypersensitivity to category I TB chemotherapy  
2. Known history of MDR and XDR TB (patients with Mycobacterium tuberculosis resistant to one or more 
drugs will be excluded)  
3. Secondary immunodeficiency states: HIV, organ transplantation, diabetes mellitus, malignancy, treatment 
with corticosteroids  
4. Hepatitis B and C positivity
5. Participants with known extrapulmonary TB 
6. Currently receiving cytotoxic therapy, or having received it within the last three months 
7. Pregnancy and lactation
8. Participants with a known seizure disorder
9. Participants with known symptomatic cardiac disease, such as arrhythmias or coronary artery disease
10. Participants with abnormal renal function 
11. Participants with abnormal hepatic function (bilirubin = 1.5 mg/dl; AST, ALT, SAP more than 1.5 x ULN; PT
= 1.3x control)
12. Participants with haematological abnormalities 
13. Seriously ill and moribund patients with the complications of low lung reserve, marked tachypnoea, chronic 
cor pulmonale, congestive cardiac failure, BMI<15, and severe hypoalbuminaemia (< 2.5 g/dl) 
14. Participants unlikely to survive for more than six months
15. Participants unable to comply with the treatment regimen 
16. Participants with a history of alcohol or drug abuse
Interventio
ns 
Intervention: Intradermal injection of Mycobacterium w
A total of 6 doses are given: 0.2 ml at baseline and then 0.1 ml after interval of two weeks up to eight weeks
Control: placebo
Outcomes PRIMARY OUTCOME MEASURES




Participant's and physicians' global assessment of clinical cure
Starting 
date March 2007 
Contact 
information 




















Methods Interventional, treatment, randomised, double-blind (participant, caregiver, investigator, 
outcomes assessor), placebo controlled, factorial assignment, safety and efficacy study 
Participants INCLUSION CRITERIA 
Participants with a suspected tuberculous pericarditis will be eligible if they meet all three of the 
following criteria: 
1. A confirmed pericardial effusion on echocardiography;  
2. Evidence of definite* or probable** tuberculous pericarditis; and  
3. Within one week of starting of anti-tuberculous treatment. 
  
EXCLUSION CRITERIA 
1. Presence of an alternative cause of pericardial disease e.g. penetrating chest trauma in 
the preceding 12 months, or malignancy  
2. Use of corticosteroids within the previous month  
3. Hypersensitivity or allergy to the Mycobacterium w vaccine  
4. Pregnancy  
5. Age < 18 years 
Interventions PREDNISOLONE / PLACEBO  
Intervention: six-week tapering course of prednisolone 
Control: same number of identically-coated placebo tablets 
Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 
120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third 
week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth 
week 
MYCOBACTERIUM w / PLACEBO  
Intervention: five doses of 0.1 ml of Mycobacterium w intradermally (on enrolment, at two 
weeks, four weeks, six weeks, and three months) 
Control: Identical regiment of normal saline placebo injections 
Outcomes PRIMARY OUTCOME MEASURES 
Composite end-point of death, constriction, or cardiac tamponade requiring pericardial drainage 
SECONDARY OUTCOME MEASURES 
Safety of immuno-modulator treatment 
Long-term feasibility of conducting a multi-centre trial in Africa and India 
Starting date December 2008 to December 2011 
Contact information Professor Bongani Mayosi bongani.mayosi@uct.ac.za 
Dr. Mpiko Nstekhe             mpiko.ntsekhe@uct.ac.za 
Notes The pilot phase of this study has been successfully completed, and the investigators have 





















DATA AND ANALYSES  
1 SPUTUM CONVERSION  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
1.1 Sputum negative at Day 15 3 341 Risk Ratio (M-H, Random, 95% CI) 2.31 [1.75, 3.06] 
  1.1.1 Category I TB 3 158 Risk Ratio (M-H, Random, 95% CI) 2.25 [1.64, 3.09] 
  1.1.2 Category II TB 3 176 Risk Ratio (M-H, Random, 95% CI) 2.45 [1.33, 4.51] 
  1.1.3 Uncertain Category I or II TB 1 7 Risk Ratio (M-H, Random, 95% CI) 5.60 [0.39, 79.70] 
1.2 Sputum negative at Day 30 3 341 Risk Ratio (M-H, Random, 95% CI) 1.83 [1.12, 2.98] 
  1.2.1 Category I TB 2 158 Risk Ratio (M-H, Random, 95% CI) 1.34 [1.07, 1.66] 
  1.2.2 Category II TB 2 176 Risk Ratio (M-H, Random, 95% CI) 2.28 [1.37, 3.77] 
  1.2.3 Uncertain Category I or II 1 7 Risk Ratio (M-H, Random, 95% CI) 7.20 [0.53, 97.83] 
1.3 Sputum negative at Day 60 3 341 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.99, 1.92] 
  1.3.1 Category I TB 2 158 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.88, 1.56] 
  1.3.2 Category II TB 2 176 Risk Ratio (M-H, Random, 95% CI) 1.50 [1.10, 2.03] 
  1.3.3 Uncertain Category I and II TB 1 7 Risk Ratio (M-H, Random, 95% CI) 2.40 [0.66, 8.79] 
1.4 Sputum negative at Day 120 4 183 Risk Ratio (M-H, Random, 95% CI) 1.35 [1.05, 1.72] 
  1.4.2 Category II TB 3 176 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.15, 1.91] 
  1.4.3 Uncertain category I or II TB 1 7 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.62, 1.60] 
1.5 Sputum negative after day 120 2 176 Risk Ratio (M-H, Random, 95% CI) 1.34 [1.11, 1.62] 
  1.5.2 Category II TB 2 176 Risk Ratio (M-H, Random, 95% CI) 1.34 [1.11, 1.62] 
  
2 MORBIDITY AND MORTALITY  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
2.1 Mortality 1  Risk Ratio (M-H, Random, 95% CI) No totals 





















FIGURE 2  
 
Risk of bias graph: authors' judgements regarding each risk of bias item presented as percentages across all included studies. 
FIGURE 3  
 
















FIGURE 4 (ANALYSIS 1.1)  
 
Forest plot of comparison: 1 Sputum Conversion, outcome: 1.1 Sputum negative at Day 15. 
FIGURE 5 (ANALYSIS 1.2)  
 






















FIGURE 6 (ANALYSIS 1.3)  
 
Forest plot of comparison: 1 Sputum Conversion, outcome: 1.3 Sputum negative at Day 60. 
FIGURE 7 (ANALYSIS 1.4)  
 















FIGURE 8 (ANALYSIS 1.5)  
 
Forest plot of comparison: 1 Sputum Conversion, outcome: 1.5 Sputum negative after day 120. 
FIGURE 9 (ANALYSIS 2.1)  
 
Forest plot of comparison: 2 Morbidity and Mortality, outcome: 2.1 Mortality. 
FIGURE10 (ANALYSIS 2.2)  
 























MYCOBACTERIUM W  ADJUVANT IMMUNOTHERAPY IN 
PULMONARY TUBERCULOSIS
DATA EXTRACTION SHEET 
Effect of an Immunomodulator Containing Mycobacterium W on Sputum Conversion in 
Pulmonary Tuberculosis 
Naresh Patel, MM Deshpande, Maya Shah 
Study Verification Meets inclusion criteria 
Methods Pilot study 
Included 134 consecutive participants (sputum positive 
pulmonary tuberculosis – new(fresh) cases as well as retreatment
cases
Randomised to usual TB treatment plus Mycobacterium w, or TB 
treatment only
M w administered on day 1, then fortnightly. Not specified for 
how long.
Sputum collected before treatment, and then at Days 15, 30, 45 
and 60 for examination. Laboratory examiner was blinded to type 
and duration of treatments. 
Participants 134 consecutive sputum positive patients 
69 randomised to M w (21= 1+sputum positive, 13= 2+, 35=3+) 
65 randomised to usual therapy (24=1+, 11=2+, 30=3+) 
Interventions 69 received standard TB Rx and M w. 0.2ml loading dose (0.1ml in 
each deltoid). Then 0.1ml fortnightly. 
65 of control group received standard TB treatment. No placebo 
vaccine. 
Outcomes and results M w treatment group had a significantly faster sputum conversion 
rate at day 15, 30, and 45 for all groups of sputum positivity, and 
for both new (fresh) and retreatment participants. The sputum 
conversion rate achieved at day 60 in control was achieved at day 
30 in M w group for sputum that was 1+.  M w pre-poned sputum 
conversion by at least 30 days. 
















CAT I cure rates: 
Mw 100% 19/19 
Control 94.4% 34/36 
 
CAT II cure rates: 
Mw 48/49 97.9% 
Control 21/27 77.7% 
Notes No comment about hard outcomes: all cause mortality or TB 
death. 
No placebo vaccine given. 
No comparisons given for 2+ sputa 
Only graphs provided. No statistical tables. 
Only pilot study 
Small numbers 
More retreatment patients in the control group. Sub-group 
analysis done after initial randomisation. 
Duration of vaccination not stated 
No comment about compliance (drop outs or drop ins). 
 
Data table 
 1+ 3+ Retreatment Overall 
 M w Control Mw Control Mw Control Mw Control 
Number 21 24 35 30 49 27 69 65 
Day 15 57% 22% 13% 6% 22% 8% 21% 12% 
Day 30 78% 34% 35% 10% 49% 21% 43% 28% 
Day 45 92% 44% 35% 13% 56% 32% 50% 32% 
Day 60 99% 78% 43% 17% 62% 43% 57% 43% 

















Sputum conversion: CAT-I vs. CAT-II 
Days CAT I CAT II 
 Mw Control Mw Control 
Day 15 25% 13.1% 22.4% 7.4% 
Day 30 55% 31.5% 48.9% 22.2% 
Day 45 60% 34.2% 55.1% 33.3% 
Day 60 60% 42.1% 63.2% 44.4% 
Day 90 95% 84.2% 71.4% 48.1% 
Day 120   75.5% 51.8% 
 
RISK OF BIAS 
Item Judgment Description 
Adequate sequence 
generation 
Unsure Details not provided. Authors did not respond to 
correspondence 
Allocation concealment Unsure  
Blinding Yes - 
Single 
Laboratory technician was blinded to treatment 
type and duration 
Participants not blinded because no placebo 
Because no clinical outcomes measured no 
blinding of participants or clinical examiners 
Incomplete outcome data 
addressed? 
Yes All allocated participants were accounted for, for 
the full duration of the study. 
Free of selective reporting? No No comments made about 2+ sputum group. 
Actual values and statistical tables, as well as 
statistical methods of analysis not provided.  






















All-cause mortality Not assessed 
Death from tuberculosis Not assessed 
Sputum culture negative at 2 months and at 
the end of anti-tuberculous chemotherapy 
Yes 
Rate of resolution of pleural effusion or other 
effusive forms of extrapulmonary tuberculosis. 
Not applicable 
Secondary outcomes 
Serious adverse reactions, i.e. fatal, life 
threatening or requiring hospitalisation 
None
Adverse events related to the 
immunotherapy 
Only self limiting events reported 
Systemic adverse events, e.g. fever None 
Immunological adverse events, e.g. increase 


















MYCOBACTERIUM W  ADJUVANT IMMUNOTHERAPY IN 
PULMONARY TUBERCULOSIS 
 
DATA EXTRACTION SHEET 
Improved Cure Rates in Pulmonary Tuberculosis Category II (Retreatment) with 
Mycobacterium w 
Naresh Patel, SB Tripathi 
  
Study Verification Meets Criteria (Sub-group analysis) 
Methods Post-Hoc analysis 
Records review of TB Category II (retreatment) 
participants that were originally enrolled into Mw versus 
control group (previous study mentioned) 
Participants randomised to Mw vaccine all received 0.2ml 
Mw (0.1ml in each deltoid) at day 1, then 0.1ml fortnightly 
for 2 months. No placebo given to control group. 
Sputum analysis for bacterial load were analysed at 3.5 
and 8 months (for sputum negative participants) and at 4, 
6 and 9 months (for sputum positive participants). 
Laboratory technician was blinded to treatment type and 
duration. 
 
Participants Follow-up of retreatment cases (1 month of TB treatment 
previously taken: Defaulters, previous TB,  
Total number of retreatment cases: 76 
Number in the Mw group: 49 (12=1+, 17=2+,20=3+) 
Number in control group: 27 (11=1+, 2=2+, 14=3+) 
Interventions Participants randomised to Mw vaccine all received 0.2ml 
Mw (0.1ml in each deltoid) at day 1, then 0.1ml fortnightly 
for 2 months. No placebo given to control group. 















Outcomes and Results Sputum clearance at 3 months, 4 months, and 2 months 
post intensive phase (5 or 6 months depending on 
whether intensive therapy was 3 or 4 months) were all 
statistically significantly better in the Mw group. 
Mw also had statistically significantly lower treatment 
failure rate. 
No major adverse events were reported.  
Notes No comment about hard outcomes: all cause mortality or 
TB death. 
No placebo vaccine given. 
No comparisons given for 2+ sputa 
Only graphs provided. No statistical tables or methods of 
analysis provided. 
Large number of total cohort turned out to be retreatment 
patients (76/134 (56.7%)). This is unusual for enrolling 
consecutive patients. Would expect the rates of new (fresh 
cases) to be equal to or more than retreatment cases. 
Likely secondary to referral bias or selection bias. Possibly 
a reflection of too few participants enrolled.  
Post hoc analysis of non a priori non specified sub group. 
Unequal numbers in the two comparative groups. Much 
fewer participants in the control group and very small 
numbers, makes the statistical value of the data 




 M w Control 







4 months 37 (75%) 14 (51.4%) 
2 months post intensive phase 48(97.9%) 21 (77.7%) 
Overall 48 (97.9%) 21 (77.7%) 
















RISK OF BIAS 
Item Judgment Description 
Adequate sequence 
generation 
No Post hoc analysis of a non- a prior (non-pre-
specified) subgroup  
Allocation concealment Unsure Not specified 
Blinding Yes - single Laboratory technician was blinded to type and 
duration of therapy. 
Clinical reviewers were not blinded to Mw 
therapy because no placebo was given. 
Incomplete outcome data 
addressed? 
N/A All participants completed treatment 
Free of selective reporting? No Subgroup analysis 
No reporting on 2+ sputum conversion 
No formal reporting of adverse events. Because 
no placebo used, reporting of adverse events 
would apply only to Mw group. 









All-cause mortality Not assessed 
Death from tuberculosis Not assessed 
Sputum culture negative at 2 months and at 
the end of anti-tuberculous chemotherapy 
Yes 
Rate of resolution of pleural effusion or other 



















Secondary outcomes   
Serious adverse reactions, i.e. fatal, life 
threatening or requiring hospitalisation 
None reported 
Adverse events related to the 
immunotherapy 
None reported 
Systemic adverse events, e.g. fever None reported 
Immunological adverse events, e.g. increase 

































MYCOBACTERIUM W  ADJUVANT IMMUNOTHERAPY IN 
PULMONARY TUBERCULOSIS 
DATA EXTRACTION SHEET 
Role of Mw Vaccine in management of Hydropneumothorax as an adjuvant to ATT (Anti 
Tuberculosis Therapy) with ICTD (Intercostal Tube Drainage). Paper presented at: TBV 
2006 - TB Vaccines for the World, 2006; Vienna, 
Austria. 
Parikh H, Shah N, Tewari T, Parswani JP, Maseeh A. 
Study Verification Yes 
Methods Randomised, double blind, placebo-controlled, comparative clinical 
trial.
CAT I (new diagnosis) and CAT II (Retreatment) were treated as per 
WHO guidelines
Both smear + and smear – patients were included
Participants received Mw intradermally 0.2ml on day 0 followed by
0.1ml on days 15,30,60,120, 180 till the end of ATT
Primary aim was to evaluate if the addition of M w would reduce the 
time to ICTD removal
Light’s criteria was used to detect exudative effusions 
Distinction between TB and bacterial effusions was on the basis of 
lymphocyte/neutrophil ratio, ADA, LDH levels
Participants with bacterial infections were treated accordingly 
Participants Both CAT I and CAT II TB patients were included 
Both smear positive and smear negative patients were included 
Diagnosis of TB exudative effusions was made using Light’s criteria 
Bacterial effusions were excluded 
Total of 18 participants were randomised to Mw + ATT + ICTD(4/18 
smear positive, 14/18 smear negative, 2/18 CAT I, 16/18 CAT II) 
Total of 16 participants were randomised to ATT + ICTD (control 
arm) (3/16 smear positive, 13/16 smear negative, 2/16 CAT I, 















Interventions Participants received Mw intradermally 0.2ml on day 0 followed by 
0.1ml on days 15,30,60,120, 180 till the end of ATT 
CAT I patients received RHZE (2 months) + 
RH(4months). 
CAT II patients ( smear +ve & smear – ve) received SHREZ (2 
months) + HREZ ( 
1months)+ HER ( 5 months). 
Outcomes and Results M w arm had faster removal of ICTD with 72% removal within 22 
days vs. 37.5% in the control arm 
Student’s t-Test used to compare number of days taken for removal 
of ICTD between 2 groups: Group A had a faster (15.1+- 8.58 days) 
removal as compared to control group B (43.9 +- 31.6 days) with 
p<0.001 
Sputum conversion was faster in group A (18.8 +- 7.5 days) vs. 
Group B 96.7+-40.4 days) p<0.012 
Also demonstrated faster weight gain in Group A vs. Group B 
Notes No comment about mortality 
Very small study 
Unreliable sputum conversion analysis because so few participants 
were sputum positive to start with (7/34) 
Unusually high number of CAT II patients (?selection bias, referral 
bias) 
No comment about adverse reactions to Mw  
Indications or evaluation of effusion resolution not stipulated 
Labeled as a double blind study, but no mention of a placebo vaccine 









CAT I CAT II 
Group A 
Mw/ATT/ICTD 
18 4 14 2 16 
















Total 34 7 27 4 30 
 
Days to ICTD Removal Group A: Number of pt Group B: Number of pt 
0-7 3 1 
8-14 4 2 
15-21 6 3 
22-30 4 3 
31-60 1 3 
61-90 0 2 




RISK OF BIAS 
Item Judgment Description 
Adequate sequence 
generation 
Unsure Not detailed in paper 




No placebo vaccine given. Unlike in other studies 
were primary outcome was laboratory 
determined (sputum smears), decisions with 
regard to when ICTD needs to be removed in 
clinically determined. If participants did not 
receive a placebo vaccine then examiners and 
participants would know whether or M w was 
administered 
Incomplete outcome data 
addressed? 
N/A  
Free of selective reporting? Yes No exclusions in the study 



















Death from tuberculosis 
Sputum culture negative at 2 months and at 
the end of anti-tuberculous chemotherapy 
Rate of resolution of pleural effusion or other 
effusive forms of extrapulmonary tuberculosis. 
Secondary outcomes 
Serious adverse reactions, i.e. 
fatal, life threatening or 
requiring hospitalization 
Adverse events related to the 
immunotherapy
Systemic adverse events, e.g. 
fever 
Immunological adverse 















MYCOBACTERIUM W  ADJUVANT IMMUNOTHERAPY IN 
PULMONARY TUBERCULOSIS 
DATA EXTRACTION SHEET 
Mycobacterium w as an adjuvant to chemotherapy in management of pulmonary tuberculosis 
Dr. Luhadia S., Dr.  Saugat R., Dr. Joshi V.   
Study Verification Meets inclusion criteria 
Methods Placebo controlled, single blind study 
200 participants (100 New TB / Category I) (100 Retreatment /
Category II) randomised to Mw or placebo plus DOTS therapy for 
TB
0.1 ml Mw or saline placebo given intra-dermally on day 0, 15, 30, 
60 and then 2 monthly until treatment was complete
TB was diagnosed on sputum examination
Participants were followed up at 0, 15, 30, 60, 120 days and at the
end. Sputum smears were done at each visit.
X-rays were taken at 0, 60, 120 days and at the end.
Participants Category I and Category II TB sputum smear positive.
Category I (50 Mw: 3+=32, 2+=5, 1+=13) (50 placebo: 3+=28,
2+=9, 1+=13)
Category II (50 Mw: 3+=34, 2+=6, 1+=10) (50 placebo: 3+=30,
2+=9, 1+=11)
Interventions 0.1 ml Mw or saline placebo given intradermally on day 0, 15, 30, 
60 and then 2 monthly until treatment was complete 
Outcomes and Results Death: 
Category I 


















both Category I and II participants versus placebo. Decreased time 
to sputum conversion by at least 45 days in both groups. 
Cure: 
Cure rate was improved by 25% in category II participants 
Other: 
Mw group also had improved weight gain, clinical improvement 
and radiological resolution 
Adverse reactions: 
No systemic adverse reactions seen with Mw 
Localised reaction documented in 2 Cat II participants receiving 
Mw 
*not stated number of participants that developed “Normal Local 
Reaction”= pustule 4-5 days, ulcer 7-10 days, scab 1 month
Notes No comment on type of randomisation
Unusual (but not impossible) to get exact numbers 
(50/50/50/50) across the 4 groups 
The nature of the single blind not stated. SURELY BOTH THE 
EXAMINER AND THE PATIENT would be blinded in a placebo 
control study. No comment about whether the lab tech were 
blinded or not. 
No details of type of statistical analysis provided.
Excluded “Normal Local reaction” as an adverse event
Small numbers
Difficult to make a comment about mortality (but this was not a 
Primary objective) because so few events 















RISK OF BIAS 
Item Judgment Description 
Adequate sequence 
generation 
Unsure Information not provided. Author did not 
respond to correspondence 
Allocation concealment Unsure 
Blinding Yes Single blind 
Incomplete outcome data 
addressed? 
No Not discussed in paper (assumption is that all 
data was complete) 
Free of selective reporting? Yes 
Free of other bias? Yes 
OUTCOMES 
Primary 
All-cause mortality Yes. Too few events to make a 
statistical assessment
Death from tuberculosis Not specified 
Sputum culture negative at 2 months and at 
the end of anti-tuberculous chemotherapy 
Yes: Benefit 
Rate of resolution of pleural effusion or other 
effusive forms of extrapulmonary tuberculosis.
No directly addressed. Radiological 
improvement was noted 
Secondary outcomes 
Serious adverse reactions, i.e. 
fatal, life threatening or 
requiring hospitalization
Nil 
Adverse events related to the 
immunotherapy 
Yes 2 = accelerated local 
reaction 
























Table 1 • Characteristics of Patients Studied 
Catl Colli 
Paf'ome'ers M.w. Control M.w. Control 
n _ 50 "- so n _ 50 n-SO 
AvorOGo A 0 ev&<u'$) 36 36 33 37 
S •• M 38 36 39 40 
F 38 36 39 .0 
Avorago WI M 41 41 42 41 
(Kg) F 3' 31 34 3' 
Radiological 
Mild 10 9 5 3 
Moderoto 33 31 11 1. bton' 
S~ere 7 10 3' 33 
Grading of 
+3 32 28 34 30 
+2 5 9 6 9 Sputum 
+ 1 13 13 10 11 
Table 2 • Death and Adverse Reaction 
Cat I Calli 
Death 
M .w. group I Nil I 2 
Control group I Nil I 2 
Adverse Reactions 
M .w. group I Nil I 2" 
Control group I Nil I N il 
• lCKOI $i10 OCC:OlorotOCJ rooction 
Table 3 Ch . rona ogy 0 fN ormo oea e I L I R action 
Pus tule 4 -5 days 
Ulcer 7 · 10 days 


















 New Retreatment 
 Mw Control Mw Control 
Number 50 50 50 50 
Day 15 97% 42% 41% 17% 
Day 30 97% 75% 60% 29% 
Day 60 100% 90% 62% 39% 
Day120   71% 48% 




















Mw Control Mw Control 
Number 50 50 50 50 
Death 0 0 2 2 
Adverse Reaction 
Accelerated local rxn 0 0 2 2 
